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Abstract 
New imidazotetrazinones have been synthesised that possess features in their structures 
to release aziridinium ions upon ring opening. Unstable 2-aminoethylisocyanates were 
required in this preparation, which were synthesized with BOC-protection of the amino 
group to counteract the reactivity of the amine towards the isocyanate group in the case 
of aliphatic amines; in contrast, anilinoethylisocyanates were synthesized unprotected. 
Substituents with a range of electron-withdrawing and electron-releasing properties 
were introduced at the p-position of the aniline ring. A 13C-labelled study confirmed the 
release of the aziridinium ion by these imidazotetrazinones in neutral pH buffer 
solution. Furthermore the kinetics of the hydrolysis in neutral aqueous solution of some 
these new tetrazines were similar to temozolomide, in addition to useful acid stability. 
Other imidazotetrazinones were synthesised for the purpose of releasing alcohols and 
phenols. Their synthesis was performed with a one-carbon linker between the 
imidazotetrazinone   3-position and the alcohols or phenols to be released. The release 
of alcohol and phenol through the hydrolysis of the intermediate diazonium ions to the 
unstable hemiacetals that decomposed to the alcohol and phenol was confirmed by 1H 
NMR. The kinetics of the hydrolysis of these tetrazines in neutral aqueous solution 
showed a faster reaction rate compared with temozolomide (t1/2 = 0.53 and 0.36 h 
compared with temozolomide 1.4 h).  
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INTRODUCTION
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Chapter 1 Introduction 
1.1 Imidazotetrazinone origin as a prodrug delivery system 
 
Imidazotetrazinones 1 are compounds characterized by arrays of nitrogen atoms which 
confer unique chemical and biological properties. 1 Their structure is a variation of the 
commonly-known triazenes (acyclic system). They developed from pyrazolotriazine 2 
and aryldimethyltriazines 3 in the early 1960s, to the imidazolyltriazene dacarbazine 4 
(DTIC).  
N N
N
N
N
NH2O
O
R
1
1 a: R = CH3
    b:        CH2CH2Cl
   c:        CH2CH3
   d:        CH2CH2Br
   e:        CH2CF3
N
N
N
N
2
N
N
N
R
3 N
NH
O
NH2 N N
N
4
8
2
3
1
4
5
7
6
8a
                         
DTIC entered clinical practice in the 1970s, on the basis of its potent activity against a 
range of rodent tumours. It required metabolic activation in the liver,  the metabolic 
activation is a P450-mediated metabolic oxidative demethylation through the formation 
of hydroxymethyl precursor 5 that loses a molecule of formaldehyde to form 
monomethyl triazene MTIC 6,2 which is the active agent of the prodrug Scheme 1. 
However MTIC possesses a poor tissue distribution that is responsible for the 
unassuming clinical performance of DTIC. This prompted the synthesis of 
imidazotetrazinone prodrug temozolomide 1a, which liberates the same active agent 
(MTIC).3 
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                        Scheme 1. Metabolic Activation of Dacarbazine                                              
Temozolomide 1a is a good delivery system for MTIC to the site of action at DNA, 
with good tissue distribution. Its propensity to ring opening is enhanced by the bicyclic 
system with bridgehead nitrogen atom of the imidazotetrazinone ring, resulting in the 
activation of temozolomide under the chemical control of the pH rather than metabolic 
activation in the liver.4 
In 1980 Robert Stone synthesized the first example of the new ring system imidazo 
[5,1-d]-1,2,3,5-tetrazine azolastone (mitozolomide 1b) making use of a published new 
route, to fused 1,2,3,5-tetrazines from the interaction of diazoazoles and isocyanates by  
Ege & Gilbert in 1979.5 Mitozolomide 1b,6  the bifuntional alkylating agent, entered the 
clinic with high hopes in 1983. Unfortunately, despite its curative activity in mice, 
mitozolomide was found to cause severe and unpredictable myelosuppression which 
limited its clinical usage.7 At this stage temozolomide 1a which is the N-methyl 
congener of mitozolomide, was selected as a less toxic, second generation analogue for 
clinical trial. 
Temozolomide 1a demonstrated a different toxicological profile, it is a mono-functional 
methylating agent,3  characterized by an unusual stability in acidic pH which allows its 
excellent oral bioavailability,8 it possesses a good tissue distribution and can penetrate 
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into the central nervous system, such penetration was not exhibited by other MTIC 
prodrugs.9, 10 
Vaupel et al., 198911 showed that there are differences in pH between healthy brain 
tissue (pH 6.96-7.05) and glioma (7.15-7.22), these differences may contribute to the 
selective toxicity of temozolomide towards gliomas. The lower pH of healthy tissue 
would stabilise the prodrug and favour passage of the intact prodrug to the tumour cell. 
However, it is of great importance to consider other factors that affect temozolomide 
toxicity such as the activity of DNA repair enzymes MMR & MGMT which influence 
the susceptibility of tumor to temozolomide.12                                                               
1.2 Imidazotetrazinone chemistry 
1.2.1 Imidazotetrazinone aqueous reaction 
 
The hydrolysis of imidazotetrazinones is unusually pH dependent. These compounds 
are stable in 1 M sulphuric acid and can even be recovered unchanged from hot 
concentrated sulphuric acid, in addition to the photostability of their aqueous solution.6 
In the alkali 5 % sodium carbonate, they decomposed rapidly by the tetrazine ring-
opening Figure 1.13 This figure shows temozolomide stability at acidic pH and being 
labile above pH 7. The stability of temozolomide in acidic media allows its survival in 
the strong acid in the stomach and is important for its absorption intact, therefore it can 
be administered orally.8 A 15N NMR study has shown that this unusual stability in acid 
is due to the protonation on the temozolomide taking  place at N-7 rather than O-4, 
which would be required to catalyze the ring-opening reaction, Structure 7.14                      
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  Figure 1. Plot of Stability Constant (kob) versus pH of Temozolomide and MTIC15                           
 
The temozolomide reaction in neutral aqueous medium provides an indication to its 
biological activity as a pro-drug.3 In 0.1 M phosphate buffer pH 7.4 at 37 ºC, 
temozolomide undergoes ring-opening to the open-chain triazene MTIC 6 with half-life 
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of 1.83 h,15 Scheme 2. MTIC is same metabolite formed upon the metabolic activation 
of the antitumor  prodrug DTIC 4.16 MTIC on the other hand is unstable below pH 7 but 
more stable at the alkaline pH values, Figure 1.15  
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Scheme 2. Temozolomide Reaction in Aqueous Medium 
Addition of water (1a      8) is the rate-limiting step in the aqueous decomposition of 
temozolomide 1a, Scheme 2. Base-catalysed addition of water to C-4 forms tetrahedral 
adduct 8, which undergoes ring-opening to give unstable carbamic acid 9, spontaneous 
decarboxylation leads to MTIC 6. This is then followed by the acid-catalysed 
fragmentation of MTIC to form AIC 10 and methyldiazonium ion 11.15 
The methyldiazonium ion 11 is the methylating agent, it is relatively stable and this 
stability comes as a result of the proton loss and gain equilibrium with diazomethane 12. 
Moreover, the stability of the methyldiazonium ion was proved by deuterium 
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incorporation and it responsible for the life time of the ion, which allows it to encounter 
its DNA target in cells.15  
Figure 2 shows the results of the NMR study of temozolomide decomposition in 
deuterated phosphate buffer solution (pD 7.8 at 37 ºC). The figure shows deuterium 
incorporation into CH3OD, CH2DOD, CHD2OD in addition to the phosphate esters. 
This implies that methyldiazonium 11 is in equilibrium with diazomethane 12 and D2O, 
Scheme 2. 
 
Figure 2. Methyl region of 1H NMR spectrum of decomposition of temozolomide in 
deuterated phosphate buffer pD 7.8 at 37 ºC (Adapted from ref 15)15 
In contrast, 3-ethylimidazotetrazinone 1c is devoid of antitumor activity,4 it undergoes a 
ring opening in the phosphate buffer  pH (7.4) to the ethyltriazine 13, which upon 
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further fragmentation results in ethyldiazonium ion 14, which characterized by a short 
lifetime for finding its biological target, compared with that of methyldiazonium ion 
11.17         A 1H NMR study of the decomposition in phosphate buffer showed a small 
peak of ethene with a peak for  ethanol, this reflects the immediate reaction of the 
diazonium ion with water to alcohol or by elimination to ethene,  Scheme 3.17   
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1c 13 14  
                 Scheme 3, Ethylimidazotetrazinone neutral aqueous decomposition 
The 3-(2-chloroethyl)imidazotetrazinone mitozolomide 1b, follows a similar aqueous 
decomposition to temozolomide. Its decomposition was studied in 5% aqueous sodium 
carbonate and resulted in the chloroethylating agent MCTIC 15.6 MCTIC acts as a 
bifunctional alkylating agent. Acid-catalysed fragmentation gives 2-chloroethyl-
diazonium ion 16 and AIC 10; participation of the chloro group with one of its unshared 
electron pairs gives cyclic chloronium ion 17.  This reacts with water in the medium to 
give 2-chloroethanol 18 and nitrogen,6, 14 Scheme 4.  
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                     Scheme 4. Mitozolomide neutral aqueous hydrolysis 
3-(2,2,2-Trifluoroethyl)imidazotetrazinone 1e, which possesses more potent in vitro 
anitumour activity than both mitozolomide and temozolomide,17 has a totally different 
pattern of decomposition in phosphate buffer pH 7.4 from that observed in the case of 
mitozolomide and temozolomide.17 The strongly electron-withdrawing trifluoroethyl 
group of 1e significantly affects the electronic character of the tetrazine ring, which 
results in weakening and thus breaking of the bonds 2/3 and 4/5,17 Scheme 5. The major 
products detected were the result of hydrolysis of   trifluoroethylisocyanate 19 and 
cyclization of  diazo-IC 20 to 2-azahypoxanthine 21. Minor products detected were AIC 
10 and trifluoroethanol 22, which were assumed to be produced by the usual tetrazine 
ring opening mechanism i.e analogous to that of temozolomide.17 
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Scheme 5.  3-(2,2,2-Trifluoroethyl)imidazotetrazinone 1e  decomposition in aqueous 
medium 
 
                                                                                                                                 
1.2.2 Reaction with DNA 
 
The reactions of imidazotetrazinones discussed in the previous section with the model 
nucleophiles OH2, PO42- will be extended to the consideration of reactions where the 
nucleophiles are sites on DNA. Guanine bases in DNA have a more negative molecular 
electrostatic potential than other bases.15, 18  The atom with the most negative potential 
is the N7 of guanine which is also the most sterically accessible. This explains why this 
atom is most frequently alkylated by electrophilic drugs e.g. N-methyl-N-nitrosourea, 
cisplatin, nitrogen mustards, and bisulfan.19 
Calculations of partial atomic charges in nucleic acid bases and the electrostatic 
contribution to DNA base-pairing,20 show that a run of three consecutive guanines has a 
 10 
 
higher dipole moment than other sequences of bases, this is consistent with  the 
observed enhanced nucleophilicity and basicity of the major-groove microenvironment 
G-rich sequences and any associated water molecules, which may facilitate sequence-
selective conversion of the prodrug temozolomide to MTIC.21 The second factor that 
determines the selectivity for guanine alkylation is the steric ease of access to guanine in 
the major groove.22  A study by Abraham & Smith20 tested the accessibility of different 
potential electrophile-acceptor atoms in DNA, it confirmed that N7(G) accessibility is    
10 Å2, whereas O6(G) is 8 Å2 and N7(A) is 8 Å2 (Table 1), the study also showed that 
N7 guanine has the greatest negative potential.20 
Upon treating DNA with 14C-labelled temozolomide, 70% of the label transferred to 
DNA was associated with N7 guanine, 5% with O6 of guanine, and 25% with other 
sites.23 Moreover, studies also showed that the favoured site of MTIC reaction is at 
GN7.21 These data are consistent with both the steric accessibilities and electrostatic 
potentials shown in Table 1. 
There was a proposal, supported by molecular modelling studies, that indicated 
temozolomide could make a productive, hydrogen-bonded association with DNA in 
which the role of carboxamide group may be vital in orienting the drug towards 
guanine-cytosine sites.15 On the other hand, the fact that unstable species MTIC also 
favoured the methylation of N7 residue of the middle guanine in runs of guanines in 
isolated DNA confuses the picture stated by the molecular modelling study.24  
The study made by Clark  also found no evidence of the weak association of 
temozolomide and mitozolomide with DNA at the major groove: the rate of reaction 
was not sequence dependent and they concluded that the conversion of 
imidazotetrazinone prodrug to drug occurs in free solution under influence of the local 
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pH, rather than in the major groove catalysed by a target DNA sequence as previously 
proposed.24 This fact is in agreement with half-life (1.83 h) of temozolomide in 
phosphate buffer (pH 7.4 at 37 ºC) being comparable with its mean plasma half-life in 
patients (1.81 h).15 Furthermore, the Clark study shows no rate enhancement observed 
by the presence of the guanine rich oligonucleotides in the buffer solution used for 
testing the rate of prodrug activation.24  
Atom Accessibility    
(Å2) 
Potential 
(kcal mol-1) 
Groove 
N7 (G) 10 -683 Major 
O6 (G) 8 -654 Major 
N7 (A) 8 -650 Major 
O4(T) 3 -612 Major 
O2 (T) 7 -663 Minor 
N3 (A) 2 -668 Minor 
O2 (C) 4 -645 Minor 
N3 (G) 2 -670 Minor 
 
Table 1. Steric surface area accessibilities and potentials of atoms in B-DNA 
 
In several respects, temozolomide most closely resembles the promutagen N-methyl-N-
nitrosourea (MNU), which also does not require metabolic activation but is chemically 
activated at pH 7.4 to generate methyldiazonium, Scheme 6.25  
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Scheme 6. Fragmentation mechanism for the base-induced decomposition of MNU in 
water 
 
1.2.3. Imidazotetrazinone Synthesis 
 
The  synthesis of azolotetrazinones by Ege and Gilbert5 from the interaction of 
diazoazoles and isocyanates provided the impetus for the synthesis of  the first 
imidazotetrazinone mitozolomide 1b,  from the reaction of diazo-IC 20 with                   
2-chloroethylisocyanate 24b in dichloromethane at 25 ºC in the dark.6 This reaction was 
used for the synthesis of different imidazotetrazinones, the interaction of methyl, n-
propyl isocyanate and aryl isocyanates with diazo-IC in dichloromethane or ethyl 
acetate shown by  Scheme 7  led to the different  imidazotetrazinones.6 
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Scheme 7. Two possible attacks between the diazo-IC ring and isocyanates in the 
synthesis of different imidazotetrazinones 
 
Temozolomide 1a was synthesised from the reaction of methylisocyanate 24a with 
diazo-IC 20. This reaction took a long time in solvents such as dichloromethane and 
ethyl acetate but it is characterized by a high yield and high purity of the product. The 
reaction time was improved by using DMSO as the reaction solvent, this route of 
synthesis gives access to a wide range of analogues26 and it can be used for the 
synthesis of bisimidazotetrazinones 26 when  the diisocyanates 25 were reacted with 
diazo-IC 20 Scheme 8.26 
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Scheme 8. Synthesis of bisimidazotetrazinones 
The original method can accommodate modifications that led to preparation of a variety 
of isotopically labelled forms of the drug.27  Sites of temozolomide that have been 
prepared with 15N (N-2, N-3) and 13C (CH3) for nuclear magnetic resonance (NMR) 
studies27 and 11C (CH3) for positron emission tomography (PET) imaging are indicated 
on Figure 3.28 Mitozolomide has also been radiolabelled with 14C (C-6) for 
pharmacokinetic experiments.29  
 
                             
N N N
N
N
H2NOC
CH3
O
15N
11C, 13C,2H3
11C14C  
Figure 3. Isotopically-labelled forms of temozolomide 
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The original route of synthesis of the tetrazines, Scheme 7, faced some problems, the 
first of which was the low boiling point of methylisocyanate (39 ºC) and second one is 
the instability of the diazo-IC. The third is the failure to obtain some tetrazine products 
by using these reagents30 e.g. 4-thiotemozolomide was not formed by reacting 
methylisothiocyanate with 5-diazoimidazole-4-carboxamide in DMSO.30  
 
In 1997 Wang and Stevens31 modified the method for synthesis of temozolomide and its 
analogues. In this method, 4-aminoimidazole-4-carboxamide hydrochloride (AIC 10 
salt) instead of the potentially unstable diazoimidazole was used to react with the 
isocyanate to the urea 27, diazotization of the urea resulted in the unstable diazo urea 28 
which cyclised in situ to give the imidazotetrazinones 1, Scheme 9.30 
 
N N N
N
N
H2NOC
R
O
HN
NH
H2NOC
NH2
Cl
+ RNCO
DMSO
Et3N / 0 - 5  C
N N
H2NOC NH2
O
NHR
NaNO2
2M HCl/0-25 C
N N
H2NOC N+2
O
NHR
a R = Me
 b R = (CH2)2Cl
 c R = Et
 d R = Bn
10
27 28
1
oo
 
        Scheme 9. Alternative tetrazines synthesis without using of diazo-IC 
 
In an alternative synthesis,  Scheme 10,32 temozolomide  was prepared by the reaction 
of commercially-available, non-volatile ethyl isocyanatoacetate and diazo-IC 20 to give 
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ester 29 in 80% yield. Hydrolysis to the acid 30 was accomplished in 80% yield. The 
direct conversion of ester 29 or the acid 30 to temozolomide failed, so the carboxylic 
acid was converted to reactive mixed anhydride 31 with isobutylchloroformate/ N-
methylmorpholine and then to 1-substituted pyridine2(1H)-thione 32. Homolytic 
cleavage of 32 with AIBN (initiator) and tributyltin hydride gave   temozolomide, 1a 
Scheme 10. 
An alternative route to the ester 29 in Scheme 10, is by carbamoylation of the AIC 10 
used in form of its hydrochloride salt to give the urea 33 which cyclised to the ester 
29.32    
                                                                                            
N N
N
H2NOC N
N N N
N
N
CH2R
O
CONH2
29 R = CO2Et
HN NHCl
N N
H
N
NH2
CH2CO2Et
O
CONH2
33
i
iii
ii
iv
10
20
30 R = CO2H
31R = CO2CO2CH2CHMe2
32 R = O2CN
S
v
vi
vii
Temozolomide 1a R = H
viii
CONH2
NH2
           
Scheme 10. Reagents and conditions: (i) NaNO2 (excess), 2 M HCl 0 ºC; (ii) 
EtO2CCH2NCO, DMSO, pyridine, 20 ºC; (iii)EtO2CCH2NCO, DMSO, 25 ºC 
(iv)NaNO2, 2 M HCl, 0 ºC; (v) 5 M aq. HCl, 45 ºC; (vi) Me2CHCH2OCOCl, N-
methymorphine, DMF, –15 ºC; (vii) 2-mercaptopyridine-N-oxide, Et3N, –15 ºC; (viii) 
Bu3SnH, AlBN (catalyst), DMF, h, 25 ºC                                            
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In addition temozolomide can be synthesised via a condensation reaction between 
nitrosoimidazole 38 and hydrazides and subsequent cyclization of the resulted triazene 
39, Scheme 11.33 This gave temozolomide in an overall yield of 44%. In this method   
4-nitroimidazole 34 was used as starting material and the carboxamide substituent 
present in temozolomide was introduced to the starting 4-nitroimidazole in the form of a 
nitrile group to give the 5-nitro-4-carbonitrile 35. The 5-nitro-4-carbonitrile can also be 
synthesized by the cine substitution reaction of the 1,4-dinitroimidazole using potassium 
cyanate.34  Protection of the NH group of the imidazole ring of 35 with dihydropyran 
was used to give THP-derivative 36 which improves the imidazole solubility. 
Controlled reduction of the nitro group of 36 resulted in the hydroxylamine 37; 
oxidation of the hydroxylamine gave the nitroso compound 38.  Condensation of the 
nitroso compound with the hydrazide and the deprotection of THP resulted in the 
triazene 39, hydrolysis of the cyano group of 39 in strong acidic conditions resulted in 
the triazene with a carboxamide group 40. The cyclization of 40 was achieved by 
irradiation at 366 nm in acetone-MeOH to give temozolomide.  
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Scheme 11. Reagents and conditions: (i) HNO3, Ac2O, 85%; (ii) KCN, NaHCO3, 
MeOH, H2O; rt, 62%; (iii) dihydropyran, p-TsOH, EtOAc; (iv) H2, 10% Pt/C, EtOAc; 
rt, 60 min; (v) 2 eq. NaIO4 in H2O, EtOAc; 0 ºC, 30 min; (vi) DCM-AcOH 5:2; rt, 2 h; 
(vii) TFA-AcOH-MeOH 3:6:10; rt, 5 h; (viii) conc. Aq. HCl-AcOH 2:1; 60-65 ºC, 25 
min; (ix) acetone-MeOH 2:1, 366 nm; rt, 1 h.  
 
Regardless of the development of alternative methods of synthesis of temozolomide, 
which do not required the use of methylisocyanate or the potentially unstable diazo-IC, 
the original synthesis remains the method of choice for large scale and laboratory 
production of imidazotetrazinones.                                                                                          
1.3 Clinical Effects Imidazotetrazinones  
 
The antitumor activity of temozolomide is largely attributed to the methylation of 
DNA,15 it is mediated via the formation of O6-methylguanine adducts. Although this 
accounts for only a small percentage of DNA adducts that are formed, it is potentially 
carcinogenic, mutagenic and cytotoxic.35 
 In addition to the inhibitory effect on DNA replication, DNA methylation by 
temozolomide may also disturb other DNA-dependent processes, such as regulation of 
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gene expression. A series of studies showed that temozolomide could induce 
differentiation in the K562 human erythroleukaemia cell line.36 
It was also suggested that the formation of a carbamoylating isocyanate as in case of 
mitozolomide, may result in the inhibition of certain enzyme activities, such as the 
inhibition of cellular esterase activity observed in EMT6 mouse mammary tumour 
cells.37 
Early pre-clinical experimentation with temozolomide indicated that it possessed good 
antitumour activity when administered intraperitoneally (i.p.) against both 
haematological (L1210 and P388 leukaemias) and solid (e.g. M5076 sarcoma, 
ADJ/PC6A plasmacytoma, B16 melanoma, Lewis lung carcinoma) murine tumour 
models.3 This activity was found to be schedule-dependent,3 with multiple 
administrations being more effective than a single bolus dose.  
Like mitozolomide, temozolomide demonstrated good tissue distribution, including 
penetration across the blood-brain barrier, and was found to have a bioavailability of 
0.98 when administered orally.38 Antitumour activity was therefore maintained when 
temozolomide was administered orally to L1210-bearing mice.3 
The plasma pharmacokinetics of temozolomide following oral administration to mice 
were characterized by a rapid absorption phase (the peak plasma concentration of 
temozolomide being achieved within 30 min of administration) and mono-exponential 
elimination (with elimination half-life of 1.29 h).3 
The predominant route of temozolomide elimination is by renal excretion and occurs 
with 5 – 10% as unchanged drug, although an unidentified acidic urinary metabolite is 
also produced.39 These observations were found to correlate with the subsequent finding 
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of phase I clinical studies, which indicated that rapid absorption of temozolomide also 
occurred in man (the peak plasma concentration occurred within 0.7 h of oral dosing) 
and the drug elimination could be best described by a one-compartment model with a 
half-life of 1.81 h.8 
In addition to the unresolved metabolite, the urine of patients was also found to contain 
the     8-carboxylic acid metabolite of temozolomide, which has equivalent cytotoxicity 
to temozolomide and is thought to be generated extrahepatically.39 
Temozolomide crosses the blood-brain barrier with 9 – 29% of the serum concentration 
detected in the cerebrospinal fluid.40 Biodistribution has also been studied by PET 
scanning, by using 11C4 and 11CH3 lablled temozolomide, to investigate the uptake of 
the drug by brain tumours. This study confirmed the capability of temozolomide to 
cross the blood-brain barrier.41  
The pharmacokinetics of temozolomide were explored, by the analysis of plasma after 
the treatment with temozolomide or the 11C-lablled temozolomide and for its 
metabolites and the breath analysis for the 11CO2. The study showed the higher levels of 
11CO2 in the plasma and the breath and lower level of temozolomide, this provides 
evidence that temozolomide undergoes decarboxylation and ring opening in plasma. On 
other hand positron emission tomography (PET) imaging was used to confirm that              
11C- labelled temozolomide at the methyl group, achieved a selective methylation to 
brain tumors relative to the surrounding healthy brain tissue.41  
Treatment with temozolomide is schedule-dependent,3 a 5-day schedule repeated every 
28 days was studied. The recommended dose of temozolomide is 200 mg/m2 daily for   
5 days repeated every 4 weeks.  No clinical activity was seen with the single dose 
 21 
 
schedule but activity was seen in some patients with melanoma and a patient with 
mycosis fungoides.8 
Temozolomide was used in a trial treatment of metastatic malignant melanoma and it 
showed activity comparable with other currently-used agents. In addition to its uses in 
the central nervous system tumours, temozolomide shows 8% response in soft tissue 
sarcoma. However no response was shown in renal cell cancer42 and biopsies taken in 
this study demonstrated high levels of O6-methlguanine-DNA methyltransferase 
(MGMT) a protein responsible for repair of DNA damage caused by temozolomide in 
kidney tissue.43    
The cytotoxicity of temozolomide is affected by different DNA-repair mechanisms. 
Scheme 12 shows some of these mechanisms and their relationship to the cyototoxicity 
of temozolomide: 
 
1) O6-methylguanine-DNA methyltransferase (MGMT); 
2) DNA – mismatch repair (MMR); 
3) Base excision repair (BER). 
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Scheme 12. The role of the different DNA repair mechanisms in the cytotoxicity of 
temozolomide 
                                                                                                                                                               
1.4 Resistance to Temozolomide treatment 
  1.4.1 O6-Methylguanine-DNA methyltransferase MGMT 
 
DNA damage by temozolomide is liable to repair by the protein ATG which also known 
as O6-methylguanine-DNA-methyltransferase (MGMT), which is a protein considered 
as one of the components of cellular resistance to alkylating drugs. It repairs many 
adducts at the O6-position of guanine including ethyl-, 2-chloroethyl- and other 
aliphatic groups and also benzyl and pyridyloxobutyl adducts. MGMT works by 
accepting the methyl group from the O6-Me guanine in DNA to an internal cysteine 
residue (Cys145) within its active site. It works through a Glu-His-Water-Cys hydrogen 
bonded network, in which His146 acts as a water-mediated base resulting in the 
formation of the thiolate anion at Cys145 to act as a nucleophile to cleave  a methyl 
group from the O6-G, in an irreversible stoichiometric reaction. This restores guanine in 
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DNA but inactivates MGMT, Scheme 13.44 The protein mechanism of action requires 
different roles to be played by the different domains that form its structure, some of the 
amino acids form the DNA binding site responsible for the conformation that leads to 
the flipping of the methylated guanine in to the active catalytic site in a suitable 
orientation to the Cys145 for methyl transfer. Arg128, located at the beginning of the 
recognition helix is an arginine finger that interacts through the minor groove via 
charged hydrogen bond with the orphaned cytosine (previously base paired to the 
flipped-out guanine) to stabilise the extrahelical DNA conformation, Figure 4. This is in 
addition to the role of the hydrophobic part of the active site which responsible for the 
selectivity of the protein to repair the O6-methylated guanine.45 
          
Figure 4. MGMT bond to DNA showing the flipped-out O6MeG in the active site of 
the protein and the Arg128 finger stabilizing the extrahelical structure of DAN by 
hydrogen bonded to the orphaned cytocine. Figure courtesy of Richard Wheelhouse 
using coordinates from refrence no 46.46 
 
The protein, after accepting the methyl group, undergoes proteolysis, the restoration of 
activity and the protective mechanism require de novo protein synthesis which takes up 
to 72 h.47 
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Scheme 13. Proposed reaction mechanism for MGMT, His 146, by intervention of a 
bridging water molecule, deprotonates Cys145 to facilitate nucleophilc attack at the O6-
alkylcarbon with simultaneous protonation of N3 by Tyr11448                                                
                                                
Generally the level of MGMT in tumour cells is higher than normal cells especially in 
higher grade glioma  and in advanced ovarian carcinoma.49 
Studies have suggested a link between pre-treatment MGMT levels and clinical 
outcome.50 Glioblastoma and melanoma, the tumours that are currently treated with 
temozolomide, show the lowest mean MGMT concentration.51  
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Inactivation of alkyltransferase 
 
An important factor in developing anticancer therapies that target MGMT is that 
MGMT-mediated repair is stoichiometric. Therefore, since one MGMT molecule is 
needed for each offending alkyl-G molecule, the level of MGMT in the cell can be 
completely depleted by excess O6-alkylated guanines. Reaction with any O6-
alkylguanine pseudosubstrate can inactivate it and, once removed, the restoration of 
activity and the protective mechanism require new protein synthesis which takes up to 
72 h.47 Therefore treating cell with non-toxic MGMT pseudosubstrates e.g O6-
benzylguanine inactivates MGMT through the covalent transfer of the benzyl group to 
the active site cysteine and by doing so, sensitises tumor cells to temozolomide and 
other alkylating agents such as BCNU. Benzylguanine is rapidly converted to another 
equally potent MGMT inhibitor, 8-oxo-O6-benzylguanine in human by CYP1A2 and 
CYP3A4. Therefore, combination with DTIC is not appropriate because DTIC 
activation occurs using the same enzymes. The irreversible mechanism of MGMT has 
been used clinically in the pre-treatment of patients with agents that react with the 
protein and result in its inactivation, which then enhance the antitumour activity of the 
alkylating drug.52 
O6-Benzylguanine (O6-BG) 41 has been used since it is a good substrate for the 
enzyme; the benzyl group is a more efficiently displaced group than methyl group 
(methylguanine) in the bimolecular displacement reaction, the stability of the benzyl 
carbocation over that of the methyl one is behind this advantage of benzyl guanine.53 
Near-complete inactivation (>99.5%) of MGMT activity was achieved with 5 μM O6-
benzylguanine for 4 h, while 100 μM O6-methylguanine was needed to obtain a 
maximal effect of 80% reduction in the protein activity. 53  
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 Pretreating cells with MGMT activity of >15 fmol/mg protein with the MGMT 
inhibitor, O6-benzylguanine (O6-BG), potentiated chemosensitivity to temozolomide. 
In contrast, O6-BG did not sensitise a cell line (ZR-75-1) expressing very low levels of 
this protein. When BG pretreatment was combined with repeat doses of temozolomide a 
dramatic potentiation (300 fold) was seen in MAWI cells, which express high levels of 
MGMT, but not in a cell line (U373) expressing lower levels of MGMT.12  
O6-(4-bromothienyl)guanine (PaTrin-2) 42 is another agent under development as a 
pre-treatment to enhance the activity of temozolomide and other alkylating agents. It is 
orally available and more potent in decreasing the maximum tolerated dose of the 
alkylating agent than O6-BG.54 It was synthesized during the clinical trials of O6-BG 
which was started late in 1992 at Trinity College Dublin. The study showed that 
replacement of the benzyl group of O6-BG with a heterocyclic ring as in case of O6-
furfurylguanine 43 and O6-thenylguanine (PaTrin-1) 42 led to improvement in the 
activity as an MGMT inhibitor. The IC50 of O6-BG, O6-furfurylguanine and O6-
thenylguanine were 0.02, 0.03 and 0.018 M respectively.54    
The large size of the sulphur atom in the thiophene ring gives similar steric character as 
the six membered ring of the benzyl group in O6-BG.55 The introduction of halogen 
substituents on the thiophene ring of PaTrin-1, confered the greatest activity, of which 
the bromo group at position 4 provided the most active O6-(4-bromothenyl) guanine 
(PaTrin-2) 42 (IC50 0.0034μM).54  
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1.4.2 DNA – mismatch repair 
MMR is a system for recognizing and repairing erroneous insertions/deletions loops 
(IDLs), and mis-incorporation of bases that can arise during DNA replication and 
recombination, as well as repairing some forms of DNA damage. It primarily corrects 
single base-pair mismatches and small misalignment IDLs, which arise during 
replication. The MMR is strand-specific. As the newly synthesized (daughter) strand 
commonly includes errors, the MMR machinery distinguishes the newly-synthesized 
strand from the template, excising the mismatch nucleotide from the nascent strand, 
therefore providing the DNA polymerase with another chance to generate an error-free 
copy of the template sequence. In the absence of MMR base-base mismatches remain 
uncorrected, which results in a mutator phenotype that may turn into cancer. The MMR 
machinery has to satisfy two criteria: 
1) it must efficiently recognise base-base mismatches and IDLs; 
2) it must direct the repair machinery to the newly-synthesised DNA strand, which 
carried the erroneous genetic information. 
The MMR system is also involved in the signalling and / or the appropriate processing 
of different types of DNA damage: MMR-deficient cell lines are more resistant to death 
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that is induced by several different types of chemical than matched MMR-proficient 
ones. Some cell lines that express low levels of MGMT still show resistance to 
temozolomide, which indicates that other mechanisms for resistance, may be involved. 
This is due to low levels of the mismatch repair mechanism (MMR).56, 57  
There are two types of mismatch repair: long patch and short patch. Long patch can 
repair all types of mismatches (although it is primarily replication associated) and can 
excise tracts up to a few kilobases long. Short patch repair handles only specific 
mismatches caused by damage to the genome, and removes lengths of around 10 
nucleotides. Successful mismatch repair requires the error-free execution of three 
events:58 
1) detection of a single mismatch, of which there are eight kinds, in the newly-
synthesized DNA;  
2) determining which of the two bases in the pair is incorrect;  
3) correcting the error by excision repair.  
The mismatch repair machinery has a number of cues which distinguish the newly 
synthesized strand from the template (parental). In gram-negative bacteria transient 
hemimethylation distinguishes the strands (the parental is methylated and daughter is 
not). In other prokaryotes and eukaryotes the exact mechanism is not clear.58 
The intact DNA-mismatch repair pathway is very important for temozolomide activity 
and any mutation affecting the correct functioning of the pathway results in loss of 
sensitivity to temozolomide. Figure 5 shows the mismatch pairing of O6-MeG to 
thymidine as a result of guanine methylation with temozolomide. The recognition of 
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mismatch pairing by the active MMR mechanism following DNA replication, leads to 
the futile cycle of deoxythymidine excision and replacement opposite the modified 
guanine site of the parent strand, that generates long lived-strand breaks,  which end in 
apoptotic cell death.59      
C G
CH3N2
+
Temozolomide
CO6-MeG
TO6-MeG
O6-MeG
Replication
Apoptosis
Futile mismatch repair loop
                
                  Figure 5. Mechanism of temozolomide cytotoxicity.59        
                                           
1.4.3 Base excision repair and PARP 
Base excision repair (BER) is a cellular mechanism that can repair damaged DNA 
during DNA replication. Repairing DNA sequence errors is necessary so that mutations 
are not induced during replication. 
Single bases in DNA can be chemically mutated, for example by deamination or 
alkylation, resulting in incorrect base-pairing and consequently mutations in the DNA. 
Base excision repair is a family of enzymes that catalyze reactions collectively 
responsible for efficient repair of DNA. 
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The BER pathway begins with the excision of a damaged base by an enzyme called 
DNA glycosylase. DNA glycosylases bind to chemically-altered (damaged) bases and 
catalyzes the cleavage (hydrolysis) of the bond linking the modified base to its sugar, 
which result in the release of the modified base from the DNA chain. In order to fill the 
gap (replace the missing nucleotide), DNA polymerase inserts the correct nucleotide 
into the gap and links it to the normal nucleotide.  
Temozolomide cytotoxicity correlates largely with the formation of O6-MeG. However 
this is one of several methylation sites in DNA, with 70% of lesions caused by the drug 
at N7-position on guanine. Repair of this lesion by BER results in lack of toxicity 
through this alkylation.60 
Poly(ADP-ribose)polymerase (PARP) is involved in sensing and signalling of DNA 
damage generated by methylating agents at N7. Non-toxic PARP inhibitors such as      
3-aminobenzamide 44, benzamide 45, 3,4-dihydro-5-methoxyisoquinolin-1(2H)-one 46 
and 8-hydroxy-2-methylquinazolin-4(3H)-one 47 enhance the cytotoxicity of 
temozolomide-generated N 7-guanine methylation in tumour cell lines, Scheme 11.61 
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1.5 Design and Rationale 
 
The limitation of temozolomide treatment, represented in the repair mechanisms 
discussed in the previous section, promotes the design and synthesis of new 
imidazotetrazinones that may possess all the advantage features of the 
imidazotetrazinones that are shown by temozolomide: 
i) good delivery system as a prodrug; 
ii) acid stable then orally intended, in addition to 100% oral availability; 
iii) crossing of the blood brain barrier; 
iv) it is chemically activated, no need for metabolic activation; 
v) tumour localizing potential. 
In addition, other new structure features may enable their overcoming the clinical 
limitations of temozolomide. In this study the imidazotetrazinone synthesis was planned 
for the release aziridinium ions upon the aqueous hydrolysis and ring opening at 
physiological pH 7.4. Aziridines are clinically-useful intermediates, sufficiently stable 
to find their target on DNA as shown by other alkylating agents e.g. the nitrogen 
mustard alkylating agents cyclophospamide, melphalan, chlorambucil and nitrosoureas, 
e.g. BCNU.62 
1.5.1 Aziridinium ions of biological interest 
 
Aziridinium ions have received much attention in biological studies, several aziridinium 
ions generated in situ from halogenated ethylamines are reagents for the alkylation of 
biological nucleophiles (nucleic acids, proteins); the formation of aziridinium ions from 
the antitumour nitrogen mustard 2-chloro-N-(2-chloroethyl)-N-methylethanamine, is 
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believed to be the first step in the cross linking of double stranded DNA and consequent 
antitumour action of this drug of the nitrogen mustard class, 62 Scheme 14.   
 
              
NN
ClCl
Cl
Cl
                         
                    Scheme14. Cyclisation to the aziridinium ion in nitrogen mustard  
 
Moreover, the in situ generation of aziridinium ions from diethyl-2-chloroethylamine 
hydrochloride at pH 7 and 37 ºC, has been applied as a measurement technique to 
compare the alkylation reactivity of nucleic acid bases in double helical DNA, 
polynucleic acids and monomer nucleic acid bases. It was used to compare 1) the 
influence of the stacking of the bases in double helix DNA on enhancing such 
alkylation, 2) the effect of the negative phosphate of the backbone in increasing their 
nucleophilicity, and 3) the effect of the hydrogen bonds in blocking the reactive 
nucleophilic centres e.g adenine base compared with the accessible nucleophiles of 
guanine. The study reflects the helpful in situ generation of aziridinium ions in 
identifying bases of high potential for such alkylation. Guanine in double helical DNA 
was found to be of the highest potential compared with other bases.63 
 
 In another application, aziridinium ions 49 from N-(2-chloroethyl)norapomorphine 48, 
Scheme 15 were used in a dopamine antagonist, for their irreversible alkylation of a 
membrane receptor. Another application for aziridinium ions, they were used based on 
the similarities that they possessed to parts of certain molecules or its affinity to interact 
irreversibly with certain reactive parts or interacting with a proteins carriers.62  
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                 Scheme 15. Aziridinium ion from N-(2-chloroethyl)norapomorphine 
 
Scheme 16 outlines another application for aziridinium ions in the synthesis of 
glucosylceramide synthase inhibitor 50. Glucocerebroside, 1-O-β-D-
glucopyranosylceramide is widely distributed in normal and pathologenic tissue, 
including normal human serum, plasma, erythrocytes, kidney and aortic tissue, as well 
as in the central nervous system. It is the major cerebroside found in the spleen of 
patients with Gaucher’s disease. The biosynthesis of glucosylceramide relies on the 
coupling of UDPglucose to C-1 of an N-acylsphingosine (ceramide) mediated by 
glucosylceramide synthase, inhibition of this process is a promising target for cancer 
chemotherapy.64 
 
In this study the new imidazotetrazinones were designed to combine the advantages of 
the imidazotetrazinone nucleus, with the possibility of formation of aziridinium ions 
using an ethylamine side chain, upon the ring opening the new imidazotetrazinones may 
result in a good delivery prodrug for aziridinium ions to their site of action.  
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Scheme 16. Synthesis of glucosylceramide synthase inhibitor 50. Reagents and 
conditions: (i) C12H25CHO, TsOH, C6H6, heat (98%); (ii) AlCl3, LiAlH4, Et2O (91%); 
(iii) Ti(OPri)4, (+)-DET, TBHP, CH2Cl2 (76%); (iv) TsCl, pyridine (70%); (allyl)2NH, 
KI, DMF (81%); (v) TMSOTf, CH2Cl2, – 78 °C; (vi) morpholine, – 78 °C to rt; K2CO3, 
MeOH (61%); (vii) Pd/C, MeSO3H, H2O (82%); (viii) p-nitrophenyl palmitate, pyridine 
(63%) 
 
1.5.2 Design of Aziridinium-ion-release imidazotetrazinones 
 
Imidazotetrazinones, designed with an ethyl substituent at position 3 linked to an 
aliphatic or aromatic amino group contain the functional groups required to result in 
aziridinium ion formation. The design considers all the possible substitutions on the 
amine side chain and the aromatic ring that can result in different influences on the 
stability of the synthesized molecule and required for the optimum reactions in the 
aqueous conditions later. Accordingly, the pH-influenced ring opening of the new 
designed imidazotetrazinones should result in ethyldiazonium ion 52 with an internal 
nucleophilic nitrogen atom, which then reacts in a favoured 3-exo-tet intramolecular 
cyclization reaction in which the diazo group leaves as molecular nitrogen and results in 
the aziridinium ion. The process was design to resemble the release of the chloronium 
ion from mitozolomide 1b, Scheme 4, and the aziridinium ion release by nitrogen 
mustards, Scheme 14.62  
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According to the above mentioned features, the new imidazotetrazinones showed in the 
general structure 51 are predicted to undergo aqueous hydrolysis at neutral pH 
according to Scheme 17 to AIC 10 and diazonium ion 52 that may cyclise subsequently 
to an aziridinium ion, 53. 
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R, R' Aliphatic and / or Aromatic groups. 
              Scheme 17. The proposed mechanism of general imidazotetrazinone 51    
 
According to the designing scheme 17 the targeted molecules for synthesis are: 
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Chapter 2 Synthesis of Imidazotetrazinones for 
Aziridine Release 
2.1 Introduction 
The target molecules for synthesis were defined at the end of the previous chapter and 
are summarised in Figure 6 
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        H       
      CH3
       R'
       H     
       CH2Ph
x =  F         
       OCH3 
       CH3
 
                                            Figure 6. Target molecules for synthesis 
2.2 Synthesis 
 
The retrosynthetic analysis outlined in Scheme 18 was used to plan the route of the 
synthesis of the target imidazotetrazinones. The disconnection follows the original 
synthesis of imidazotetrazinones by Stevens et al.6 The synthesis starts with the 
preparation of isocyanates which are then reacted with diazo-IC to from the 
imidazotetrazinones. This retrosynthetic analysis was used for all imidazotetrazinone 
compounds in this thesis.  
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                        Scheme 18. General retrosynthesis plan for imidazotetrazinones  
β-Aminoisocyanates, 60,  are highly unstable compounds, able to undergo cyclization 
by nucleophilic attack of the amino group on the isocyanate group, this makes the 
protection of the amino group crucial for ensuring their stability against such 
cyclization. The substituents shown on the amino group nitrogen of the isocyanate in 
Scheme 18 were either a BOC protecting group or an aromatic ring, both were required 
to add a steric effect and an electronic effect to reduce the reactivity of the lone pair on 
the nitrogen, by doing so they prevent the favoured 5-exo-trig intramolecular reaction 
with the isocyanate group. A BOC group was used as a protecting group for the 
isocyanates synthesized from aliphatic amines, its bulk (hindrance effect) and electron-
withdrawing effects greatly increased the stability of the isocyanates, Figure 7. 
                  
N
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ORR  
              Figure 7. Carbamate resonance contribution to β-aminoisocyanate stability 
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In the case of the isocyanates synthesized from aromatic amines (anilines) the aromatic 
ring and the N-methyl group add steric hindrance around the nitrogen of the amine; 
delocalization of the unshared electrons of the nitrogen into the aromatic ring also 
reduced its nucleophilicity towards the isocyanate group, Figure 8.   
N
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C
OR
N
N
C
OR
N
N
C
OR       
                                Figure 8. Aromatic ring contribution to isocyanate stability                                  
The bisimidazotetrazinone synthesis was designed to react a suitable bisisocyanate with 
diazo-IC 20. The retrosynthetic analysis outlined in Scheme 19 showed that the 
bisisocyanate was synthesized from an aliphatic or aromatic amine. BOC protection was 
again used in the case of the aliphatic amines; bisisocyanates synthesized from anilines 
were used without additional protection.  
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                    Scheme 19. Retrosynthetic plan for bisimidazotetrazinones 
 
 39 
 
2.2.1 Synthesis of the Isocyanates 
Routes to Isocyanates 
 
There are many different routes by which isocyanates can be synthesized. They differ in 
their yields and the ease of isolation of the pure isocyanate.  The following methods are 
examples that show different ways of isocyanate synthesis from industrial to research 
laboratory  methods. 
1) Isocyanates from amines and phosgene/triphosgene 
i) The generation of amino acid ester isocyanates has been achieved in 
yields of 72% – 95%  by the addition of a commercially-available 
solution of phosgene in toluene to a mixture of an amino acid ester 
hydrochloride and pyridine,65 Scheme 20. 
       
OR'
H3N
R
O
Cl + COCl2 solution in toluene
pyridine / CH2Cl2
0  C / 2ho OR'
OCN
R
O
                                                                                                                   
                                        Scheme 20. Isocyanates from amines and phosgene 
ii) In a related preparation, reaction of aliphatic amines with 
trichloromethyl chloroformate (diphosgene) at 0 ºC in the presence 
of the non-nucleophilic base 1,8-bis(dimethylamino)naphthalene can 
afford isocyanates in yields of  78% , Scheme 21. 66 
              
R NH2 + Cl OCCl3
O
+
NMe2NMe2
DCM
º0 C
R NCO
 
                            Scheme 21. Isocyanates from aliphatic amine and diphosgene  
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iii) The synthesis of isocyanates by heating amines and triphosgene in 
ethyl acetate affords a 56% yield, Scheme 22. 
           O O Cl
Cl
Cl
Cl O
ClCl NH2+
NCOEtOAc
 
                             Scheme 22. Isocyanate from triphosgene and amines 
The toxicity of the phosgene and quantity of HCl produced during the reaction limit the 
use of this method. The potential for salt formation made this method unsuitable for     
β-aminoisocyanate formation.  
2) Thermolysis of ureas and carbamates 
i) Isocyanates from the mild reaction of an active carbonate and an 
amine. Reaction of alkylamines and arylamines with the active 
carbonate di-tert-butyl dicarbonate (BOC2O), in the presence of 
DMAP gives isocyanates in reported yields, which range according 
to the hindrance around the amine, from 49% – 97%,67 Scheme 23. 
Although it is a quick reaction (10 min) the isolation methods used 
are not suitable for amino-isocyanates: in one method strong 
sulphuric acid was used which might drive the amino-isocyanate into 
the aqueous layer; another method used cold column 
chromatography for purification which might increase the loss of 
material in small scale production in the case of amino-isocyanates; 
moreover, recombination of the isocyanate product with tert-butanol 
is possible which greatly reduced the yields.  
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                       Scheme 23. Isocyanates from active carbonate and amines 
 
ii) The conversion of carbamate esters to isocyanates and diisocyanates 
of industrial importance is possible using BCl3 in the presence of 
Et3N; the reaction is simple in execution and work-up, occurring 
under mild conditions and affording isocyanates in excellent yields 
70 – 79%,68 Scheme 24. Although good yields are generated from 
this method which is mainly used in industry, usage of a Lewis acid 
limits its application for amino-isocyanates due to the basic nitrogen 
that could associate with it. 
R
N
H
O
O
R'
Et3N
B
Cl
Cl Cl
Et3NH
R N
BCl2
O
O
R'
RNCO + BCl2(OR')
     
          Scheme 24. Isocyanates from carbamates, employing boron trichloride   
 42 
 
iii) Isocyanates synthesized by thermolysis of  carbamate esters 
(urethanes).69 
In this method an alcohol is eliminated from a carbamate ester in the 
presence of chlorocatecholborane 61 and triethylamine. The 
chlorocatecholborane combines with the alcohol that results from the 
decomposition of the urethane and avoids the back reaction of 
alcohol with the produced isocyanate. This method is used for large 
scale production of isocyanates in industry, the yields range from 
45% – 70%, Scheme 25. 
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R
OMe
O
+ Et3NHCl
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B + R
N
C
O
OMe
61
                    
                   Scheme 25. Thermolysis of carbamate esters to isocyanates 
3) Isocyanates from alkyl halides and silver cyanate 70 
Benzyl isocyanate has been prepared by the reaction of silver cyanate with 
benzyl bromide or chloride, the product purity by this method was not good and 
the product was always contaminated with chlorine or bromine, Scheme 26. 
          
Br O
C
N
Ag+
NCO
+ AgBr
 
                     Scheme 26. Isocyanates from alkyl halides and silver cyanate 
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4)  Curtius rearrangement 
i) In situ generation of isocyanate 63 was achieved by heating of azide 
62 in toluene and subsequently trapped by N-hydoxysuccinimide to 
form the carbamate 64 in a yield of 60%. In this method, BOC- 
protected amino acids were converted to acyl azides by reaction of 
their mixed anhydrides (formed with ethyl chloroformate / N-
methylmorpholine [NMM] with NaN3, Scheme 27.71 This method is 
quite similar to the method selected in this study.    
           
N
H
O
OH
R
O
O i,ii
N
H
O
N3
R
O
O
iii
iv
N
H
H
N
R
O
O
O
N
O
O
O
62
63 64
O
O
N
H
R
NCO
 
Scheme 27. Reagents and conditions: (i) EtOCOCl, NMM, THF, – 20 ºC; (ii) NaN3, 
H2O; (iii)    toluene, 65 ºC; (iv) N-hydroxysuccinimide, pyridine. 
 
ii) Direct conversion of a carboxylic acid to a urethane may be achieved 
by heating under reflux an equimolar mixture of the carboxylic acid, 
triethylamine and the thermally-stable diphenylphosphorylazide 
(DPPA) in the presence of an alcohol for 5 – 25 h. This reaction is a 
modified Curtius method, performed through the intermediate 
carboxylic acid azide which undergoes thermolysis to the isocyanate. 
It was then reacted with the alcohol to form a urethane 50 – 75% 
yields.72 The method showed the in situ usage of the isocyanate so 
no isolation methods for the isocyanate were mentioned, Scheme 28. 
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                        Scheme 28. In situ isocyanate generation in urethane synthesis  
iii) Thermal sigmatropic rearrangement or Curtius rearrangement is the 
thermal decomposition of carboxylic azides to produce isocyanates, 
this method is the most convenient, the product purity is relatively 
high as only nitrogen is generated as a by-product from the 
thermolysis of the azide.73 
                       R N
O
N
N
N2 + R NCO    
Curtius rearrangement is a thermal rearrangement of carboxylic acid azides. There are 
different syntheses of azides available. Examples include reacting activated acid 
derivatives e.g. acid chlorides or acid anhydrides with NaN3 or by heating a carboxylic 
acid and the thermally-stable organic azide DPPA in the presence of triethylamine. In 
the latter reaction, the carboxylate anion reacts in a nucleophilic substitution reaction 
with phosphyl azide to form the acylazide, Scheme 28. Diazotization of hydrazides is 
another method of azide synthesis. The hydrazides were synthesized from activated acid 
derivatives by their reaction with hydrazine.  
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In our laboratory the Curtius rearrangement has been frequently used for the synthesis 
of isocyanates: anhydrous solvents and dry conditions have been applied to generate 
material that needs little purification. Azides have been synthesized from the 
diazotization of hydrazides in a mixed aqueous/organic solvent system using NaNO2 
and a suitable acid, Scheme 29; the hydrazides were formed by reaction of esters with 
hydrazine monohydrate. This route consists of three steps through which the purity of 
the isocyanate can be achieved. At the ester stage, purification could be by solvent 
selectivity or distillation; the hydrazides were then pure. The hydrazide stage is a further 
purification step, especially as most were solids and could be readily recrystallised.  
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Scheme 29. Reagents & conditions: i) NH2NH2·H2O, EtOH or i-PrOH; ii) NaNO2 / 
Acid, 0 ºC; iii)   anhydrous DCM, rt (R, R′ either BOC aliphatic or aromatic). 
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2.2.2 Synthesis of imidazotetrazinones for aziridinium ion release 
 
Two types of imidazotetrazinone for the release of aziridinium ion were synthesised: 
1) imidazotetrazinones bearing aliphatic amines; 
2) imidazotetrazinones bearing anilines. 
2.2.2.1 Imidazotetrazinones bearing aliphatic amines: 
 
 Synthesis of the 3-(2-aminoethyl)-imidazotetrazinone HBr salt 54 
 
                                                     
N N
N
N
N
O
NH2O
Br
54
NH3
  
 
                                                                                                                            
In this method, the BOC-protected aminoacid ester was used to avoid the reaction of the 
free amino group with the isocyanate group. In one trial reaction, acetyl protection was 
used, Scheme 30. Synthesis of the hydrazide 67 was successful but isocyanate 69 was 
not isolated. Analysis of the reaction mixture at the thermolysis stage by IR did not 
show the characteristic strong band at 2275 cm-1 of the isocyanate. Cyclic urea 70 
formation was confirmed by 1H NMR as a result of cyclization of                   
N-acetylaminoethylisocyanate 69; the mass spectrum showed cyclic urea (M+H)·+ m/z 
129.3 and the IR showed  bands at 1653 for NHCONH and 3261 for CONH instead of 
the isocyanate band. This result showed that the acetyl group is not sufficiently 
electron-withdrawing or bulky for such protection.  
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 Scheme 30. Cyclization of acetyl-protected-β-aminoisocyanate 69. Reagents and 
conditions: (i)acetic anhydride, Et3N, DCM, 40 ºC, 95%; (ii) NH2NH2·H2O, i-PrOH, 
60%; (iii) NaNO2 / HCl 37%, DCM/H2O, 0 – 5 ºC; (iv)   anhydrous DCM, rt.  
 
 
Changing to BOC protection74 facilitated preparation of the isocyanate 71, which was 
reacted further under nitrogen with diazo-IC 20 in anhydrous DMSO to give a BOC-
protected imidazotetrazinone. The process of the synthesis started by converting β-
alanine methylester 72 to the BOC-protected ester 73 then to hydrazide 74 by reaction 
with hydrazine monohydrate.75 Diazotization of hydrazide 74 using aqueous 
NaNO2/HCl gave a product presumed to be azide 75,76 Scheme 31. An isocyanate was 
prepared by Curtius rearrangement of the azide.73 The isocyanate was reacted with 
diazo-IC to give an imidazotetrazinone.77 Characterization (MS, CHN, 1H NMR) of the 
compound presumed to be protected tetrazine 76, showed that the isolated molecule 
differed from that expected.  
The backward checking of the reaction process and the 1H NMR of the intermediates, 
showed that at the stage of the azide preparation by  hydrazide diazotization, a nitroso 
group had been introduced at the carbamate nitrogen  i.e. N-nitrosoamide 79 was 
formed rather than BOC-protected amine 76, Scheme 32. This was not surprising as 
these are the exact conditions used for the synthesis of N-nitrosoamides.78 The 1H NMR 
spectra of ester 73 and hydrazide 74 both show a peak due to the BOC-NH-  at δ 5.18 
whereas the same peak disappeared from the 1H NMR of the azide 77, the  isocyanate 
78 and  the imidazotetrazinone 79. Accurate mass measurement LSIMS (FAB) showed 
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(M+H)  ٠ + m/z 353 and the elemental analysis showed molecular formula C12H16N8O5 
which fits imidazotetrazinone 79 with the N-nitroso group, Scheme 32. 
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Scheme 31. Expected synthesis route to the imidazotetrazinone salt 54. Reagents and 
conditions:  i) BOC2O, Et3N, 100 ºC, 60%; ii) NH2NH2.H2O, i-PrOH; iii) NaNO2, 10 M 
HCl, DCM/H2O; iv) anhydrous DCM, 30 ºC, 48 h; v) 20, DMSO, 30 ºC vi) HBr 48%, 
acetonitrile, rt. 
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Scheme 32. Route to the imidazotetrazinone salt 54. Reagents and conditions: (i) 
BOC2O, Et3N, 100 ºC, 60%; (ii) NH2NH2.H2O, i-prOH, 94%; (iii) NaNO2, 10 M HCl, 
DCM/H2O, 68%; (iv) anhydrous DCM, 30 ºC, 48h, 60%; (v) 20, DMSO, 30 ºC, 14%; 
(vi) HBr 48%, acetonitrile, rt, 88%.    
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Deprotection of the BOC group was achieved in acetonitrile using HBr, Scheme 32. 
This reaction resulted in both deprotecting the BOC group and reduction of the N-
nitroso group which was removed in the form of ammonia to give the hydrobromide salt 
54, which precipitated from acetonitrile. Another solid was collected by evaporation of 
the acetonitrile layer. This solid was found to contain, in addition to salt 54, another 
imidazotetrazinone. Spiking with authentic 3-(2-bromoethyl)imidazoterazine-4-one 1d 
prepared from commercially-available 2-bromoethylisocyanate confirmed its identity, 
Figure 9.  
 
Figure 9 Confirmation of the identity of the by product as 3-(2-
bromoethyl)imidazotetrazinone-4-one 1d. Spectra of the mixture (A), tetrazine salt 54 
(B), spiked with bromoethylimidazotetrazinone 1d (C).  
 
A proposed mechanism for the acid-catalysed deprotection of the tetrazine 79 is shown 
in Scheme 33. In route A HBr reduction of the N-nitrosamide could lead to the BOC-
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protected amine 76 with the loss of ammonia in form of ammonium bromide; 
subsequent acidolysis of the BOC group would give the amine hydrobromide salt 54. 
Evidence that the N-nitroso may be cleaved by reduction route A appears on page 60, 
where its reduction proceeds with unexpected bromination of aniline ring. However, if 
the BOC group cleaved first, route B, reaction of the N-nitrosoamine could yield the 
alkyldiazonium intermediate 80. Nucleophilic substitution by bromide ion would give 
the 3-(2-bromoethyl)imidazotetrazinone-4-one 1d. 
The N-nitroso group gave the impression that it acts as a separate protecting group, the 
ease of its removal resulted in the imidazotetrazinone hydrobromide salt 54 in higher 
yield compared with the byproduct 3-(2-bromoethyl)imidazotetrazinone-4-one 1d 
(10:1). Consideration of likely reaction mechanisms suggests that the nitrosocarbamate 
competes with the BOC during acid deprotection such that the final product obtained is 
determined by the site of first protonation.  
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Scheme33. Mechanism for the formation of the amine salt 54 and 
bromoethylimidazotetrazinone 1d from N-BOC-N-nitroso tetrazine 79. 
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Synthesis of the aliphatic amine-linked-bisimidazotetrazinone 55 
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The route that led to bisimidazotetrazinone salt 55, started with the synthesis of the 
dimeric ester 82, Scheme 34, which was prepared by the aza-Michael addition of 
ammonia to methyl acrylate 81. The reaction resulted in a mixture of two esters 82 and 
83, which were separated by fractional distillation (82 b.p. 80 – 90 ºC, 0.05 mmHg; 83 
left pure in distillation flask, identity confirmed by 1H NMR). The major product was 
the trimer ester 83. This might be attributed to the higher reactivity of the secondary 
amine compared with ammonia and the primary amine.  
 
81 83
+
82
O
O
O
O
N
H
O
O O
O
N
O
O
OO
NH3
i
+
 
 Scheme 34.  Dimeric ester 82 synthesis. Reagents and conditions: i) MeOH, rt, o/n, 
25%. 
 
The 2°-amino group of the dimeric ester 82 was BOC-protected; BOC-protected ester 
84 was converted to hydrazide 85 in reaction with 10 equivalents of hydrazine 
monohydrate, the product was collected as a pure solid in good yield. Azide 86 was 
prepared by the diazotization reaction of the hydrazide using NaNO2/HCl in a yield of 
 53 
 
57%; the product was identified by IR, which showed the characteristic band at 2138 
cm-1 and 1H NMR also confirmed symmetrical dimeric azide formation, Scheme 35. 
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Scheme 35. Route to the bisimidazotetrazinone 55. Reagents and conditions: i) BOC2O, 
Et3N, 100 ºC, 66%; ii) NH2NH2·H2O, i-PrOH, 70%; iii) NaNO2, 10 M aq. HCl, 
DCM/H2O, 57%; iv) anhydrous DCM, 30 ºC, 48 h, 52%;  v) 20, DMSO, rt;  vi) aq. HBr 
48%, acetonitile, rt, 57%.                                                                         
 
Curtius rearrangement to bisisocyanate 87 was achieved by stirring an anhydrous DCM 
solution of azide 86 under nitrogen at room temperature without additional heating.                   
Bisimidazotetrazinone synthesis from the reaction of bisisocyanate 87 and diazo-IC 20 
in anhydrous DMSO gave a product that showed two non-equivalent 
imidazotetrazinones in the 1H NMR spectrum, Figure 10A. The characterization by MS 
and CHN confirmed the BOC-bisimidazotetrazinone 88. The magnetic non-equivalence 
of the imidazotetrazinone rings shown in the 1H NMR spectrum may be attributed to 
 54 
 
restricted rotation about the carbamate N–C(O) bond, Fig 11.  HBr deprotection led to 
the symmetrical product the bromide salt 55, Figure 10B. 
 
 
 
 
 
 
 
Figure 11. 3D minimised molecular model showing BOC-imidazotetrazinone-
interaction in bisimidazotetrazinone 88 structure 
 
 55 
 
 
                                                                                                                
                            Figure 10A.  1H NMR spectrum of BOC-bisimidazotetrazinone 88 
 
      Figure 10B.  1H NMR spectrum of bisimidazotetrazinone hydrobromide salt 55     
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Synthesis of 3-(N-Benzylaminoethyl)imidazotetrazinone HBr salt 56 
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The synthesis of imidazotetrazinone salt 56 is outlined in Scheme 36. In this method 
benzylamine was reacted with methyl acrylate to give 3-benzylaminopropionic acid 
methyl ester 89, which was carried through to imidazotetrazinone 56 without NH 
protection.  
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Scheme 36. Synthesis of 3-(N-benzylaminoethyl)imidazotetrazinone HBr salt 56. 
Reagents and conditions: (i) MeOH, , 60%; (ii) NH2NH2·H2O, EtOH, 88%; (iii) 
NaNO2, 10 M aq. HCl, DCM/H2O; (iv) anhydrous DCM, 30 ºC, 48 h, 40%; (v) Diazo-
IC, DMSO, rt, 20%; (vi) aq. HBr 48%, acetonitile, rt, 48%. 
 
Once again, this synthesis resulted in two imidazotetrazinones which showed different 
1H and 13C NMR peak positions Figure 12, the mass spectrum showed the only the 
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molecular ion of the imidazotetrazinone 93a with the N-nitroso group at the secondary 
amine. Backward checking of the reaction showed that at the stage of the azide 
formation, two different azides were formed and as a result, two different isocyanates. 
The story was understood clearly from the final imidazotetrazinone product, one of the 
imidazotetrazinones showed an N-nitroso group at the amine nitrogen, which was 
confirmed by its mass spectrum whereas the other one did not. Moreover, the evidence 
of having another imidazotetrazinone that resulted from a reaction of isocyanate 92b 
with the diazo-IC, means that β-aminoisocyanate 92b was relatively stable since no 
intramolecular cyclization took place. The ratio of the two products was 6:5 with the    
N-nitrosoaminoethylimidazotetrazinone slightly more, which might be due to the 
powerful electrophilicity of the NO+. 
 
                                                                   
Figure 12. 1H NMR of   3-(benzylamino)-ethylimidazotetrazinone that showed the 
formation of two tetrazines.  
 
Upon the addition of hydrobromic acid to the tetrazine mixture, only one 
imidazotetrazinone HBr salt 56 was observed, Figure 13. Scheme 37 outlines a proposal 
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reaction to the reductive removal of the NO group by hydrobromic acid. In addition to 
the removal of the N-nitroso group HBr was expected to act as a debenzylating agent to 
give the tetrazine salt 54 but no debenzylation took place, only N-nitroso removal was 
observed. Performing other debenzylation methods is difficult in the presence of the 
imidazotetrazinone ring which is unlikely to survive catalytic hydrogenation.  
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Scheme 37. N-Nitroso removal from 3-(N-benzylaminoethyl)imidazotetrazinone 93a to 
the hydrobromide salt 56 with aq. HBr 48%, CH3CN  
 
 
 
 
                                   Figure 13.  Imidazotetrazinone 56 HBr salt 
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2.2.2.2 Imidazotetrazinones bearing anilines 
Both p-substituted primary anilines and N-methylanilines were used for the synthesis of 
imidazotetrazinones, a range of substituents was used including electron-releasing and 
electron-withdrawing groups. 
Imidazotetrazinones synthesized from p-substituted anilines  
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The synthesis of the monomeric imidazotetrazinone 57 is outlined in Scheme 38, the 
synthesis started with p-toluidine without protection of the primary aromatic amine. 
Ester 94, synthesized by the reaction of p-toluidine and methyl acrylate was collected as 
a low melting point solid in a good yield and it was then converted to hydrazide 95, 
diazotization of the hydrazide 95 gave azide 96. The 1H NMR spectrum of azide 96 
showed the disappearance of the NH peak at δ 3.86 which had been observed in the 
spectra of ester 94 and hydrazide 95. The formation of N-nitrosoimidazotetrazinone 57 
was later confirmed by its mass spectrum & elemental analysis. Moreover, no 
intramolecular cyclization reaction was observed for the isocyanate 97. This means the 
N-nitroso group acted as a protecting group to prevent the intramolecular cyclic urea 
formation. The isocyanate 97, when reacted in anhydrous DMSO with diazo-IC 20 
under N2 resulted in the tetrazine 57 with an N-nitroso group at the aromatic amino 
group, MS showed its molecular ion m/z 342.31.  
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Scheme 38. Synthesis of 3-(N-(4-methylphenyl)-N-
nitrosoamino)ethylimidazotetrazinone 57. Reagents and conditions: (i) MeOH, , 90%; 
(ii) NH2NH2·H2O, EtOH, 85%; (iii) NaNO2, 10 M aq. HCl, DCM/H2O; (iv) anhydrous 
DCM, rt , 48 h, 59%; (v) 20, DMSO, rt. (vi) aq. HBr 48%, acetonitile, rt.  
 
 
A trial N-nitroso group removal by 48% HBr in CH3CN at room temperature was 
performed, a white precipitate was collected. 1H NMR showed an imidazotetrazinone 
with only two protons on the aniline substituent (integral = 2H compared with 4H for 
tetrazine 57). Furthermore, the coupling had disappeared so that the aniline ring of 
compound 98 showed only a simple singlet. The MS showed the M٠+ ion of m/z 469.8, 
471.8, and 473.8 in a ratio 1:2:1, which is characteristic of a compound bearing two 
bromine atoms. Furthermore, the mass spectrum showed fragments with m/z 332.8, 
334.8 and 336.8 in a ratio 1:2:1 which is for isocyanate 100 with a dibrominated aniline 
ring and also showed the diazo-IC ion 20, Figure 14. Fragmentation in the mass 
spectrometer led to generation of the moieties from which the imidazotetrazinone was 
synthesized; the mechanism of the thermal break down may involve a [1,5] sigmatropic 
shift via an unstable spirobicycle 99,13 Scheme 39.  
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The bromination that occurred on the aniline was referred to previously as evidence of 
the removal of the N-nitroso group from tetrazine 79 by a reduction reaction with HBr, 
Scheme 33.   
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Scheme 39. Fragmentation in hot non-nucleophilic solvent (acetonitrile) observed in the 
mass spectrum of tetrazine 98 
 
 
 
                                                       
Figure 14. Mass spectrum showing bromination of the aniline ring of 
imidazotetrazinone 57 during HBr reduction N-nitroso group. 
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Synthesis of bisimidazotetrazinones 58a, b and c 
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The synthesis of bisimidazotetrazinones 58a, b and c started from p-substituted anilines, 
Scheme 40 outlines the general reaction sequence followed. In this synthesis the          
p-substituted anilines were pushed to react with excess methyl acrylate (10 equivalents) 
to give the dimeric esters, using CuCl as catalyst in acetic acid.79 Esters were collected 
clean and in good yields, by fractional distillation as in case of ester 101a and with 
solvent/solvent extraction (CHCl3/aqueous Na2CO3) in case of 101b and c. The 
hydrazides were synthesized from the reactions of esters with 10 equivalents of the 
hydrazine monohydrate in ethanol and were isolated as clean solids in high yields.  
 
The azide synthesis was completed but with nitrated products as impurities as a result of 
aromatic ring nitration. The nitrosation occurred due to two factors: (i) the powerful 
electrophile (NO+) and (ii) the highly activated aniline ring, Figure 15. The nitration 
occurred at the most activated and accessible positions on the aromatic ring, mainly the 
о-position to the amine as the p-position was blocked by another substituent. Such 
nitration was a major problem in the case of imidazotetrazinone 58b due to the high 
reactivity of the aromatic ring, resulting from the electron releasing effect of both the 
amino and OCH3 groups. Controlling of the temperature and the acid strength resulted 
in reduction of the incidence of nitration. The temperature was reduced to less than 5 ºC 
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and diluted acetic acid was used (0.16 – 0.64 M), this greatly reduced the nitrated azide 
impurities.  
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Scheme 40. Synthesis of dimeric tetrazines 58a, b and c. Reagents and conditions: (i) 
AcOH, CuCl, , 60 – 80%; (ii) NH2NH2·H2O, EtOH, 60 – 90%; (iii) NaNO2, AcOH, 
DCM/H2O; iv) anhydrous DCM, rt, 48 h, 55 – 70%; (v) 20, DMSO, rt, 15 – 25%.   
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                                          Figure 15.  Aromatic ring о- nitration 
 
The bisisocyanates were formed upon stirring the anhydrous DCM solutions of the 
crude azides at room temperature without further heating. It is quite important to keep 
the thermal situation to the lowest necessary for the Curtius rearrangement to proceed, 
in order to avoid any decomposition impurities which were observed to occur at 
temperatures higher than those required for the isocyanate formation. The isocyanate 
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was detected after 24 h, but the reaction only completed after 48 h, except in the case of 
the isocyanate with a p-fluoro group where the reaction finished in 24 h. The 
imidazotetrazinones were prepared from the bisisocyanates when mixed in anhydrous 
DMSO under N2 with diazo-IC. Small amounts of imidazotetrazinone impurities were 
observed, mostly due to nitration of the aniline rings, which were separated by column 
chromatography purification. Imidazotetrazinones move on silica only when acetic acid 
is one of the solvent constituents, different amounts of acetic acid were used in 
chloroform for the purification of these imidazotetrazinones, fortunately 
imidazotetrazinones are stable in acidic media. After chromatography, the 
imidazotetrazinones showed some impurities that seemed to be washed out from the 
silica by acetic acid; these were removed by     re-dissolving the isolated tetrazines in 
DMF from which the imidazotetrazinones were then precipitated by addition of water. 
 
Imidazotetrazinones from p-substituted-N-methylaniline 
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N-methylanilines were used for the synthesis of five different imidazotetrazinones, 
Scheme 41, prepared following the general method. Unlike the monomeric ester 
synthesized from aniline, the esters synthesized from N-methylanilines, especially those 
substituted with electron-withdrawing groups (F, Cl), showed a low reactivity towards 
methyl acrylate, which required use of the catalyst CuCl and acetic acid in methanol. 
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Hydrazides were synthesized from the esters and six equivalents of hydrazine 
monohydrate in ethanol. Hydrazides were collected as clean solids in good yields by 
recrystallisation from ether. The azide synthesis was performed under very mildly acidic 
conditions, dilute acetic acid was used (0.16 M – 0.64 M), in addition to low 
temperature (< 5 °C) to avoid nitration on the aromatic rings.  
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Scheme 41. Synthesis of monomeric imidazotetrazinones 59a-e. Reagents and 
conditions: i) MeOH, CuCl, AcOH, , 67 – 98%; (ii) NH2NH2·H2O, EtOH, 72 – 95%; 
(iii) NaNO2, AcOH, DCM/H2O; (iv) anhydrous DCM, rt , 48 h, 70 – 90%; (v) 20, 
DMSO, rt, 6 – 22%.   
 
 
In the case of the tetrazine 59e the azide was prepared from the hydazide of 
unsubstituted N-methylaniline 107b and in this case the diazotization was performed in 
relatively strongly acidic conditions (37% aq. HCl) and a higher temperature was used 
(5 ºC), this was required to push the reaction, in addition to diazotization of the 
hydrazide, to nitrate the aniline ring. The main nitrated products formed were at the p-
position and   о- position in a ratio 3:1 due to hindrance at the о- position, Scheme 42. 
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The lowest yield was obtained with tetrazine 59e, the nitration reaction leads to a 
mixture of both the p-isomer and the o-isomer, after the chromatography separation 
only 6% was found from 59e. 
Anilinoethylimidazotetrazinones 59a-e were separated by column chromatography from 
any nitrated impurities, different ratios of acetic acid in chloroform were used from     
10 – 20%. 
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Scheme 42. Synthesis of monomeric imidazotetrazinone 59e. Reagents and conditions: 
(i) NaNO2, HCl 37%, DCM/H2O; (ii) anhydrous DCM, rt , 48 h, 90%; (iii) 20, DMSO, 
rt, 6 %. 
 
 
Reflection on the Chemistry of the Anilinoethylimidazotetrazinones 
 
Generally the synthesis of imidazotetrazinones having a secondary amine or BOC-
protected primary amine in the ester intermediate used, proceeded with N-nitroso 
formation, in which the NH group played a very important role in trapping the powerful 
electrophile (NO+) that was generated during the diazotization reaction. NO+ replaced 
the proton and accordingly resulted in N-nitroso imidazotetrazinones Figure 16. N-
Nitroso group removal was found to be easy by reduction with HBr to remove it in the 
form of ammonia, evident as the δ 7.1 triplet in the 1H NMR spectra (Figures 9 and 13).           
N-Nitroso group removal from imidazotetrazinone 57 resulted in bromination on the 
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aniline ring which was not observed in case of tetrazine 93A; this was attributed to the 
highly activated aromatic ring in case of imidazotetrazinone 57 and provides further 
evidence of the reductive nature of the reduction reaction by HBr that took place 
generating Br+ and resulting in the formation of 1d as a by-product as proposed in 
Scheme 33.  
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                          Figure 16.  Imidazotetrazinones that showed an N-nitroso group 
 
In contrast, for those anilinoethylimidazotetrazinones synthesised from esters having 
tertiary aromatic amines (58a-c and 59a-d) Figure 17, which lacked an NH group, the 
NO+ electrophile attacked the aniline ring in an electrophilic substitution reaction and 
resulted in nitrated by-products. Even when the reaction was closely monitored and 
controlled with temperature reduction and low acid strength, there was evidence of such 
nitration.  
 
Purification Control 
 
The impurities observed in the synthesis of the imidazotetrazinones (57, 79 and 93A) 
were observed to be different from those observed in the case of 
anilinoethylimidazotetrazinones (58a-c and 59a-d). In the first case, those synthesized 
from esters having secondary or BOC-protected-primary amines, impurities were 
observed to be from the previous synthetic intermediates i.e amine, ester or the 
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hydrazide. These were soluble in chloroform, whereas the tetrazines synthesized from 
them were only partially soluble in chloroform, accordingly the impurities could be 
easily washed out from the finished product with cold chloroform. Another possible 
impurity came from cyclization of diazo-IC to the triazine azahypoxanthine. This is 
insoluble in chloroform, whereas the imidazotetrazinones with the N-nitroso group 
showed partial solubility in large volumes of chloroform; in these cases the 
imidazotetrazinones were purified by filtration of their chloroform solutions after drying 
over anhydrous MgSO4.  
 
For the anilinoethylimidazotetrazinones derived from esters having tertiary anilines 
(58a-c and 59a-d), the impurities were mainly the nitrated by-products, which showed 
very similar solubility properties to the desired tetrazines in most organic solvents; 
consequently their purification by washing or solvent/solvent extraction was limited and 
only column chromatography was useful. 
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      Figure 17.  Imidazotetrazinones synthesized from esters lacking the NH group 
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The synthesis of 13C-1'-labelled imidazotetrazinone  
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The imidazotetrazinone 59a was synthesized with a 13C-label at position 1' of the side 
chain, Scheme 43. In this synthesis, butyl [2-13C]acrylate, instead of methylacrylate, 
was used (the only commercially-available, labelled acrylate). The butylacrylate showed 
less reactivity compared with methylacrylate, this might be due to the butyl group in 
both its electronic inductive and steric hindrance effects. The rest of the reaction was 
performed as in case of the unlabelled tetrazine 59a. The labelled imidazotetrazinone 
was characterized by 1H NMR, 13C NMR (Fig 18 A & B) and MS, all confirmed the 
labelled imidazotetrazinone formation.  
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Scheme 43. Synthesis of 13C-lablled imidazotetrazinone 59a. Reagents and conditions: 
(i) CuCl, AcOH,  (ii) NH2NH2·H2O, EtOH (iii) NaNO2, AcOH, DCM/H2O (iv) 
anhydrous DCM, rt , 48 h (v) 20, DMSO, rt   
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               Figure 18A.  1H NMR Spectrum of labelled tetrazine 59a. 
 
 
 
 
Figure 18B. 13C-CPD and DEPT 135(top) NMR spectra of labelled tetrazine 59a. 
 
1JCH = 143.5 Hz 
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A trial for preparing bisimidazotetrazinone 58a with a 13C-label was started by the 
reaction of unlabelled butyl acrylate with p-toluidine for the ester formation. The trial 
considered two important issues i) the expensive labelled material to be handled and ii) 
the amount of labelled material (100 mg) to be carried over 5 steps to the final product. 
The dimer ester formation from butyl acrylate and p-toluidine was a slow reaction and 
showed the presence of the monomer ester even under reflux in the presence of the 
catalyst CuCl and acetic acid. To avoid the distribution of the labelled material between 
the monomer and dimer and to avoid need to handle tiny amounts of these esters, the 
trial moved to the formation of the dimer ester by another way. 
First monomer butyl ester formation, in a reaction of butyl acrylate in methanol under 
reflux with excess amount of p-toluidine, led to the monomer ester together with 
unreacted p-toluidine. This mixture was then reacted with excess methyl acrylate; two 
dimer esters formed one with different arms (methyl and butyl) and the symmetrical 
dimethyl ester, Scheme 44. Transesterification (butyl to methyl) was achieved by 
heating the mixture of the two esters in methanol in the presence of H2SO4 under reflux. 
This avoided having esters with two different reactivities (butyl and methyl) in the 
subsequent step. The hydrazide was successfully made from the swapped ester, and as 
in the case of synthesis of tetrazine 58a the rest of the steps proceeded smoothly.  
The conditions were then transferred to the labelled butyl acrylate. Preparation of the 
butyl monoester was successful, but the reaction of the monoester with excess methyl 
acrylate showed a complete loss of the labelled material. This result appears to 
demonstrate that the Michael addition is completely reversible so that, in the presence of 
an excess of un-labelled acrylate, the entire label was lost from the labelled mono ester 
111. 
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Scheme 44. Dimeric ester formation from butyl and methyl acrylate. Reagents and 
conditions: (i) MeOH, Reflux; (ii) CuCl, AcOH,  (iii) Conc H2SO4, MeOH, Δ; (iv) 
NH2NH2·H2O, i-PrOH 
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New Imidazotetrazinones Available for Biological Evaluation 
 
A. Bisimidazotetrazinones 
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B. Monomer imidazotetrazinones 
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Table 2 shows selected chemical-shift (1H and 13C) data for imidazotetrazinones 
synthesized by the modified original method compared with the literature data for 
temozolomide synthesized by the original method. 
 
                                                                                                                   
Table 2. H-6 and 13C Chemical-shift data (δ) for synthesized tetrazines compared with 
temozolomide literature data 
 
 
 
 
Tetrazine H -6 C-4 C-6 C-8 C-8a 
Ethylimidazotetrazinone 1e 8.80 139.3 129.1 131.0 135.1 
Bromoethylimidazotetrazinone 
1d 
8.97 139.6 129.6 131.7 134.6 
Mitozolomide (lit) 1b80 8.88 139.5 129.7 131.7 134.6 
Temozolomide (lit) 1a80 8.84 140.1 129.4 131.4 135.5 
Imidazotetrazinone 79 8.85 139.5 129.7 131.9 134.4 
Imidazotetrazinone HBr 54 8.92 140 129.5 131.7 134.8 
BisimidazotetrazinoneHBr salt 
55 
8.93 139.9 129.6 131.9 134.7 
Imidazotetrazinone HBr salt 56 8.96 140 129.6 131.8 134.7 
Imidazotetrazinone 57 8.78 139.4 129.5 131.7 134.4 
Bisimidazotetrazinone 58a 8.65 139.7 129.3 131.3 134.8 
Bisimidazotetrazinone 58b 8.76 139.6 129.2 131.3 134.8 
Bisimidazotetrazinone 58c 8.76 139.7 129.3 131.4 134.8 
Imidazotetrazinone 59a 8.72 139.5 129.1 131.2 134.7 
Imidazotetrazinone 59b 8.78 139.5 129.2 131.3 134.6 
Imidazotetrazinone 59c 8.78 139.6 129.2 131.4 134.7 
Imidazotetrazinone 59d 8.77 139.5 129.2 131.3 134.7 
Imidazotetrazinone 59e 8.81 139.7 129.5 131.6 134.7 
Imidazotetrazinone 117a 8.87 140 130.1 131.9 134.7 
Imidazotetrazinone 117b 8.87 139.7 130.4 132.4 134.4 
CHAPTER 3 
MECHANISTIC EVALUATION 
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Chapter 3 Mechanistic Evaluation of 
Imidazotetrazinones for Aziridinium Ion Release 
3.1 Introduction 
The aims of the mechanistic evaluation of imidazotetrazinones for the release 
aziridinium ions, summarised at the end of Chapter 2, are two-fold: 
1) NMR studies of the imidazotetrazinone ring opening mechanism at neutral pH 
as evidence for aziridinium ion formation. 
2) UV-Visible studies of the kinetics of decomposition of these tetrazines in acidic, 
neutral and alkaline pH, to compare the pH-dependence of the aqueous 
hydrolysis of these imidazotetrazinone with temozolomide.  
3.2 NMR Studies of the ring opening reaction 
 
The aim of the study was to establish evidence for the mechanism of breakdown of the 
imidazotetrazinone ring. In particular, for the release of aziridinium ions at neutral pH 
which may indicate a likely biological mechanism of action. 
 
1H NMR spectroscopy was used to investigate the imidazotetrazinones synthesized for 
release of aziridinium ions; 13C-labelled and unlabelled imidazotetrazinone 59a were 
selected for this study. Reaction of tetrazines with deuteriated phosphate buffer pD 7.8 
(equivalent to pH 7.4) at 37 ºC was investigated by acquiring 1D 1H NMR spectra every 
30 min for 15 h, Figure 19A. The spectra showed the disappearance of 
imidazotetrazinone 59a and appearance of its decomposition products with time. In the 
decomposition of the unlabelled imidazotetrazinone 59a, the imidazole all reacted to 
AIC 10 and the 3-substituent group gave rise to another two products. Spiking with an 
authentic sample of alcohol 115 confirmed the identity of the minor product. The major 
product showed two different coupling patterns for the protons on the two aliphatic 
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carbons (quartet and triplet) unlike the minor product that showed only two triplets for 
both methylene groups, this coupling pattern is consistent with production of 
phosphomonoester 114.  Scheme 45 outlines the possible decomposition products of 
imidazotetrazinone 59a based on the available nucleophiles in the system.  
 
N
N N
N
N
N
O
NH2O
37  Cº
N
O
P
O
O
O
N
OH
N
NH
NH2
O
NH2
+
+
59a
10 113
N
N2
114115
PO4 buffer pD 7.8
H2O
1:10
PO2-4
 
           Scheme  45. Neutral pH hydrolysis of unlabelled imidazotetrazinone 59a  
 
The spiking of the product mixture at the end of the reaction with authentic AIC 10 and 
N-methyl-p-tolylaminoethanol 115 confirmed their identity, it showed an increase in the 
AIC singlet peak, whereas alcohol 115 addition resulted in the increase of the size of the 
minor two small triplet peaks at δ: 3.30 & 3.62 (compare spectrum B with spectrum A 
in Figure 19B). The quartet at 3.77 and triplet at 3.34 is for something else. The 
presence of the negatively charged phosphate of the buffer suggested these peaks to be 
the phosphate ester 114 and the quartet peak is due to the 3JPH coupling. The presence of 
an additional phosphorus-containing compound was confirmed by 31P NMR Figure 
19C. 
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Figure 19A. Decomposition of imidazotetrazinone 59a in phosphate buffer pH 7.4 at 37 
ºC showing the 3-substituent giving rise to two products. 
Figure 19B. 1H NMR spectra of (A) decomposition products of imidazotetrazinone 
59a; (B) spiked with N-methyl-N-p-tolylaminoethanol, (C) spiked with AIC. 
 
Figure 19C. 31P NMR spectrum of the final decomposition products of 
imidazotetrazinone 59a 
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Scheme 46 outlines a proposal for the decomposition mechanism of the unlabelled 
tetrazine 59a. The proposal suggests the formation of a diazonium ion as the usual 
decomposition product of an imidazotetrazinone (AIC 10 + diazonium ion 113) and due 
to the presence of the nitrogen of the aniline, which acts as a nucleophile, cyclization of 
the diazonium ion 113 to the aziridinium ion 116 took place. The scheme proposes the 
nucleophilic attack of a negatively charged phosphate at one of the two equivalent 
carbon sites of the aziridinium ion. Either would result in phosphomonoester 114, which 
showed a quartet coupling for the protons attached to the carbon adjacent to the 
phosphate, this product was also confirmed by negative ion MS that showed              
m/z = 245.1.  
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Scheme 46. Proposed decomposition mechanism for unlabelled imidazotetrazinone 59a 
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Evidence for the aziridinium ion intermediate 116 came from a study performed on the 
13C-labelled imidazotetrazinone 59a under the same conditions. The 1H NMR spectra 
that resulted from the study showed that the decomposition products are same as those 
mentioned above. Once again the 3JPH couplings were evident in the –P-O-CH2-CH2 
unit, Figure 20.  
 
The gated decoupled 13C spectrum acquired for the products at the end of the reaction of 
the labelled-imidazotetrazinone 59a (30000 scan over 99 h) showed that the reaction 
gave two products, the phosphomonoester 114 and the alcohol 115, Figure 21.  In 
the phosphomonoester the label was completely scrambled so it appeared equally at 
both CH2 positions (44 %: 44 %) phosphomonoester 114a & b Scheme 47. In the case 
of the alcohol product, the label was also scrambled but with a small excess of label in 
the position adjacent to the OH group (8%: 4 %). This result greatly helped in the 
confirmation of aziridinium ion formation; the scrambling of the labeled products, 
whether the phosphomonoester or alcohol, confirmed that these products resulted from 
the equal attacks of the system nucleophiles on the aziridinium ion sites, Figure 21, 
Scheme 47. The phosphomonoester 114a&b shows the carbon-phosphorus coupling 
and it showed the ratio of phosphomonoesters 114 to alcohol 115 (10:1) which is due to 
the reactivity of the negatively charged phosphate over H2O. The ratio shown for 
alcohols conclude that alcohol was produced as a result of two routes: (i) the direct 
hydrolysis of the 13C-labelled-diazonium ion 113a before cyclization and (ii) the equal 
H2O attacks to the two sites of aziridinium ion, Scheme 47. Alcohol resulting from 
direct diazonium ion hydrolysis was shown to be half the amount of alcohol produced 
by H2O attacks to the two sites of the aziridinium ion,  this is an indication to how fast 
is the cyclization of the diazonium ion to the aziridinium ion. 
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Scheme 47. 13C-labelled diazonium ion cyclization to the aziridinium ion and products 
of system nucleophile attacks.  
 
 
The NMR study on the aziridinium-ion-release-imidazotetrazinones exemplified by the 
tetrazine 59a (13C-labelled and unlabelled), showed the possibility of taming of the 
diazonium ion by the cyclization reaction that resulted in the aziridinium ion. This 
concluded that imidazotetrazinones synthesized for the release of aziridinium ion indeed 
can release aziridinium ions by aqueous hydrolysis at neutral pH. This reflects the 
possibility of chemical activation at the physiological pH for a future drug and the 
release aziridinium ions at their target of action. Moreover the study confirmed the 
similarity of the neutral aqueous hydrolysis of these imidazotetrazinones to that of 
temozolomide. 
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3.3 Hydrolysis Kinetics of Aziridinium-ion-release 
imidazotetrazinones 
In the previous section, the NMR studies showed the ring opening mechanism and 
confirmed aziridinium ion release by imidazotetrazinone decomposition at neutral pH. 
In this section, the kinetics of hydrolysis of aziridinium-ion-release imidazotetrazinones 
under acidic, neutral and alkaline conditions will be investigated using UV-Visible 
spectrophotometry. The study was designed to show the kinetics of the aqueous 
hydrolysis of these tetrazines at the neutral and alkaline pH and compare the results with 
temozolomide under the same condition. Pseudo 1st order rate constants (k׳) and half-
lifes (t1/2) at each studied condition were measured. 
 
The expected reaction kinetics are pseudo first order reaction since the rate limiting step 
is addition of water (or  hydroxide ion) to initiate the ring opening reaction. The 
concentration of water (or –OH) is effectively constant in the buffer solution. 
Accordingly the reaction rate is described by the integrated rate equation (1). 
 
ln[A] = – k׳ t + ln[A]o ...................(1) 
 
Where [A] is the concentration of imidazotetrazinone at time (t) and [A]o is the initial 
concentration. 
The plotting of ln[A] against time (t) will give a straight line with 
gradient = – k׳ 
The half life of the pseudo-first-order reaction is independent of the starting 
concentration and is given by equation 2. 
 
t1/2 = ln(2)/ k׳.................................(2) 
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The study was performed on the 9 imidazotetrazinones summarised at the end of 
Chapter 2, in three different phosphate-citrate buffers of pH 4, 7.4 and 8 at 37 °C. The 
different pH values were chosen based on the known properties of temozolomide and 
their significance for acid stability in oral administration and the need for chemical 
activation at physiological pH. 
3.3.1 Hydrolysis kinetics at pH 4 
 
The pH 4 was selected to investigate the stability of aziridinium-ion-release-
imidazotetrazinones under the acidic conditions. The gastric pH = 0.8,81 so good 
stability at pH 4 will reflect a good stability under the gastric acid conditions so may 
facilitate oral bioavailability similar to temozolomide. 
 
Time-dependent UV spectra of imidazotetrazinone 59d are shown in Figure 22A. The 
imidazotetrazinone showed a strong absorbance at 327 nm which decreased with time. 
The absorbance bands of the aniline and AIC (the final u.v-active hydrolysis products of 
the imidazotetrazinone) overlapped in the 240 – 280 nm region so could not be 
resolved. The lnA327 vs time plot is shown in Figure 22B. This was straight line giving                   
k׳ = 0.5 × 10-5 sec-1 and t1/2 = 35.6 h. Other tetrazines (58a-b, 59a-c and 59e) gave 
similar plots under these conditions. 
 
The only exception was imidazotetrazinone 58c, it is a bisimidazotetrazinone with a 
fluoro group at the p-position of the aniline ring. It showed non-linear kinetics, Figure 
23A, the kinetics appeared fast at the beginning of the reaction with reaction rate 2.3 × 
10-5 sec-1, t1/2 8.3h, whereas at the end substantial curvature and slower reaction were 
seen, Figure 23B. This might be attributed to the non-equivalency in decomposition 
between the two imidazotetrazinone rings as a result of the electron-withdrawing effect 
 85 
 
exerted by the fluoro group and one of the imidazotetrazinone rings on the second one, 
showing a fast decomposition rate of 1st ring at the beginning, then a slower rate for 
decomposition of the second ring. 
  
Figure 22A. U.V. spectra of imidazotetrazinone 59d kinetics of decomposition pattern 
at pH4 
 
   
 
                      Figure 22B. Imidazotetrazinone 59d hydrolysis kinetics at pH4 
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Figure 23A. U.V. spectra of imidazotetrazinone 58c  kinetics of decomposition pattern 
at pH4 
 
 
                Figure 23B. Imidazotetrazinone 58c hydrolysis kinetics at pH4 
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3.3.2 Hydrolysis kinetics at pH 7.4 
 
The kinetics of decomposition at pH 7.4 were measured to show the aqueous hydrolysis 
at the neutral pH, to see whether behaviour of the new imidazotetrazinones was similar 
to temozolomide. Temozolomide showed a comparable half-life in phosphate buffer pH 
7.4 at 37 °C (1.83 h) to the mean half-life measured in a group of patients (1.81 h).15 
In this study aziridinium ion-release-imidazotetrazinones (58a-c, 59a-e and 55) 
solutions in buffer pH 7.4 were scanned at a time interval of 4 min for 1 h. The study 
showed that the decomposition of the tetrazines with time at this pH was a linear 
pseudo-first order reaction, for example compound 59b, Figure 24A & B. The rate 
constants ranged between 14 – 33 × 10-5 sec-1, compared with temozolomide that 
showed a                       k׳ = 14 × 10-5 sec-1 under the same conditions. 
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Figure 24A. U.V. spectra of imidazotetrazinone 59b kinetics of decomposition pattern 
at pH 7.4 
 
 
 
 
                      Figure 24B. Imidazotetrazinone 59b hydrolysis kinetics at pH 7.4 
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Bisimidazotetrazinone 58c showed a more complex decomposition pattern when the 
kinetics of its hydrolysis were performed at the same concentration used for other 
tetrazine but upon 10-fold dilution a usual pattern of tetrazine hydrolysis was observed 
with rate constant k׳ = 10.3 × 10-5 sec-1 which is unexpectedly less than that measured 
for temozolomide, Figure 25A & B. The complex pattern of decomposition observed at 
the relatively high concentration might be due to precipitation of the tetrazine when its 
DMSO solution was added to buffer solution.  
 
The bisimidazotetrazinone HBr salt 55 showed shifting of the isosbestic point from 300 
to 290 nm during the reaction and this appears to show rapid hydrolysis at the start of 
the reaction with rate constant  k'1 = 61.2  10-5 sec-1 and t1/2 = 0.3 h and then slowing 
once a substantial proportion of the tetrazine has been consumed, Figure 26A&B. This 
may be due to the combination of the positive nitrogen and imidazotetrazinone acting as 
powerful electron-withdrawing substituents. Once the first tetrazine ring has been 
converted to the alcohols the electron-withdrawing effect is less and hydrolysis of the 
second tetrazine is therefore slower with a rate constant k′2 = 20.8 10-5 sec-1,              
t1/2 = 0.9 h.   
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Figure 25A. U.V. spectra of imidazotetrazinone 58c kinetics of decomposition pattern 
at pH 7.4 
 
 
 
 
 
Figure 25B. Imidazotetrazinone 58c hydrolysis kinetics at pH 7.4 and hydrolysis 
products AIC and aniline. 
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       Figure 26A U.V. spectra of decomposition of bisimidazotetrazinone HBr 55 at pH 
7.4 
 
 
      Figure 26B. The fast hydrolysis reaction of bisimidazotetrazinone 55 at pH 7.4   
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Imidazotetrazinone 59e, the monomer with p-nitro group on the aniline ring, showed in 
addition to AIC at λ max = 245 nm and the p-nitroaniline at λ max  = 412 nm as another 
decomposition product (in the visible region) Figure 27A & B. It showed a linear 
decomposition with rate k'2 = 33.3    10-5 sec-1, t1/2 = 0.6 h. 
 
     Figure 27A.  U.V. spectra of decomposition of Imidazotetrazinone 59e at pH 7.4     
 
Figure 27B.  U.V. spectra of decomposition of Imidazotetrazinone 59e at pH 7.4     
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3.3.3 Hydrolysis kinetics at pH 8 and 37 °C 
 
The kinetics of hydrolysis at pH 8 were investigated to find out the degree of the 
instability of the aziridinium-ion-release-imidazotetrazinones under alkaline conditions 
and the results were compared with the instability observed for temozolomide under the 
same conditions.  pH 8 is six-times less acidic than pH 7.4 (1 pH unit is corresponds to 
a 10 fold change in [H]+) and is the pH found at the beginning of the alkaline pH range, 
accordingly any instability or high rate of decomposition shown by the 
imidazotetrazinone at this pH will reveals it instability at the alkaline pH of the ileum 
and the small intestine (pH = 8.1 – 9.3). 81 
 
In common with other aziridinium-ion-release imidazotetrazinones, that showed linear 
decomposition at previous pH conditions and in this condition, the p-F 
bisimidazotetrazinone 58c showed a linear pseudo first order kinetics but with relatively 
unexpected lower reaction rate and higher t1/2 (k' = 24.6  10-5 sec-1, t1/2 = 0.8 h), Figure 
28B. Figure 28A shows that bisimidazotetrazinone 58c gave a simple pattern of 
decomposition of to AIC and aniline, unlike those observed at pH 4 and 7.4. This may 
be attributed to the strong nucleophiles present in this alkaline solution which result in 
equal attack to both tetrazine rings at the same time, so leads to their opening at the 
same rate. 
 
Bisimidazotetrazinone HBr salt 55 showed the highest rate and shortest t1/2 (k' = 110.5  
10-5 sec-1, t1/2 = 0.2 h) in a biphasic linear-decomposition pattern, Fig 29A & B, it may 
be attributed to the strength of electron withdrawing effect exerted by the aliphatic 
amine nitrogen and the effect of one of tetrazine rings on each other, which leads to the 
higher instability of this tetrazine at this alkaline condition.  
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Figure 28A.  U.V. spectra of decomposition of bisimidazotetrazinone 58c at pH 8 and 
37 °C 
 
Figure 28B. Linear pseudo first order hydrolysis of bisimidazotetrazinone 58c at pH 8 
and 37 °C 
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Figure 29A. U.V. spectra of decomposition of  bisimidazotetrazinone HBr salt 55 at pH 
8 at 37 °C 
 
 
Figure 29B. Linear kinetics of  bisimidazotetrazinone HBr salt 55 hydrolysis in buffer 
pH 8 at 37 °C 
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3.4 Conclusions  
NMR study conclusion 
The NMR study for the ring-opening reaction of aziridinium-ion-release-
imidazotetrazinones concludes the following: 
1) The tetrazine aqueous hydrolysis at neutral pH studied by NMR confirmed that 
aziridinium-ion-release imidazotetrazinones decomposed according to the usual 
ring opening of the imidazotetrazinones to AIC and the diazonium ion and it is 
comparable to temozolomide. 
2) All the imidazotetrazinones studies by NMR showed the reaction mechanism of 
the decomposition at pH 7.4 that results in the release of the aziridinium ion, the 
aqueous neutral hydrolysis observed can be a good indicator of the chemical 
activation and aziridinium ion release at physiological pH for any future drug. 
3) The NMR study demonstrated the fast diazonium ion intramolecular cyclization 
to the aziridinium ion formation (96% cyclized). 
U.V. kinetics study conclusion 
 
The rate of the decomposition (k' sec-1) and the half-life (t1/2) for aziridinium ion-release 
imidazotetrazinones and temozolomide studied at pH 4, 7.4, and 8 are presented in table 
3. 
 
The study showed that electron-withdrawing groups increase the rate of the 
decomposition and shorten the t1/2 of the imidazotetrazinone ring.  For example, the 
linear decomposition at pH 7.4 shown by monomer anilinoimidazotetrazinones 59c, d 
and e, those having chloro, fluoro and nitro groups at p-position to aniline respectively, 
in contrast electron-releasing substituents which decrease the rate of hydrolysis are 
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represented by imidazotetrazinone 59a. Imidazotetrazinone 59b the one with hydrogen 
substituent at the p-position of the aniline ring (H), was taken as reference.  
Imidazotetrazino
ne 
pH 4.0 
k' a                     t1/2b 
pH 7.4 
k' a                    t1/2b 
pH 8.0 
k' a                     t1/2b 
58a 0.4 ± 0.006 48.5 14.4 ± 0.7  1.3  45.1±1.5 0.4  
58b 0.2 ± 0.001 99.7 15.8±0.42  1.2  49.4±0.77 0.4  
58c 2.3 ± 0.06 8.3 10.3±0.8 1.9 24.6±1.08      0.8  
59a 0.5 ± 0.003 41.5 15.2 ± 0.3  1.3  49.5±0.36 0.4  
59b 0.4 ± 0.001 54.8 17 ± 0.48  1.1  55.0±0.85 0.4 
59c 0.2 ± 0.001 90.6 19.3 ± 0.9  1.0  61.8±1.0 0.3 
59d 0.5 ± 0.008 35.6 21.5 ± 0.5  0.9  70.0±0.42 0.3  
59e 0.4 ± 0.013 53.2 33.3 ± 1.2  0.6  61.5±0.89 0.3 
55 1.4 ± 0.007 13.5 61.2 ± 2.3  0.3  110.5±3.0 0.2  
Temozolomide1a 0.1 ± 0.001 235.0 14.0  1.4  46.2±0.2 0.42  
a k'   = pseudo first order rate constant,  10-5 sec-1, data are mean ± SD of 3 
independent determinations. 
b t1/2 = half life in hours. 
  
 Table 3. Kinetic data for the hydrolysis of imidazotetrazinones at pH 4.0, 7.4, 8.0     
 
 
 
Figure 30.  Tetrazine hydrolysis reaction rate constants versus Hammett constant (σ) 
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Figure 30 shows the linear correlation of the electronic effect (Hammett constant) 
against reaction rate at pH 7.4, p-fluoro tetrazine 59d k' 21.5  10-5 sec-1 showed nearly 
similar effect to 59c (p-chloro, k' = 19.3  10-5 sec-1). 
 
Moreover, at pH 7.4 the bisimidazotetrazinones 58a (p-CH3-aniline) showed reaction 
rate and t1/2 (k' = 14.4  10-5 sec-1, t1/2 1.3 h), 58b (p-OCH3-aniline) showed reaction rate 
and t1/2 (k' = 15.8  10-5 sec-1, t1/2 1.2 h), and the monomer tetrazine 59a (p-CH3-aniline) 
showed reaction rate and t1/2 (k' = 15.2  10-5 sec-1, t1/2 1.3h) were observed to a great 
extent to be comparable in their rate of decomposition and t1/2 to temozolomide at the 
same conditions (14  10-5 sec-1, t1/2 1.4 h ).  
 
In the kinetics of hydrolysis evaluation in buffer pH 8 at 37 °C,  bisimidazotetrazinone 
58a showed k' = 45.1  10-5 sec-1, t1/2 = 0.4 h, 58b k' = 49.4  10-5 sec-1, t1/2 = 0.4 h and 
the monomer tetrazine 59a k' = 49.5  10-5 sec-1, t1/2 = 0.4 h, once again observed to a 
great extent to be comparable with temozolomide  k' = 46.2  10-5 sec-1, t1/2 = 0.42 h 
which reflects the same instability under these conditions.  
 
The kinetics study of hydrolysis performed at the three different pH on the aziridinium-
ion-release imidazotetrazinones concludes the following: 
1) The aqueous UV-Visible kinetic study showed that electron releasing groups 
optimized the pattern of decomposition and gave results of decomposition and 
stability quite similar to the lead drug temozolomide. In contrast, electron 
withdrawing groups quicken the rate of decomposition and sometimes lead to 
odd chemical behaviour e.g is the decomposition pattern observed from 
bisimidaotetrazine 58c in pH 7.4 when relatively high concentration used, the 
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expected rate should be higher due to the withdrawing group but the reverse 
happened, it showed hydrolysis at two separate rates may be due to precipitation 
of either the tetrazine or the decomposition products specially AIC, upon        
10-folds dilution to the first concentration a usual decomposition pattern of 
imidazotetrazinones was been observed. 
2) The neutral aqueous hydrolysis study showed to a great extent, equivalent 
chemical behaviour to temozolomide by bisimidazotetrazinones 58a, 58b and 
the monomer imidazotetrazinone 59a, whereas their stability in the acidic 
condition was observed to be less than temozolomide, although it looks 
reasonable stability when compared with the time required for oral absorption of 
any future drug. 
3) The bisimidazotetrazinone HBr salt 55 showed a relatively lower stability in all 
pH studies compared with the other imidazotetrazinones, it shows neither 
optimum rate at the neutral aqueous hydrolysis nor reasonable acid stability. In 
addition to the biphasic kinetics of hydrolysis with two different rates, higher 
rate at the starting of the reaction, which slow down at the end of the reaction, 
this can conclude the independent hydrolysis of the two imidazotetrazinone 
rings of this imidazotetrazinone HBr salt.  
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Chapter 4 Imidazotetrazinones for Alcohol or Phenol 
Release 
4.1 Introduction 
 
This is a study of the synthesis and hydrolysis of alcohol- or phenol-release 
imidazotetrazinones that may be used for improving the delivery of highly polar 
alcoholic or phenolic drugs. It is proposed that the favourable uptake and distribution 
properties of the imidazotetrazinone may be conferred on the linked drug and that 
hydrolysis of the imidazotetrazinone at the site of action may liberate the free alcohol or 
phenol. The target molecules for synthesis are summarised in Figure 31 
            
N N
N
N
N
NH2O
O
O
O
117a                            
N N
N
N
N
NH2O
O
O
117b        
                        Figure 31.  Alcohol and phenol target molecules for synthesis      
4.2 Design 
 
The usual aqueous hydrolysis at neutral pH of the imidazotetrazinone ring to AIC and 
diazonium ion, in addition to the potential hydrolysis reaction of the diazonium ion to 
alcohol, promoted the idea for the synthesis of alcohol or phenol-release 
imidazotetrazinones. The hypothesis behind such synthesis was based on the following 
criteria: 
1) imidazotetrazinone ring opening should result in diazonium ion release at pH 
7.4. 
2) the hydrolysis product of the diazonium ion should be the unstable hemiacetal. 
Scheme 48, outlines the proposed imidazotetrazinone prodrug and the mechanism of 
alcohol or phenol release. 
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 Scheme 48. The proposed mechanism of alcohol or phenol release 
4.3 Synthesis 
 
The retrosynthetic analysis outlined in Scheme 18 (Section 2.2) was adapted to plan the 
route of synthesis of the target alcohol and phenol-release-imidazotetrazinones, Scheme 
49. The synthesis starts with the preparation of isocyanates which were then reacted 
with diazo-IC 19 to give the imidazotetrazinones. 
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O
19
R    Furfuryl or phenyl
       
       Scheme 49. Retrosynthesis plan for alcohol-and phenol-release 
imidazotetrazinones.                                            
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4.3.1 Synthesis of the Isocyanates                                                              
The Curtius thermal rearrangement of azides was used for the synthesis of the 
isocyanates. The azides were synthesized by the diazotization of the hydrazides as 
discussed in Chapter 2 previously; hydrazides were synthesized from esters by reaction 
with hydrazine monohydrate. The esters were synthesized from the reaction of ethyl 
bromoacetate with the alcohol or phenol, Scheme 50 outlines the general route used for 
isocyanate synthesis. 
O
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N C
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+ O HR
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O
NH2
R
N3O
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R
 
 
Scheme 50. General scheme for isocyanate preparation used in alcohol- and phenol-
release imidazotetrazinone  synthesis. 
 
4.3.2 Synthesis of an imidazotetrazinone for the release of furfuryl 
alcohol 
 
Scheme 51 outlines the synthesis of imidazotetrazinone 117a for furfuryl alcohol 
release. In this synthesis, ester 118a was formed upon the stirring of the furfurylalcohol 
in THF with NaH at room temperature to generate the reactive alkoxide (powerful 
nucleophile), which then reacted under reflux with the ethyl bromoacetate. The ester 
118a was collected by solvent/ solvent extraction after the solvent evaporation clean and 
in a good yield. The hydrazide 119a was formed by the reaction of ester 118a with six 
equivalents of hydrazine monohydrate and was collected clean and in good yield as a 
thick brown oil. The azide 120a was formed with the diazotization mixture NaNO2/HCl 
in DCM/H2O solvent mixture. The anhydrous DCM solution of the azide was stirred 
under nitrogen directly at room temperature to give the isocyanate 121a without further 
heating. The isocyanate was collected by the evaporation of DCM under reduced 
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pressure under cold conditions (ice bath) to avoid isocyanate loss by evaporation. The 
tetrazine 117a formed by the reaction of the isocyanate 121a and diazo-IC 20 in 
anhydrous DMSO at 35 °C protected from light. The tetrazine was extracted into CHCl3 
from an H2O suspension of the reaction mixture. Further purification by column 
chromatography gave pure, white solid, 117a.  
N N
N
N
N
O
O
NH2O
O OH OBr
O
+
i O O
O
O
ii
O O
NH
O NH2
iii
O O
N3
O
O O
N C
Oiv v
O
118a 119a
120a 121a 117a
 
Scheme 51 Synthesis of the imidazotetrazinone 117a. Reagents and conditions: (i) 
NaH, THF,  , 97%; (ii) NH2NH2٠H2O, EtOH, 93%; (iii) NaNO2,10 M aq. HCl, 
DCM/H2O; (iv) anhydrous DCM, rt , 48 h, 58%;  (v) Diazo-IC, DMSO, 35 °C, 48 h, 
13%. 
 
4.3.3 Synthesis of an imidazotetrazinone for the release of phenol 
 
Scheme 52 outlines the synthesis of the imidazotetrazinone 117b, the scheme showed 
similar reaction steps to those used in the synthesis of imidazotetrazinone 117a, The 
only difference is the base used for generation of the phenoxide ion at the step of the 
ester formation, a mild base K2CO3 was used rather than NaH, and this is due to the 
higher acidity of phenolic proton compared with furfurylalcohol. The 
imidazotetrazinone 117b was collected pure after column chromatography. 
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Scheme 52 Synthesis of the imidazotetrazinone 117b. Reagents and conditions: i) 
K2CO3, THF,  70 °C, 50%; (ii) NH2NH2٠H2O, EtOH, 54%; (iii) NaNO2,10 M aq. HCl, 
DCM/H2O; iv) anhydrous DCM, rt , 24 h, 73%; ( v) Diazo-IC, DMSO, 35 °C, 48 h, 
32%. 
 
4.4 Mechanistic Evaluation of the Imidazotetrazinones for 
Alcohol and Phenol release 
 
Imidazotetrazinones 117a & 117b were evaluated for their release of alcohol or phenol 
respectively, by the studying of their ring-opening mechanism at neutral pH at 37°C by 
1H NMR. The kinetics of release of alcohol or phenol were studied at acidic, neutral and 
alkaline pH by UV-Visible spectrophotometry. 
4.4.1 NMR Evaluation of alcohol and phenol-release-
imidazotetrazinones   
 
For the confirmation of the release of furfuryl alcohol by imidazotetrazinone 117a, the 
tetrazine ring opening mechanism under neutral aqueous condition, was studied in 
deuteriated phosphate buffer pD 7.8 at 37 °C by 1H NMR. The 1H NMR spectra showed 
the disappearance of the imidazotetrazinone and the appearance of the decomposition 
products with time, Figure 32A. Spiking of the final hydrolysis products of 
imidazotetrazinone 117a with authentic samples of furfurylalcohol, AIC and 
formaldehyde confirmed their identities, Figure 32B. 
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The study of phenol-release imidazotetrazinone 117b hydrolysis reaction in phosphate 
buffer pH 7.4 at 37 °C was performed by the same method used for the 
imidazotetrazinone 117a except that the total collection time for 1H NMR spectra was 
reduced to 12 h. Figure 33A shows the disappearance of the tetrazine with time and the 
appearance of the decomposition products; it was a faster decomposition than that 
observed for all the previously studied imidazotetrazinones under the same conditions. 
Spiking of the final decomposition products with authentic samples of phenol and AIC 
confirmed their identities as a decomposition products of tetrazine 117b, Figure 33B. 
This study confirmed the release of phenol according to the proposal Scheme 48.  
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Figure 32A. Kinetics of decomposition of furfuryl-release imidazotetrazinone 117a 1H 
NMR 
 
 
 
Figure 32B. Reaction products of hydrolysis of imidazotetrazinone 117a (A), spiked 
with authentic furfuryl alcohol (B) and AIC + HCHO (C). 
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           Figure 33A.  Kinetic of decomposition of phenol-release-imidazotetrazinone 
117b 
 
 
 
 
Figure 33B.  Final products of hydrolysis of  imidazotetrazinone 117b (A), spiked with 
phenol (B) and AIC (C). 
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4.4.Kinetics of alcohol- and phenol-release imidazotetrazinone 
hydrolysis 
 
The kinetics of hydrolysis for the release of alcohol and phenol by imidazotetrazinones 
117a & 117b were measured in phosphate-citrate buffer pH 4, 7.4 and 8 at 37 °C (as in 
Chapter 3, Section 3.3). This study was performed to investigate the neutral aqueous 
hydrolysis of imidazotetrazinones 117a & 117b for the release of alcohols and phenols, 
and to assess how their stability under acidic conditions and instability under alkaline 
conditions compared with temozolomide. Kinetic data (k' and t1/2) are summarised in 
Table 4.  
 
The U.V. spectra of the kinetic studies performed at pH 4 for both imidazotetrazinones 
117a and 117b showed a relatively high rate of decomposition. Imidazotetrazinone 
117b observed the highest rate and the shortest t1/2 (1.3  10-5  sec-1, t1/2 15.1 h) in this 
buffer and both of these tetrazines showed a linear pseudo-first-order decomposition, 
Figure 34A & B, accordingly both tetrazines showed far lower acid stability than that 
observed for temozolomide under the same conditions.  
The kinetic study of these tetrazines under neutral conditions, showed much higher rates 
than that observed for temozolomide. Once again, imidazotetrazinone 117b for the 
phenol release showed the highest rate of decomposition and the shortest t1/2 (53.8  10-
5 sec-1, t1/2 0.36 h) with a linear decomposition to the AIC with a normal 
imidazotetrazinone pattern of decomposition, Figure 35A & B. Figure 35A showed the 
bands of phenol (λ = 268 nm) quite separate and resolved. The much higher rate of 
decomposition for these tetrazines was also observed at pH 8, also following pseudo 1st 
order kinetics.   
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Fig 34A Decomposition pattern of decomposition of furfurylacohol-release-
imidazotetrazinone 117a in buffer pH 4 at 37 °C 
 
 
 
 
Fig 34B Linear kinetic of decomposition of furfurylacohol-release-imidazotetrazinone 
117a in buffer pH 4 at 37 °C 
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Figure 35A. Decomposition pattern of phenol-release-imidazotetrazinone 117b in 
buffer pH 7.4 at 37 °C 
 
 
 
Figure 35B.  Linear kinetic of decomposition of phenol-release-imidazotetrazinone 
117b in buffer pH 7.4 at 37 °C 
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4.4.2 Conclusion 
 
Imidazotetrazinones synthesized for the purpose of alcohol and phenol release were 
synthesized successfully with a one-carbon linker between the imidazotetrazinone and 
the alcohol or phenol to be released. The mechanistic evaluation for their release of 
alcohol and phenol by NMR showed that they followed the usual pattern of 
decomposition of imidazotetrazinone (AIC + diazonium ion) upon aqueous hydrolysis; 
the diazonium ion 122 then hydrolyzed to the unstable hemiacetal 123 that 
spontaneously decomposed to the alcohol or phenol and formaldehyde 125, Scheme 53. 
N N
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N
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R
H2O
O
R H
O
R +
H H
O
O
HH
Base
Buffer pH 7.4
37  C° N
NH
O
NH2 NH2
+
RON2
123 125
117 10
122
124
O
H
R =
OH2C
a
R = b
 
Scheme 53. The aqueous hydrolysis of alcohol-phenol-release imidazotetrazinone 117a 
& b  
 
The 1H NMR spectra of the final product mixtures showed the formaldehyde peak δ = 
4.82. This study confirmed the release of furfurylalcohol and phenol by 
imidazotetrazinones 117a and b.  
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Phenol-release imidazotetrazinone 117b demonstrated a rapid decomposition rate; the 
imidazotetrazinone disappears in a very short time compared with that observed by 
furfuryl alcohol-release imidazotetrazinone 117a and temozolomide. This may be 
attributed to the strong electron-withdrawing effect created by the phenolic oxygen 
which releases its unshared electrons, by resonance, into the aromatic ring, Figure 36. 
The 1H NMR of the imidazotetrazinone 117a showed the singlet of the two protons of 
the CH2 attached to the imidazotetrazinone ring at δ 5.69, whereas imidazotetrazinone 
117b CH2  protons were at δ 6.22, Figure 37. 
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       Figure 36 Phenoxy oxygen electron delocalization into the aromatic ring 
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Figure 37. 1H NMR spectra of imidazotetrazinones 117a and b showing the positions 
of the “formaldehyde” methylene group 
 
The kinetics study of the hydrolysis of imidazotetrazinones 117a and b in buffer 
solutions of pH 4, 7.4 and 8, rates constants (k') and t1/2 were summarised in table 4. 
 
Imidazotetrazinone pH 4.0 
           k' a              t1/2b 
pH 7.4 
   k' a             t1/2b   
pH 8.0 
    k' a           t1/2b 
117a 0.48 ± 0.01 40.1 36.1 ± 0.8 0.53 55.6 ± 0.7 0.35 
117b 
Temozolomide 1a 
1.3 ± 0.1 
0.1±0.001 
15.1 
235.0 
 53.8 ±0.2 
 
      14.0 
0.36 
1.4 
122.3±0.8 
46.2±0.2 
0.16 
0.42 
a k'   = pseudo first order rate constant,  10-5 sec-1; 
b t1/2 = half life in hours. 
 
Table 4.  Alcohol-phenol-release-imidazotetrazinones rate of decomposition and t1/2 
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This study showed the fast release of alcohol and phenol at the neutral pH, 
imidazotetrazinone 117a release furfurylalcohol with a rate constant more than double 
(36.1  10-5 sec-1) that observed by temozolomide (14  10-5 sec-1), whereas  the release 
of phenol by imidazotetrazinones 117b had nearly 4 times the rate of temozolomide 
decomposition at the same condition. This was due to the strong electron-withdrawing 
effect of the alcoholic and phenolic oxygen atoms, found to exert more effect in the case 
of tetrazine 117b due to the direct attachment of the oxygen to the aromatic ring, which 
resulted in the release of the lone pair electrons into the aromatic ring by resonance, 
therefore conferring a positive charge that increased its electron-withdrawing effect. 
 
The UV-Visible kinetic study showed the highest hydrolysis rates of any tetrazine at all 
three pH conditions studied. Although this is the case, they still showed a promising and 
reasonable acidic stability compared with the time required for absorption from the 
acidic stomach pH (0.8 h) for any future delivered alcoholic or phenolic drug.  
At all pH’s, phenol release was faster than alcohol release and both faster than 
temozolomide hydrolysis. 
 
These imidazotetrazinone can be used as a delivery system for alcoholic or phenolic 
drugs to the systemic circulation and the faster-released molecules i.e alcohol or 
phenols, may undergo normal distribution in the body on their own.  This may achieve 
oral availability for non-orally-intended drugs or a faster onset of action for polar drugs 
that are slowly absorbed. 
 
 
 
CHAPTER 5 
CONCLUSION AND FUTURE WORK 
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Chapter 5 Conclusion 
 
In this study, new imidazotetrazinones were synthesized that release aziridinium ions at 
physiological pH. Aziridinium ions have received considerable attention and interest in 
biological studies and are clinically-useful intermediates, sufficiently stable to find their 
targets on DNA, as shown by alkylating drugs, e.g. nitrogen mustards and 
nitrosoureas.62  
The imidazotetrazinones were synthesized with either an aliphatic ethylamine side chain 
or with an anilinoethyl side chain at position three of the imidazotetrazinone ring. The 
anilinoethylimidazotetrazinones were synthesized with different substituents on the p-
position of the aniline ring (electron withdrawing and electron releasing) to determine 
the different impacts on the mechanism of activation at neutral pH and the relative 
stability of the imidazotetrazinone under acidic conditions. Monomeric and 
bisimidazotetrazinones (bifunctional) tetrazines were synthesized. The synthesis of the 
new molecules proceeded successfully with high purity and all characterizations were 
performed to accepted publication standards, Figure 38. 
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                       Figure 38. New imidazotetrazinones for aziridinium ion release. 
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A trial of another application for the imidazotetrazinone ring as a delivery system was 
also undertaken. The synthesis of imidazotetrazinones for the release of alcohols and 
phenols was performed. The aim behind such synthesis was the enhancement of the 
delivery of poorly-distributed polar drugs, through the imidazotetrazinone having 
advantages as a good oral delivery system, Figure 39.  
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                 Figure 39. New imidazotetrazinones for alcohols and phenols release. 
 
The NMR evaluation study of the reaction mechanism of imidazotetrazinone ring 
opening for the release of aziridinium ions used imidazotetrazinone 59a 13C-labelled 
and unlabelled as a representative of all of the imidazotetrazinones synthesized for the 
aziridinium ion release. The study showed the ring opening to AIC and a diazonium ion 
intermediate that cyclised (96%) to the aziridinium ion at neutral pH, which can be 
considered as an indication of the possibility of the ring opening under physiological 
conditions to release the aziridinium ion. The kinetics of hydrolysis performed on the 
aziridinium-ion-release imidazotetrazinones at neutral and acidic pH showed that 
anilinoethylimidazotetrazinones with an electron releasing group at the p-position of the 
aniline ring, were quite similar to temozolomide under the same conditions, which is an 
indication to expect the same chemical activation at physiological pH and oral 
availability for any future drug.  
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A biological assay was performed previously (in collaboration with Dr Roger Phillips 
Institute of Cancer Therapeutics, University of Bradford), the bifunctionl aziridinium-
ion-release imidazotetrazinones 58a, b and the monomer 59a were tested, the cell lines 
A2780 with MMR+ expression and A2780-Cp70 which lack functional MMR were 
used, an equal number of cells were seeded, PaTrin-2 was used to deplete the activity of 
MGMT on both cell lines. Temozolomide was used as control, Table 5, the result 
showed that tetrazine 58a and b are independent on both MGMT and MMR in their 
activity, whereas the monomer 59a showed slight dependency but still not as much as 
temozolomide. Based on these findings, the possible conclusion is that the alkylation by 
the aziridinium-ion-release tetrazine might take place exactly as in the case of nitrogen 
mustards at the N7-position of the guanine base of DNA.  Accordingly, cytotoxic 
alkylation produced by these tetrazines may be through this alkylation rather than the 
cytotoxic O6-Me-guanine in the case of temozolomide which is repaired by MGMT and 
dependent on MMR. Referring to this study, the anticipated biological results for the 
monomeric aziridinium-ion-release tetrazines will be the similar especially for 
anilinoethyimidazotetrazinones carrying an electron releasing group at the p-position 
which showed an optimum effect (58a, b and 59a) compared with compounds bearing a 
withdrawing group. 
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 IC50 / μM IC50 ratios 
 
A2780 (MMR+)  
 
A2780-Cp70 (MMR-)  
MMR 
EFFECT 
A2780/Cp70 
MGMT 
EFFECT  
-/+ PaTrin-2 
-PaTrin-2 
Mean  ±  SD 
+ PaTrin-2 
Mean   ±  SD 
- PaTrin-2 
Mean ± SD 
 
+PaTrin-2 
Mean  ±  SD 
+PaTrin-2 A2780 
 
TMZ 
 
>257 
 
8.6 ±    0.32 
 
> 257 
 
>231 
 
>27 
 
>30 
 
58a 
 
0.7 ±   0.23 
 
1.3 ±   0.07 
 
6.5±   1.0 
 
7.0 ±   0.10 
 
5.8 
 
0.58 
 
58b 
 
1.4 ±    0.36 
 
2.08 ±  0.03 
 
11±  1.5 
 
11 ±  0.85 
 
5.4 
 
0.66 
 
59a 
 
54 ±    11 
 
34 ±   3.1 
 
62±  10 
 
94 ±   3.3 
 
2.8 
 
1.6 
 
54 
 
30 
 
11 ± 0.71 
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133 ± 1.0 
 
13 
 
2.9 
 
Table 5. In vitro chemosensitivity data for bifunctional and monofuctional tetrazine 
compared to temozolomide. 
 
The imidazotetrazinones carrying electron-releasing groups in the pendant phenyl rings 
(58a,b and 59a) showed kinetics of hydrolysis, at neutral pH, similar to temozolomide, 
which may be the optimum at physiological pH for a good therapeutic activity. The 
strength of electron releasing varies from group to another, the OCH3 is a stronger 
electron releasing group than CH3, resulting in a slight decrease in the activity, compare 
the chemosensitivity of 58a with 58b. This shows that the electron-releasing substituent 
is required  to optimise the ring opening but without increasing of the basicity of the 
aniline, which may delay formation of the aziridinium ion. Overall, it is the 
electropositivity of C4 of the tetrazine ring that controls the rate of ring-opening. 
Imidazotetrazinones carrying electron-withdrawing groups in the pendant phenyl rings, 
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showed relatively higher rates of hydrolysis, that reflect fast release of aziridinium ions 
with relatively less stability. 
 
Imidazotetrazinones for alcohol and phenol release is a promising study for the delivery 
of polar drugs to their targets, especially into the CNS. As part of the application, a trial 
study of linking morphine to the imidazotetrazinone ring was performed, the study was 
successful up to the stage of azide synthesis but isocyanate formation was not observed. 
For the linking of morphine to the imidazotetrazinone ring, the monomeric ester 135 
was formed by the reaction of the phenolic hydroxy group of morphine with 
bromoethylacetate, Scheme 54[1] and the dimeric ester 136 was formed by the reaction 
of both alcoholic and phenolic hydroxyl groups, Scheme 54[2]. Both esters converted to 
hydrazides and then azides but no isocyanates formed which may be due to the 
reactivity of the neighbouring tertiary amine.  
O
OHHO
N
+
O
Br
O
[1]
[2]
O
OHO
N
O
OO
N
O
O
OO
OO
135
136  
                      Scheme 54. Formation of morphine ethylacetate esters. 
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Serotonin or 5-Hydroxytryptamine (5-HT) 137 is a monoamine neurotransmitter that is 
primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system 
(CNS) of humans and animals. Low serotonin levels are believed to be the cause of 
many cases of mild to severe depression which can lead to symptoms such as anxiety, 
apathy, fear, feelings of worthlessness, insomnia and fatigue.  The most concrete 
evidence for the connection between serotonin and depression is the decreased 
concentrations of serotonin metabolites in the cerebrospinal fluid and brain tissues of 
depressed people. If depression arises as a result of a serotonin deficiency then 
pharmaceutical agents that increase the amount of serotonin in the brain should be 
helpful in treating depressed patients.  Anti-depressant medications increase serotonin 
levels at the synapse by blocking the reuptake of serotonin into the presynaptic 
cell.  Anti-depressants are one of the most highly prescribed medications despite the 
serious side-effects they can cause. The phenolic hydroxyl group of the serotonin can be 
used in a trial of linking it to the tetrazine as a vehicle to target its delivery to the brain.  
                                                 
N
H
NH2HO
137  
It may also be possible to apply the tetrazine modification, to tetrazine hydrolysis to 
release a hemiaminal (hemiacetal analogue) after hydrolysis of the diazonium ion 
intermediate. The hemiaminal may undergo decomposition similar to the hemiacetal 
resulting in the release of the amine containing drug, Scheme 55.     
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Scheme 55. Future application to imidazotetrazinone as a delivery system to primary 
amine containing drugs through unstable hemiaminal formation. 
 
This study has shown that the imidazotetrazinones have enormous potential as an 
orally-available drug delivery system. It is possible that, as with temozolomide, these 
prodrugs could cross the BBB to release drugs in the CNS under the control of local pH. 
 
Pivampicillin 138 is a prodrug that releases ampicillin when activated in the body by 
esterase enzymes;82 it is a double ester prodrug hydrolysed enzymatically to unstable 
hydroxymethylester 139, which undergoes spontaneous elimination to release ampicillin 
140 and formaldehyde, Scheme 56. This may be another application for the 
imidazotetrazinone prodrug delivery system; this example it is a delivery for carboxylic 
acid drugs Scheme 57 oulines the proposed scheme of the release of carboxylic acids 
linked to an imidazotetrazinone ring. 
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                      Scheme 56. Pivampicillin prodrug enzymatical activation  
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Scheme 57. Proposal of imidazotetrazinones aqueous hydrolysis to carboxylic acid 
release  
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Experimental 
E.1 Reagents 
Reagents were purchased from Sigma-Aldrich, Alfa Aesar and Fluka, solvents from 
Fisher Scientific.  
E.2 Instrumentation and general methods 
 
TLC was performed on highly-purified silica gel plates with UV indicator (silica gel 
F245), manufactured by Merck and visualized under UV light (366 or 254 nm) or stained 
with iodine.  Melting points were determined with an Electrothermal IA9200 digital 
melting point apparatus. Infrared data were obtained using a Perkin Elmer (Paragon 
1000) FT-IR Spectrophotometer. 
NMR spectra were acquired on a JEOL ECA600 spectrometer observing 1H at 600.17 
MHz and 13C at 150.91 MHz unless otherwise stated 13C assignments made with the aid 
of the DEPT 135 experiment. Other NMR spectra were recorded on a Bruker-
spectrospin AC400 observing 1H at 400.13 MHz and 13C at 100.62 MHz. Mass spectra 
were obtained from the EPSRC Mass Spectrometry Service centre at the University of 
Swansea and the Analytical Centre at the University of Bradford using a Micromass 
Quattro Ultima mass spectrometer. Elemental analyses were obtained from the 
Advanced Chemical and Material Analysis Unit at the University of Newcastle upon 
Tyne. A Varian-Cary 400Bio UV-Visible spectrophotometer equipped with a Peltier 
temperature controller was used for the kinetic studies.   
 
 
 
 124 
 
E.3 Synthesis of imidazotetrazinones for aziridinium ion release 
in Chapter 2 section 2.2.2 
 
Methyl 3-(t-butoxycarbonylamino)propionate 7383 
 
H3N O
O
Cl + O O O
OO Et3N
100  C N
H
O
O
O
O
72 73
1
2
3
  o
                     
A mixture of β-alanine methyl ester hydrochloride salt 72 (2 g, 14.34 mmol) and di-t-
butyl dicarbonate (5.63 g, 25.8 mmol) was heated under N2 at 100 ºC for 2 h, 
triethylamine (1.45g, 14.34 mmol) was then added to the melt gradually with stirring 
and the mixture stirred at 100 ºC overnight. A white solid was observed in an oil 
vehicle. The reaction mixture was suspended in ethyl acetate (40 ml) and the solid was 
removed by filtration. The ethyl acetate filtrate was washed with water, dried over 
anhydrous MgSO4, filtered and then evaporated to give a pale yellow oil. Distillation 
under reduced pressure gave BOC-protected aminoester 73, a colourless oil b.p. 65 – 66 
ºC, 0.1 mmHg (lit. 84 – 85 ºC at 0.4 mmHg),83 (1.7 g, 60%). 1H NMR (CDCl3) δ: 5.18 
(br s, 1H, NHCO), 3.47 (s, 3H, OCH3), 3.17 (q, J = 5.9 Hz, 2H, 3-H), 2.31 (t, J = 5.9 
Hz, 2H, 2-H), 1.39 (s, 9H, C(CH3)3); 13C NMR (CDCl3) δ: 172.6 (C-1), 
155.7(OCONH), 78.9 (OC(CH3)3), 51.5 (OCH3), 36.04 (C-3), 34.3 (C-2), 28.2 
(C(CH3)3); MS (ES) m/z  204.2 ( 50%) (M+H)+, 146.2(85%) (C7H15NO2+H)+, 105.2 
(85%) (C4H10NO2)+, 83.3 (100%). 
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3-(t-Butoxycarbonylamino)propanoyl hydrazide 7484                                             
                                                    
+
N
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12
3
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BOC-protected ester 73 (2.0 g, 984 mmol) was dissolved in i-propanol (10 ml). 
Hydrazine monohydrate (2.95 g, 59.04 mmol) was added and the mixture stirred at r.t 
over night. Volatile compounds were removed by evaporation under reduced pressure. 
The resultant white solid was re-suspended in diethyl ether (30 ml) and collected by 
filtration; it was then dissolved in hot ethyl acetate (50 ml); cold hexane (50 ml) was 
added to the mixture gradually until a white solid precipitated. After cooling on ice, the 
solid hydrazide 74 was collected by filtration and dried (1.87g, 94%) m.p. 108 – 110 ºC 
(lit. 110 – 112 ºC).84 1H NMR (CDCl3) δ: 7.31 (br s, 1H, NH2NH), 5.18 (br s, 1H, 
NHBOC), 3.91 (br s, 2H, NH2), 3.4 (q, J = 6.0 Hz, 2H, 3-H), 2.38 (t, J = 6.0 Hz, 2H, 2-
H), 1.42 (s, 9H, CH3 ); 13C NMR (CDCl3) δ: 172.2 (C-1), 156.2 (OCONH),  77.3 
(C(CH3)3), 36.7 (C-3), 34.5 (C-2), 28.5 CH3; MS (ES) m/z 204.2 (100%) (M+H)+, 148.2 
(98%) (C4H9N3O3+H)+. 
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3-(t-Butoxycarbonyl-N-nitrosoamino)propanoyl azide77  
 
N
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3
o
                                
The hydrazide 74 (1.8 g, 8.86 mmol) was suspended in a mixture of water (10 ml) and 
DCM (10 ml) and left to stir in an ice bath at 0 ºC. aq. HCl (5 ml, 10 M) was added 
gradually followed by NaNO2 (3.67 g, 53.13 mmol) solution in water (10 ml) added 
dropwise, keeping the exothermic reaction at 0 – 5 ºC.  DCM (10 ml) was added and the 
organic layer was separated, washed with water, dried over anhydrous MgSO4, filtered 
and evaporated to give azide 77 as a yellow oil (1.22 g, 68%).  Formation of the azide 
was confirmed by IR (strong band at 2145 cm-1). 1H NMR (CDCl3) δ: 3.98 (t, 2H, J = 
7.2 Hz, 1-H), 2.40 (t, 2H, J = 7.2 Hz, 2-H), 1.62 (s, 9H, CH3); 13C NMR 150.1 MHz 
(CDCl3) δ: 177.5 (C-3), 151.7(OCON),  86.01 (C(CH3)3, 35.8 (C-1), 33.8 (C-2), 28.1 
(CH3); IR (liq film) 2986w (CH), 2145s (N3), 1750s (CONNO), 1713s (CON3), 1513m 
(NO) cm-1. 
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t-Butyl N-(2-isocyanatoethyl) N-Nitroso carbamate 78 
                                                     
oN N3O
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O
N
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The azide 77 (1.22g, 5.7 mmol) was dissolved in anhydrous DCM (15 ml) and stirred 
under nitrogen at 30 ºC for 48 h. Isocyanate formation was confirmed by IR, which 
showed strong band at 2280 cm-1. The DCM was evaporated under reduced pressure at 
low temperature (an ice bath was used to lower the temperature and the isocyanate 78 
collected as a yellow oil (0.8 g, 60 %). 1H NMR (CDCl3), δ:  3.9 (t, 2H, J = 6.0 Hz, 1-
H), 3.32 (t, 2H, J = 6.0 Hz, 2-H), 1.64 (s, 9H, CH3); 13C NMR (CDCl3) δ:  151.85 
(OCON), 149.51 (NCO), 86.2 (C(CH3)3), 40.5 (C-1), 39.97 (2), 28.03 (CH3); IR (KBr) 
2280s (NCO), 1750s (CO), 1513m (NO) cm-1.                                                                         
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8-Carbamoyl-3-((N-t-butoxycarbonyl-N-nitroso)-2-
aminoethyl)imidazo[5,1-d][1,2,3,5] tetrazin-4(3H)-one 79 
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2
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7
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The isocyanate 78 (0.80 g, 4.37 mmol) was dissolved in DMSO (0.9 ml) and added to a 
suspension of diazo-IC 20 (0.6 g, 4.37 mmol) in DMSO (0.9 ml), the mixture was 
stirred at 30 ºC protected from light. The reaction was complete after 36 h as monitored 
by 1H NMR. Water (10 ml) was added and the mixture filtered, then the residue washed 
with copious amounts of water until the washings came through colourless. The solid 
was washed with i-propanol and left to dry on the filter. The solid was suspended in 
chloroform (20 ml), the solution filtered, and  the chloroform filtrate evaporated to 
dryness to give the imidazotetrazinone 79 as a pale yellow solid (0.11 g, 14 % yield), 
m.p. 154 – 157 ºC; 1H NMR (DMSO-d6) δ: 8.85 (s, 1H, 6-H), 7.70 & 7.58 (2  br s, 2H, 
CONH2), 4.36 (t, 2H, J = 6.1 Hz, 1'-H), 4.14 (t, 2H, J = 6.1, 2'-H), 1.42 (s, 9H, (CH3); 
13C NMR (DMSO-d6) δ: 161.7 (CONH2), 151.9 ((CH3)3COCO), 139.5 (C-4), 134.4 (C-
8a), 131.9 (C-8), 129.7 (C-6), 86.1 ((CH3)3C), 46.3 (C-1'), 39.8 (C-2'), 27.8 (CH3); IR 
(KBr) 3445m (NH), 3137m (NH), 2986m (CH2), 1753s (C(4)O), 1681s (CONH2), 
1454s (NO) cm-1; MS(FAB): m/z 353 (100%)(M+H)+, 307(70%), 288.9(35%),  
705(10%)(2M+H)+; CHN Found: C, 36.54; H, 3.78; N, 26.96. C12H16N8O5 · 0.5CHCl3, 
requires C, 36.44; H, 4.04; N, 27.2%.   
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3-(2-Aminoethyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 
hydrobromide salt  54 
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HBr (0.65 g, 8.03mmol) was added over 30 min to a stirred solution of BOC-protected 
imidazotetrazinone 79 (0.1 g, 0.31 mmol) in acetonitrile (6 ml). The mixture was stirred 
overnight and a precipitate formed. The solid was collected by filtration and dried under 
vacuum, 1H NMR showed some impurities. The solid was re-suspended in CH3CN, 
filtered and then dried to give the imidazotetrazinone hydrobromide salt 54 (0.088 g, 88 
%). The CH3CN layer was evaporated to dryness, an orange solid was collected as a 
second crop. This was re-suspended into two portions of CH3CN (10 ml) and the 
acetonitrile was evaporated to remove excess HBr. The solid residue was collected after 
complete evaporation of the acid and the solvent. 1H NMR showed the 
imidazotetrazinone salt second crop with a significant impurity. Spiking of the solid 
sample in DMSO-d with authentic 3-(2-bromoethyl)imidazotetrazinone 1d showed the 
impurity to be this compound as by-product. Compound 54 m.p. 145 – 148 º C; 1H 
NMR (DMSO-d) δ: 8.92 (s, 1H, 6-H), 7.74 & 7.89 (2 br s, 2H, NH2CO), 7.83 (br s, 3H, 
NH3+), 4.56 (t, 2H, J = 5.8 Hz, 1'-H), 3.30 (hex, 2H, J = 5.8 Hz, 2'-H); 13C NMR 
(DMSO-d), δ: 161.9 (CONH2), 140 (C-4), 134.8 (C-8a), 131.7 (C-8), 129.5 (C-6), 47.0 
(C-2'), 38.2 (C-1'); IR (KBr) 3410s (NH), 3137w (NH), 1750s (C(4)O), 1670 (CONH2), 
1603m, 1460m (C=C) cm-1; MS (ES): m/z  527.1(18%) (2M+ Br)+, 224.1(M+) (23%), 
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138.2(38%), 119.2 (100%), 102.2 (58%), 87.2(10%); CHN Found: C, 23.24; H, 2.94; N, 
25.95.  C7H9N7O2· 2HBr·0.3 C2H3N, requires C, 23.21; H, 3.04; N, 26.00%. 
Dimethyl 3,3-iminodipropanoate 82 and the trimethyl3,3,3-
iminotripropanoate 8385 
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Ammonia (30 g, 1.764 mol) was condensed into methanol (200 ml) using a dry ice and 
acetone trap. Methyl acrylate 81 (303.8 g, 3.53 mol) was added over 30 min and the 
reaction mixture was then stirred at rt, over night. The methanol was evaporated to give 
a colourless viscous oil. 1H NMR showed a mixture of esters 82 and 83. The ester 82 
was collected by fractional distillation at 80 – 90 ºC, 0.05 mmHg (lit. 75 ºC, 0.05 
mmHg).85 1HNMR (CDCl3) δ: 3.53 (s, 6H, 2OCH3), 2.75 (t, 4H, J = 6.3 Hz, H-3,3'), 
2.35 (t, 4H, J = 6.3 Hz, H-2,2'), 1.47 (br s, 1H, NH); 13C NMR (CDCl3) 173.0 (C-1,1'), 
51.74 (OCH3), 44.83 (C-3&3'), 34.48 (C-2&2'); IR (Liq film) 3323w (NH), 2955m (CH 
st), 1736s (CO), 1173m (C-O) cm-1; MS (ES): m/z 190.2 (100%) (M+H)+. 
The ester 83 was left behind in the distillation flask with 100 % purity as shown by 1H 
NMR and was of 3 fold yield more than the ester 82. 1H NMR (CDCl3) δ: 3.62 (s, 9H, 
3OCH3), 2.69 (t, 6H, J = 7.1 Hz, NCH2), 2.38 (t, 6H, J = 7.1 Hz, COCH2); 13C NMR 
(CDCl3) δ: 173.04 (CO), 51.6 (OCH3), 49.2 (N CH2), 32.7 (CH2CO). 
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t-Butyl-N,N-bis(3-methoxy-3-oxopropyl)carbamate 84 86  
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The aminodiester 82 (11.3 g, 59.8 mmol) was mixed with di-t-butyl dicarbonate (23.5 g, 
107.6 mmol) and heated under N2 to 100 ºC without solvent. Et3N (6.05 g, 59.8 mmol) 
was added slowly to the mixture, the reaction mixture was then stirred at 100 ºC, 
overnight. The reaction mixture was partitioned between equal volumes of water / 
chloroform (25 ml); the chloroform layer was separated, washed with H2O, dried with 
anhydrous MgSO4 and then filtered. The chloroform layer was evaporated to yield a 
yellow oil, 84 (11.00 g, 66 %). 
1H NMR (CDCl3) δ: 3.61 (s, 6H, 2  OCH3), 3.45 (t, 4H, J = 6.3 Hz, H-3,1'), 2.51(t, 4H, 
J = 6.3 Hz, H-2,2'), 1.38 (s, 9H, C(CH3)3), 13C NMR (CDCl3) 172.4 (CH2COOCH3),  
155.1 (NCOO), 80.1 (OC(CH3)3), 51.7 (OCH3), 44.2 (C-3&3'), 33.9 (C-2&2'), 28.4 
(CCH3)3; IR (liq film) 2977m (CH st), 1739 (COCH3), 1696 (BOC-CO), 1164s (C-O) 
cm-1; MS(ES): m/z 290.1(100%) (M+H)+.86  
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t-Butyl-N,N-bis(3-hydrazino-3-oxopropyl)carbamate 85 
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The BOC-protected aminodiester 84 (11.4 g, 39.5 mmol) was dissolved in  i-propanol 
(40 ml),  hydrazine monohydrate (19.8 g, 395 mmol) was added and  the mixture stirred 
at rt, overnight. Volatile compounds were removed by evaporation to give a viscous 
yellow oil. 1H NMR confirmed the product 85 with impurities. The oil was then 
dissolved in hot ethylacetate (30 ml), cold hexane (30 ml) was added and a white solid 
precipitated on cooling, the solid hydrazide 85 was collected by filtration, washed with 
chloroform and then dried. The solid was soluble in DMSO, methanol and water, 
insoluble in chloroform, dichloromethane, acetonitrile and diethyl ether. (8.10 g, 70%) 
m.p. 112 – 113.3ºC, 1H NMR (DMSO-d6), δ: 9.03 (br s, 2H, 2  CONH), 4.19 (br s, 4H, 
2  NH2), 3.30 (t, 4H, J = 6.5 Hz, H-3,3'), 2.24 (t, 4H, J = 6.5 Hz, H-2,2'), 1.39 (s, 9H, 
C(CH3)3); 13C NMR (DMSO-d6) 170.2 (C-1,1'), 154.8 (NCOO), 79.2 (C(CH3)3), 44.6 
(C-3,3'), 33.7 (C-2,2'), 28.5 (CH3); IR (KBr) 3267s  (NH), 2977m (CH st), 1688s (BOC-
CO), 1649s (CONH), 1621m (NH), 1178s (C-O) cm-1; MS (ES): m/z  290.2 (100%) 
(M+H)+, 312.2 (70%) (M+Na)+, 190.2 (25%).   
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t-Butyl-N,N-bis(3-azido-3-oxopropyl)carbamate 86  
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Hydrazide 85 (1 g, 3.46 mmol) was suspended in a mixture of H2O (10 ml) and DCM 
(10 ml) and was then stirred on an ice bath at 0 ºC. aq. HCl (4 ml 10 M) was added 
slowly to the mixture, followed by NaNO2 (2.38 g, 34.6 mmol) solution in water (20 
ml) drop-wise, keeping the exothermic reaction at 0 – 5 ºC. Further DCM (20 ml) was 
added and the DCM layer separated, washed with water, dried over MgSO4 and then 
filtered. IR confirmed formation of the azide 86 (2138 cm-1); the DCM was evaporated 
to yield a pale yellow oil (0.57 g, 57%).1H NMR (CDCl3) δ: 3.54 (t, 4H, J = 6.6 Hz, 
3,3'-H), 2.63 (t, 4H, J = 6.6 Hz, 2,2'-H), 1.48 (s, 9H, CH3); 13C NMR (CDCl3) δ: 174.0 
(C-1,1'), 155.0(NCOO),  80.6 (C(CH3)3, 36.0 (C-3,3'), 31.0 (C-2,2'), 28.3 (CH3); IR (liq 
film) 2979m (CH2 st), 2138s (CON3), 1740s (CO), 1697s (COC(CH3)3) cm-1. 
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t-Butyl-N,N-bis(2-isocyanatoethyl)carbamate 87  
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The azide 86 (0.57 g, 1.83 mmol) was dissolved in anhydrous DCM (20 ml) and the 
solution stirred under nitrogen at rt for 48 h. The IR and 1H NMR spectra confirmed the 
formation of isocyanate 87. The DCM was evaporated and the isocyanate was re-
suspended in anhydrous petroleum ether and decanted from an oily residue, evaporation 
of the petroleum ether gave brown oil as pure isocyanate 87 (0.2 g, 52.3%).1H NMR 
(CDCl3), δ:  3.46 (t, 4H, J = 6.7 Hz, 1,1'-H), 3.38 (t, 4H, J = 6.7 Hz, 2,2'-H), 1.42 (s, 9H, 
(CH3)3); 13C NMR (CDCl3) δ:  155.2 (NCOO), 151.0 (NCO), 81.2 (C(CH3)3), 49.1 (C-
1,1'), 41.6 (C-2,2'), 28.4 (CH3); IR (liq film) 2978w (CH2 st), 2272s (NCO), 1695s 
(COC(CH3)3) cm-1. 
 
 
 
 
 
 
 135 
 
t-Butyl-N,N-bis(2-(8-carbamoyl-4-oxo-3H,4H-imidazotetrazin-3-
yl)ethyl)carbamate 88 
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Isocyanate 87 (0.2 g, 0.783 mmol) dissolved in DMSO (300 l) was transferred to 
suspension of diazo-IC 20 (0.24 g, 1.7 mmol) in DMSO (600 l); the mixture was then 
stirred, protected from light, at rt. 1H NMR was used to monitor the reaction; it showed 
two imidazotetrazinone 6-H peaks. 1H NMR (DMSO-d6), δ: 8.94 & 8.88 (s, 1H, 6-H), 
7.85, 7.78 (2  br s, 2H, CONH2), 7.66, 7.62 (2  br s, 2H, CONH2),  4.62 (m, 4H, 2,2-
H), 3.67 (m, 4H, 1,1-H),  0.84 (s, 9H, C(CH3)3); 13C NMR (DMSO-d6) δ: 161.8 
(CONH2), 155.4 ((CH3)3COCO), 139.6, 139.4 (C-4), 134.6 (C-8a), 131.5, 131.2 (C-8), 
129.4, 129.2 (C-6), 79.8 ((CH3)3C), 47.7, 47.4 (C-2,2), 45.0, 44.1 (C-1,1), 27.7 (CH3); 
IR (KBr) 3420m (NH), 3137.4m (NH), 2955m (CH2 st), 1750s (C(4)O), 1668s 
(CONH2), 1598 m (C=C), 1462 m cm-1;  MS(ES): m/z 530 (25 %) (M+H)+, 552(40%) 
(M+Na)+, 144 (100 %); CHN Found: C, 42.38; H, 4.49, N, 33.82  C19H23N13O6·5 H2O, 
requires C, 41.78, H, 4.65, N, 33.08%. 
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N,N-bis(2-(8-carbamoyl-4-oxo-3H,4H-imidazotetrazin-3-
yl)ethyl)ammonium bromide 55   
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Aq. HBr (0.6 g, 6.8 mmol) was added slowly to a stirred solution of BOC-protected 
bisimidazotetrazinone 88 (0.36 g, 0.68 mmol) in CH3CN (3 ml). The mixture was 
stirred overnight at rt and a precipitated formed. The solid was collected by filtration 
washed with cold acetonitrile (20 ml) and dried under vacuum, to give product 55 (0.17 
g, 57 %), m.p.175  –  176 ºC. 1H NMR (DMSO-d6) δ: 8.93 (s, 2H, 6-H), 8.80 (br s, 2H, 
NH2+ exch. D2O),  7.88 & 7.72 (2  br s, 4H, 2   CONH2 exch D2O), 4.63 (t, 4H, J = 
5.8 Hz, 2, 2-H), 3.55 (quin, 4H, J = 5.8 Hz, 1, 1-H); 13C NMR (DMSO-d), δ: 161.9 
(CONH2), 139.9 (C-4), 134.7 (C-8a), 131.9 (C-8), 129.6 (C-6), 45.7 (C-2, 2), 45.5 (C-1, 
1); IR (KBr) 3420m (NH), 2955m (CH st), 2792 (NH2+), 1750s (C(4)O), 1668 
(CONH2), 1598m, 1462m cm-1; MS (ES): m/z  452  (13%) (M + Na)+, 430 (100%) 
(M)+, 127 (37%) (AIC + H)+; CHN Found: C, 26.80; H, 3.50; N, 29.13. C14H15N13O4· 2 
HBr·2 H2O, requires C, 26.81; H, 3.37; N, 29.03%.  
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 Methyl 3-benzylaminopropanoate 89 87  
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Benzylamine (10 g, 93.3 mmol) was dissolved in methanol (50 ml) and the solution 
stirred on an ice bath at 0 ºC; methyl acrylate  (16.1 g, 186.6 mmol) was added over 3 
min, the mixture was then stirred under reflux for 48 h, the reaction was monitored by 
1H NMR. The 1H NMR spectrum showed ester 89 and some of the dimeric ester. 
Volatile compounds were removed by evaporation under vacuum to give a pale yellow 
oil. Fractional distillation gave the methyl 3-benzylaminopropanoate 89, b.p. 77 ºC – 80 
ºC at 0.05 mmHg (lit. 145 – 147 ºC, 7 mmHg)87 (60 % yield); 1H NMR (CDCl3), δ: 7.29 
(m, 5H, Ar-H), 3.78 (s, 2H, PhCH2), 3.65 (s, 3H, OCH3) 2.9 (t, 2H,  J = 6.4 Hz, H-3), 
2.51 (t, 2H, J = 6.4 Hz, H-2), 1.71 (s, 1H, NHCH2); 13C NMR (CDCl3), δ: 173.2 (C-1), 
140.3 (ArCCH2), 128.6 (ArCH-o), 128.1 (ArCH-m), 127.0 (ArCH-p), 53.8 (PhCH2), 
53.6 (CH3),  44.5 (C-3),  34.6 (C-2); IR (liq film) 3340m (NH), 2952w (CH st), 1736s 
(CO), 1643w, 1450m (C=C), 1173m (C-O) cm-1; MS (ES): m/z  194.3  (65%) (M + H)+, 
120 (100%) (C8H10N)+, 91.3 (100%)(C7H7)+. 
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3-benzylaminopropanoyl hydrazide 90 88    
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Methyl 3-benzylaminopropanoate 89 (0.9 g, 4.7 mmol) was dissolved in ethanol (10 
ml), hydrazine monohydrate (2.6 g, 28.2 mmol) was added and the mixture stirred at rt 
for 24 h, 1H NMR showed completion of the reaction. The volatile compounds were 
removed by evaporation under reduced pressure to yield a viscous oil  90 (0.89 g, 98.8 
%).1H NMR (CDCl3), δ: 8.93 (br s, 1H, CONH), 7.21 (m, 5H, Ar-H), 4.67 (br s, 1H, 
PhCH2NH), 3.79 (br s, 2H, CONHNH2), 3.68 (s, 2H, PhCH2), 2.79 (t, 2H, J = 6.1 Hz, 
H-3), 2.26 (t, 2H, J = 6.1 Hz, H-2); 13C NMR (CDCl3), δ: 173.1 (C-1), 139.6 (ArCCH2), 
128.6 (2  ArCH-o), 128.2 (2  ArCH-m), 127.23 (ArCH-p), 53.7 (PhCH2),  44.8(C-3),  
34.3 (C-2);  IR (liq film) 3292s br (NH), 3029w (Ar-H st), 2952w (CH st), 2361&2340 
(NH st), 1648s (CONH), 1541m (C=C), 737 & 699 (mono-substituted aromatic ring) 
cm-1;  MS (ES): m/z 194.2 (100%) (M+H)+. 
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3-(N-Benzyl-N-nitrosoamino)propanoyl azide 91a and 3-
benzylaminopropanoyl azide 91b 
                                                
12
3
N
H
O
N
H
NH2
90
NaNO2 / HCl
0 5 C
N
O
N3
NOº
12
3
N
H
O
N3+
91b91a                 
Hydrazide 90 (1.5 g, 7.8 mmol) was dissolved in a mixture of H2O (10 ml) and DCM 
(10 ml). The mixture was stirred on an ice bath at 0 ºC, HCl (5 ml, 10 M) was added 
slowly, then NaNO2 (3.2 g, 46.6 mmol) solution in H2O (10 ml) was added drop-wise 
keeping the exothermic reaction at 0 – 5 ºC. Further DCM (10 ml) was added and the 
DCM layer was then separated, washed with water, dried over MgSO4.  IR confirmed 
the formation of an azide, 1H NMR showed two azides were present. The mixture of 
azides was used directly in the next step.  1H NMR (CDCl3), δ: 7.37 (m, 10 H, Ar-H), 
7.1 (d, 2H, J = 8.1 Hz Ar-H), 5.36 (s, 2H, PhCH2), 4.82 (s, 2H, PhCH2), 4.31 (t,  2H, J = 
6.6 Hz H-3), 3.64 (t, 2H, J = 6.6 Hz, H-3), 2.82 (t, 2H, J = 6.6 Hz H-2), 2.47 (t, 2H, J = 
6.6 Hz H-2) ; 13C NMR (CDCl3), δ: 178.4 & 177.7 (C-1), 134.6 & 133.9 (ArCCH2), 
129.2 & 129.1 (2  ArCH-o), 128.9 & 128.5 (2  ArCH-m), 128.3 & 128.2 (ArCH-p), 
57.1 & 47.2 (PhCH2),  46.9 & 39.3(C-3),  35.9 & 33.2 (C-2);  IR (liq film) 2924w (CH 
st), 2142s (CON3), 1715s (CO), 1454s (N-NO), 737&699 (mono-substituted aromatic 
ring) cm-1. 
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2-(N-benzyl-N-Nitrosoamino)ethyl isocyanate 92a and 2-
Benzylaminoethylisocyanate 92b 
                                               
N
N
C
O1
2
DCMN
O
N3
X rt X
9291
X = NO a
   = H    b                                           
The azides 91a & b solution in anhydrous DCM was stirred under nitrogen at rt for 24 
h. Isocyanate formation was confirmed by IR. The 1H NMR showed the formation of 
two isocyanates. The DCM was evaporated under reduced pressure at low temperature 
(an ice bath was used to lower the temperature). The isocyanates were collected as a 
crude  pale  brown oil (0.6 g).1H NMR (CDCl3), δ: 7.39 (m, 10H, Ar-H), 5.39 (s, 2H, 
PhCH2), 4.85 (s, ≈ 2H, PhCH2), 4.22 (t, 2H, J = 6.1 Hz, H-2), 3.62 (t, 2H, J = 6.1 Hz, H-
1), 3.59 (t, 2H, J = 6.1 Hz, H-2), 3.37 (t, 2H, J = 6.1 Hz, H-1); 13C NMR (CDCl3), δ: 
156.7 & 150.4 (NCO), 134.4 & 133.9 (ArCCH2), 129.3 & 129.2 (2  ArCH-o), 129.0 & 
128.5 (2  ArCH-m), 128.4 & 128.3 (ArCH-p), 57.3 & 51.8 (PhCH2),  46.9 & 43.8(C-
2),  41.8 & 39.5 (C-1);  IR (liq film) 2918w (CH st), 2274s (NCO), 1454s (N-NO), 
737&699 (mono-substituted aromatic ring) cm-1. 
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3-{2-[Benzyl(nitroso)amino]ethyl}-4-oxo-3H,4H-imidazo[1,5-
d][1,2,3,5]tetrazine-8-carboxamide 93a &  
3-[2-(Benzylamino)ethyl]-4-oxo-3H,4H-imidazo[1,5-
d][1,2,3,5]tetrazine-8-carboxamide 93b   
                                             
N N
N
N
N
N
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N
N
C
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N
N
N
N
O
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+
X
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rt
X
2
6 1
4
5
7
8 8a
3
1
2
20
X = NO  a
X = H     b
93
                                                                                                                         
Isocyanates 92a, b (0.6 g, 3.53 mmol) were dissolved in DMSO (0.7 ml) then the 
solution was transferred under nitrogen to a suspension of diazo-IC 20 (0.48 g, 3.5 
mmol) in DMSO (1.4 ml), the mixture was then stirred protected from light at rt, 
overnight. The reaction was monitored using 1H NMR, after 24 h it showed the 
formation of two imidazotetrazinones but the reaction was not yet complete. After 48 h 
the reaction mixture was suspended in water, filtered, the residue washed with copious 
amounts of water until the washings came through colourless, then dried. Small samples 
of the solid were tested for its solubility in different solvents, acetonitrile, i-propanol 
and chloroform. Isopropanol was found to dissolve only the impurities. The solid was 
then washed with i-propanol, filtered, and dried (0.2 g, 20%). The solid consisted of two 
imidazotetrazinones. 1H NMR (DMSO-d6) δ: 8.83 (s, 1H, 6-H), 8.76 (s, 1H, 6-H), 7.83, 
7.70 (2  br s, 2H, CONH2), 7.80, 7.69 (2  br s, 2H, CONH2), 7.26 (m, 5H, Ar-H), 7.24 
(m, 5H, Ar-H), 5.36 (s, 2H, PhCH2), 4.86 (s, 2H, PhCH2), 4.72 (t, 2H, J = 5.8 Hz, H-1), 
4.58 (t, 2H, J = 5.8 Hz, H-2), 4.32 (t, 2H, J = 5.7 Hz, H-1), 3.89 (t, 2H, J = 5.7 Hz, H-
2);  13C NMR (DMSO-d6) δ: 161.9, 161.4 (CONH2), 139.2 (C-4), 135.4, 135.0 
(ArCCH2), 134.6, 134.5 (C-8a), 131.9, 131.6 (C-8), 129.6, 129.3 (C-6), 129.1 (2 
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ArCH-o), 128.9 (ArCH-p), 128.5 (2   ArCH-m), 128.0,  56.4, 50.2 ( PhCH2), 47.5, 
45.6 (C-1), 47.0, 43.2 (C-2);  MS (ES): m/z 707.1 (100%)(2M+Na)+, 365.2 
(82%)(M+Na)+ , 343.2 (24%)(M+H)+, 138.1(11%)(C4H3N5O+H)+. To remove the 
nitroso group, the solid mixture of tetrazines (0.083 g, 0.24 mmol) was dissolved in 
acetonitrile (3 ml) then hydrobromic acid (0.04 g, 0.48 mmol 48%) was added drop-
wise to the solution, the mixture stirred at rt for 2 h, a solid was precipitated. The solid 
was collected by filtration, washed with copious amounts of acetonitrile and then dried. 
1H NMR showed a single compound, the tetrazine bromide salt 56.                                                 
   
1
2
3
4
56
7
8 8a
1
2N N
N
N
N
N
H2O
NH2O
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56
N N
N
N
N
N
O
NH2O
NO
aq. HBr 48%
CH3CN / rt
       
m.p. 143 – 144 ºC 1H NMR (DMSO-d6)  δ: 8.96 (br s, 2H, NH2+), 8.93 (s, 1H, 6-H), 
7.86 & 7.71 (2  br s, 2H, CONH2), 4.67 (t, 2H, J = 5.7 Hz, H-1), 4.27(t, 2H, J = 5.7 
Hz, PhCH2), 3.47 (quin, 2H, J = 5.7 Hz, H-2);  13C NMR (DMSO-d6) δ: 162.6 
(CONH2), 140 (C-4), 134.7 (C-8a), 132.2 (ArCCH2), 131.8 (C-8), 130.5 (2  ArCH-o), 
129.8 (ArCH-p), 129.6 (C-6), 129.4 (2   ArCH-m), 50.6 ( PhCH2), 45.5 (C-1), 45.3 (C-
2);  IR (KBr) 3441, 3337 m (NH2+), 3407m (Ar-H st), 3107 (NH), 2791w (CH st), 1758 
(C(4)O), 1666 (CONH), 1606 (C=C), 721 & 702 cm-1; MS (ES): m/z  473, 475 & 477 
(100%) (C14H17Br2N7O2)(1:2:1), 393&395(1:1) (100%) (C14H16BrN7O2), 313.9 (100%) 
(C14H16N7O2)+; CHN Found: C, 31.62; H, 3.17; N, 19.08. C14H15N7O2·2.6HBr·0.1H2O, 
requires C, 32.0; H, 3.41; N, 18.66%. 
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E.3.2 Synthesis of imidazotetrazinones bearing anilines in Chapter 2 
section 2.2.2.2 
Methyl 3-(4-methylphenylamino)propanoate 9489                                      
           
1
2
3NH2
O
O
MeOH
HN O
O
+
9481
6'
5'
2'
3'
4'
1'
                              
p-Toluidine (5 g, 46.7 mmol) was dissolved in methanol (15 ml), methyl acrylate  (12 g, 
140 mmol) was added  and the reaction mixture was stirred at reflux, overnight. TLC 
showed product formation with unreacted p-toluidine. The methanol was evaporated to 
give a solid in an oil vehicle. The mixture was re-suspended in diethyl ether (10 ml); a 
solid of 94 was collected by filtration after cooling, washed with cold ether and then 
dried (4.5 g, 90%). m.p 59 – 62 ºC (lit. 60 – 61 ºC);90 1H NMR (CDCl3) δ: 6.98 (½AB, 
2H, J = 8.4Hz, 3',5'-H), 6.54 (½AB, 2H, J = 8.4 Hz, 2',6'-H), 3.86 (br s, 1H, HN), 3.70 
(s, 3H, OCH3), 3.42 (t, 2H, J = 6.4 Hz, H-3), 2.60 (t, 2H, J = 6.4 Hz, H-2), 2.22 (s, 3H, 
CH3-Ar); 13C NMR (CDCl3) 173.0 (C-1), 145.4 (C-1'), 129.9 (C-2',6'), 127.2 (C-4'), 
113.4 (C-3',5'), 51.8 (OCH3), 39.9 (C-3), 33.9 (C-2), 20.5 (CH3-Ar); IR (KBr) 3391m 
(NH), 2910m (CH st), 1725s (CO), 1616s, 1524s (C=C) 803m (p-di-substituted 
aromatic ring) cm-1; MS (ES): m/z  194  (100%) (M + H)+.    
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Methyl 3-(4-methylphenylamino)propanoyl hydrazide 9591                                    
        
1
2
3HN O
O
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NH2NH2.H2O+
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rt
94 95
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5' 3'
4'
2'
1'
 
                                                                                        
Ester 94 (2.0 g, 10.35 mmol) was dissolved in ethanol (15 ml), hydrazine monohydrate 
(3.11 g, 62.1 mmol) was added and the mixture was stirred at rt overnight. Formation of 
a white solid was observed, the reaction mixture was filtered, and the solid was then 
washed with copious amounts of cold ethanol and dried to give the hydrazide 95 (1.7 g, 
85% yield) m.p. 138 – 140 ºC (lit. 138 – 139 ºC)90; 1H NMR (CDCl3) δ: 7.06 (br s, 1H, 
NHCO), 6.99 (½AB, 2H, J = 8.4 Hz, 3',5'-H), 6.55 (½AB, 2H, J = 8.4 Hz, 2',6'-H), 3.86 
(br s, 3H, Ar-NH, CONHNH2), 3.43 (t, 2H,  J = 6.1 Hz, 3-H), 2.43 (t, 2H,  J = 6.1 Hz, 
2-H), 2.23 (s, 3H, CH3-Ar); 13C NMR (CDCl3) δ: 172.5 (C-1), 145.2(C-1'),  130 (C-
2',6'), 127.6 (C-4'), 113.7 (C-3',5'), 40.5 (C-3), 34.0 (C-2), 20.5 (CH3-Ar); IR (KBr) 
3312m (NH), 2901m (CH st), 1643s (CONH), 1525s (C=C), 803m (p-di-substituted 
aromatic ring) cm-1; MS (ES): m/z  194  (100%) (M + H)+.                   
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Methyl 3-(N-(4-methylphenyl)-N-Nitrosoamino)propanoyl azide 96 
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Hydrazide 95 (0.67 g, 3.47 mmol) was dissolved in a mixture of H2O (10 ml) and DCM 
(10 ml) and was then stirred on an ice bath at 0 ºC, HCl (4 ml  10 M) was added to the 
mixture slowly, then NaNO2 (1.44 g, 20.8 mmol) solution in water (20 ml), was added 
to the reaction mixture, drop-wise keeping the exothermic reaction at 0 – 5 ºC. Further 
DCM (20 ml) was added and the DCM layer separated, washed with water, dried over 
MgSO4 and then filtered. The IR and 1H NMR spectra confirmed formation of the azide 
96. 1H NMR (CDCl3), δ: 7.32 (½AB, 2H, J = 8.3 Hz, 2',6'-H), 7.22 (½AB, 2H, J = 8.3 
Hz, 3',5'-H), 4.29 (t, 2H, J = 7.1 Hz, 3-H), 2.55 (t, 2H, J = 7.1 Hz, 2-H), 2.34 (s, 3H, 
CH3-Ar); 13C NMR (CDCl3), δ: 177.7 (C-1), 138.7 (C-1'), 138.0 ( C-4'), 130.3 (C-2',6'), 
120.2 (C-3',5'), 40.1 (C-3), 33.3 (C-2), 21.1 (CH3); IR (liq film) 2925w (CH2 st),  2142s 
(CON3), 1713s (CO), 1512m (C=C aromatic), 1454s (NO)cm-1. 
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2-(N-(4-Methylphenyl)-N-Nitrosoamino)ethyl isocyanate 97 
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The azide 96 solution in anhydrous DCM was stirred under nitrogen at rt for 24 h. 
Isocyanate formation was confirmed by IR, which showed a strong band at 2273 cm-1. 
The DCM was evaporated under reduced pressure at low temperature (an ice bath was 
used to lower the temperature). The isocyanate was collected as a pale  brown oil (0.1 g, 
59 %).1H NMR (CDCl3), δ: 7.49 (½AB, 2H, J = 8.3 Hz, 2',6'-H), 7.32 (½AB, 2H, J = 
8.3 Hz, 3',5'-H), 4.12 (t, 2H, J = 7.1 Hz, 2-H), 3.48 (t, 2H, J = 7.1 Hz, 1-H), 2.34 (s, 3H, 
CH3); 13C NMR (CDCl3), δ: 155 (NCO), 138.8 (C-1'), 138.1 ( C-4'), 130.4 (C-2',6'), 
120.5 (C-3',5'), 45.2 (C-2), 39.4 (C-1), 21.1 (CH3); IR (liq film) 2953w (CH2 st),  2273s 
(NCO), 1512m (C=C aromatic), 1454s (NO) cm-1. 
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3-{2-[(4'-Methylphenyl)(nitroso)amino]ethyl}-4-oxo-3H,4H-
imidazo[1,4-d][1,2,3,5]tetrazine-8-carboxamide 57 
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Isocyanate 97 (1 g, 5.7 mmol) was dissolved in DMSO (1.5 ml) then  added under 
nitrogen to a suspension of diazo-IC 20 (0.8 g, 5.7 mmol) in DMSO (1.5 ml), the 
mixture was stirred at r.t protected from light. The reaction was monitored by 1H NMR 
it was found completed after 72 h. The reaction mixture was then suspended in water 
(15 ml), filtered, then the residue was washed with copious amounts of water until the 
washings came through colourless, then with cold CHCl3 and dried to 57, m.p. 148 – 
150 ºC.  1H NMR (DMSO-d6) δ: 8.78 (s, 1H, 6-H), 7.77 & 7.65 (2  br s, 2H, NH2CO), 
7.40 (½AB, 2H, J = 8.1 Hz 2',6'-H), 7.21 (½AB, 2H, J = 8.1 Hz  3',5'-H), 4.49 (t, 2H, J 
= 5.8 Hz, 1-H), 4.40 (t, 2H, J = 5.8 Hz, 2-H), 2.23 (s, 3H, CH3); 13C NMR (DMSO-d6) 
δ: 161.8 (CONH2), 139.4 (C-4), 138.8 (C-1'), 137.9 (C-4'), 134.4 (C-8a), 131.7 (C-8), 
130.4 (C-2',6'), 129.5 (C-6), 120.8 (C-3',5'),  46.3 (C-1), 42.4 (C-2), IR (KBr) 3458s 
(NH), 3120m (Ar-H st), 1742s (C(4)O), 1680s (CONH), 1595m (C=C), 1458s (NO), 
818m cm-1; MS(ES): m/z  313.3 (14%) (C14H15N7O2), 343.4 (C14H14N8O3) (100%) 
(M+H)+; CHN Found C, 48.54; H, 3.90; N, 32.05. C14H14N8O3·0.25 H2O, requires C, 
48.48; H, 4.21; N, 32.31%.  
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Dimethyl N-(4-methylphenyl)iminodipropanoate 101a79 
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4-Methylaniline (1.2 g, 11.2 mmol), methyl acrylate  (9.64 g, 112 mmol), CuCl (0.18g, 
1.8 mmol)  and acetic acid (1 ml) were mixed. The reaction mixture was stirred at 140 
ºC for 72 h, monitored by 1H NMR. 1H NMR showed a mixture of the monoester 94 
and the diester 101a. The reaction mixture was partitioned between equal volumes of 
H2O / Et2O (25 ml); the Et2O layer was separated, washed with three portions of H2O 
(20ml), dried over anhydrous MgSO4, and then filtered. The Et2O was evaporated to 
give a yellow oil. The ester 94 was collected by fractional distillation at 100 – 108 ºC at 
0.05 mmHg which solidified in the condenser, whereas ester 101a was left behind pure 
(2 g, 64%), confirmed by 1H NMR.  1HNMR (CDCl3) δ: 7.03 (½AB, 2H, J =  8.6 Hz, 
3'',5''-H), 6.62 (½AB, 2H, J = 8.6 Hz,   2'',6''-H), 3.66 (s, 6H, 2  OCH3),  3.58  (t, 4H, J 
= 7.2 Hz  3,3'-H),  2.56 (t, 4H, J = 7.2 Hz  2,2'-H), 2.23 (s, 3H, CH3); 13C NMR (CDCl3) 
172.7 (C-1,1'), 150.8 (C-1''), 130.1 (C-2'',6''), 124.6 (C-4''), 113.4 (C-3'',5''), 51.8 
(OCH3), 47.3 (C-3&3'),  32.4 (C-2&2'), 20.5 (CH3); IR (liq film) 2951 (CH st), 1736s 
(CO), 1520m (C=C), 1173m (C-O), 804m (p-di-substituted aromatic ring) cm-1; 
MS(ES) m/z: 280.1 (100%) (M+H)+. 
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N-(4-methylphenyl)iminodipropanoyl dihydrazide 102a79  
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Ester 101a (1.2 g, 4.3 mmol) was dissolved in ethanol (10 ml), hydrazine monohydrate 
(2.1 g, 43.5 mmol) was added and the mixture stirred at rt for 2 h. Formation of a white 
solid was observed, the solid was collected by filtration, washed with copious amounts 
of cold ethanol and then dried. 1H NMR confirmed the hydrazide 102a (0.75 g, 63% 
yield) m.p. 162 – 163 ºC.  1H NMR (DMSO-d6) δ: 9.0 (br s, 2H, 2 CONH), 6.97 
(½AB, 2H, J = 8.6 Hz  2'',6''-H), 6.58 (½AB, 2H, J = 8.6 Hz  3'',5''-H), 4.16 (br s, 4H, 
COHNNH2), 3.43 (t, 4H,  J = 7.1 Hz, 3,3'-H), 2.22 (t, 4H,  J = 7.1 Hz, 2,2'-H), 2.16 (s, 
3H, CH3); 13C NMR (DMSO-d6) δ: 170.6 (C-1,1'), 145.5(C-1''),  130.2 (C-2'',6''), 124.8 
(C-4''), 112.8 (C-3'',5''), 47.6 (C-3,3'), 32.1 (C-2,2'), 20.4 (CH3); IR (KBr) 3277s (NH), 
2918m (CH st), 1641s (CONH), 1524s (C=C), 801m (p-di-substituted aromatic ring) 
cm-1,  MS (ES) m/z: 280.1 (100%) (M+H)+. 
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N-(4-Methylphenyl)iminodipropanoyl diazide 103a  
 
 
       
N N
H
NH2
O
N
H
O
H2N
102a
12
3
1' 2'
3'
N N3
O
N3
O
103a
NaNO2  /  Acetic acid
1 5 ºC
6''
5''
2''
3''
4''
1''
                   
                               
Hydrazide 102a (0.1 g, 0.35 mmol) was dissolved in a mixture of aq. acetic acid 
solution (5 ml  0.17 M) and DCM (5 ml). The mixture was stirred on an ice bath at 0 – 
5 ºC; a dilute solution of NaNO2 (1.44 g, 20.8 mmol) in H2O (20 ml) was added 
gradually, keeping the exothermic reaction at 0 – 5 ºC. Further DCM (10 ml) was 
added, the DCM layer was separated, washed with H2O (20 ml) dried over MgSO4, and 
then filtered. Formation of the azide 103a was confirmed by the IR and 1H NMR 
spectra. 1H NMR 400 MHz (CDCl3), δ: 7.06 (½AB, 2H, J = 8.3 Hz, 3'',5''-H), 6.65 
(½AB, 2H, J = 8.3 Hz, 2'',6''-H), 3.63 (t, 4H, J = 7.1 Hz, 3,3'-H), 2.61 (t, 4H,  J = 7.1 
Hz, 2,2'-H), 2.28 (s, 3H, CH3); 13C NMR (CDCl3), δ: 179.2 (C-1,1'), 144.4 (C-1''), 130.2 
(C-2'',6''), 127.8 ( C-4''), 114.2 (C-3'',5''), 47.4 (C-3,3'), 35.1 (C-2,2'), 20.4 (CH3); IR (liq 
film) 2919w (CH st),  2138s (CON3), 1713s (CO), 1616m, 1521s (C=C aromatic), 804 
(p-di-substituted aromatic ring) cm-1. 
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N,N-Di(2-isocyanatoethyl)-4-methylaniline 104a 
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Azide 103a solution in anhydrous DCM was stirred under nitrogen at rt for 48 h. IR 
confirmed the formation of the isocyanate 104a, it showed the strong band at 2271 cm-1. 
The DCM was evaporated to give a pale yellow oil (0.55 g, 68.6%). 1H NMR (CDCl3), 
δ: 7.03 (½AB, 2H, J = 8.6 Hz, 3'',5''-H), 6.66 (½AB, 2H, J = 8.6 Hz, 2'',6''-H), 3.47 (t, 
4H, J = 6.2 Hz, 2,2'-H), 3.38 (t, 4H,  J = 6.2 Hz, 1,1'-H),  2.20 (s, 3H, CH3); 13C NMR 
(CDCl3), δ: 144.0 (C-1''), 130.3 (C-2'',6''), 129.0 (C-4''), 124.2 (NCO), 115.4 (C-3'',5''), 
53.4 (C-2,2'), 41.0 (C-1,1'), 20.4 (CH3); IR (liq film), 2925m (CH2 st), 2271s (NCO), 
1519m (C=C aromatic) cm-1; MS (ES) m/z 245.7(100%) (M+H)٠+, 146.4 (5%), 79 
(100%) (C6H6+H)+.  
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N,N-Bis(2-(8-Carbamoyl-4-oxo-3H,4H-imidazotetrazin-3-yl)ethyl)-4-
methylaniline 58a 
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Isocyanate 104a (0.06 g, 0.24 mmol) was dissolved in DMSO (0.75 ml) then added, 
under N2, to a suspension of diazo-IC 20 (0.03 g, 0.24 mmol) in DMSO (0.75 ml). The 
mixture was stirred at 35 °C protected from light. The reaction was monitored by 1H 
NMR and was shown complete after 72 h. The 1H NMR spectrum showed the tetrazine 
58a with some impurities. The mixture was suspended in H2O (10 ml), filtered, then the 
residue was washed with copious amounts of water until the washings came through 
colourless. The crude solid was collected and then subjected to purification by flash 
column chromatography with gradient elution, glacial acetic acid in chloroform was 
used, a yellow solid was collected from the fractions at 60% acetic acid. The solid was 
dissolved in DMF (2 ml) for further purification, filtered and then precipitated by 
addition of water,  the yellow solid was collected by filtration washed with copious 
amounts of water and then  dried (0.02 g, 16%), m.p. 195 – 196 ºC 1H NMR (DMSO-
d6) δ: 8.65 (s, 2H, 6-H), 7.64 & 7.54 (2  br s, 4H, NH2CO), 6.72 (½AB, 2H, J = 8.6 
Hz,  3',5'-H), 6.58 (½AB, 2H, J = 8.6 Hz, 2',6'-H), 4.32 (t, 4H, J = 6.6 Hz, 1,1-H), 3.66 
(t, 4H, J = 6.6 Hz, 2,2-H), 1.91 (s, 3H, CH3); 13C NMR (DMSO-d6) δ: 162.0 (CONH2), 
145.1 (C-1'), 139.7 (C-4), 134.8 (C-8a), 131.3 (C-8), 129.9 (C-2',6'), 129.3 (C-6), 126.0 
(C-4'), 113.2 (C-3',5'),  49.1 (C-1,1), 46.8 (C-2,2), 20.3 (CH3); IR (KBr), 3444m (NH), 
2923w, (CH st), 1736s (C(4)O), 1682s (CONH), 1600&1521 (C=C),818m (p-di-
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substituted aromatic ring) cm-1; MS(ES): m/z  520(80%)(M+H)+, 338(70%), 246 
(70%)(C13H15N3O2+H)+, 145(75%), 79(50%)(C6H6+H)+; CHN Found: C, 48.13; H, 
3.95; N, 34.35  C21H21N13O4·0.05CHCl3 · 0.1H2O , requires C, 47.95; H, 4.06; N, 
34.54%. 
 
Dimethyl N-(4-methoxyphenyl)iminodipropanoate 101b79 
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p-Methoxyaniline (2.88 g, 23.4 mmol), methyl acrylate  (20 g, 234 mmol), CuCl (0.35g, 
3.75 mmol)  and acetic acid (20 ml) were mixed and stirred at 140 ºC for 48 h, 
monitored by 1H NMR. The reaction mixture was partitioned between CHCl3 (25 ml) 
and dilute aqueous Na2CO3 (pH 12) (25 ml); the CHCl3 layer was separated, washed 
with three portions of H2O (20ml), dried with anhydrous MgSO4, decolourised with 
charcoal and then filtered through celite 521. The CHCl3 was evaporated to give a 
yellow oil 101b (5.52 g, 80%)  1H NMR 400 MHz (CDCl3) δ: 6.86 (½AB, 2H, J = 9.1 
Hz, 2'',6''-H), 6.76 (½AB, 2H, J = 9.1 Hz, 3'',5''-H), 3.76 (s, 3H, OCH3),  3.68 (s, 6H, 2 
COOCH3), 3.55  (t, 4H, J = 7.1 Hz, 3,3'-H),  2.55 (t, 4H, J = 7.1 Hz, 2,2'-H); 13C NMR 
(CDCl3) 172.7 (C-1,1'), 152.9 (C-4''), 141.5 (C-1''), 116.5 (C-3'',5''), 115.0 (C-2'',6''), 
55.8 (CH3), 51.7 (2 COOCH3), 48.2 (C-3,3'),  32.5 (C-2,2'); IR (liq film) 2951 (CH st), 
1726s (CO), 1520m (C=C), 1173m (C-O), 804m (p-di-substituted aromatic ring) cm-1; 
MS(ES): m/z  296.1 (100%) (M+H)+. 
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N-(4-Methoxyphenyl)iminodipropanoyl dihydrazide 102b79  
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Ester 101b (5.52 g, 18.7 mmol) was dissolved in ethanol (15 ml), then hydrazine 
monohydrate (9.34 g, 187 mmol) was added and the mixture stirred at rt for 24 h. White 
solid formation was observed; the solid was collected by filtration, washed with copious 
amount of cold ethanol and then dried. 1H NMR confirmed hydrazide 102b (4.01 g, 
73%), m.p. 142 – 144 ºC,  1H NMR (CDCl3) δ: 7.40 (br s, 2H, 2 CONH), 6.88 (½AB, 
2H, J = 9.1 Hz, 3'',5''-H), 6.83 (½AB, 2H, J = 9.1 Hz, 2'',6''-H), 4.10 (br s, 4H, HNNH2), 
3.77 (s, 3H, OCH3), 3.34 (t, 4H,  J = 5.8 Hz, 3,3'-H), 2.29 (t, 4H,  J = 5.8 Hz, 2,2'-H); 
13C NMR (DMSO-d6) δ: 173.4 (C-1,1'), 155.0 (C-4''),  142.4 (C -1''), 121.5 (C-3'',5''), 
114.8 (C-2'',6''), 55.7 (OCH3), 50.8 (C-3,3'), 33.4 (C-2,2'); IR (KBr) 3277s (NH), 2918m 
(CH st), 1641s (CONH), 1524s (C=C), 801m (p-di-substituted aromatic ring) cm-1;  MS 
(ES): m/z 296.2 (100%) (M+H)+. 
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N-(4-Methoxyphenyl)iminodipropanoyl diazide 103b  
 
 
       
O
N N
H
NH2
O
N
H
O
H2N
1
2
31'
2'
3'
O
N N3
O
N3
O
NaNO2  /  Acetic acid
0 3  C
103b102b
º
2''
3''
1''
4''5''
6''
                   
                               
Hydrazide 102b (0.37 g, 1.25 mmol) was dissolved in a mixture of aq. acetic acid 
solution (5 ml 0.64 M) and DCM (10 ml). The mixture was stirred on an ice bath at 0 – 
5 º C; a dilute solution of NaNO2 (0.86 g, 12.5 mmol) in H2O (20 ml) was added 
gradually, keeping the exothermic reaction at 0 – 3 ºC. Further DCM (10ml) was added, 
the DCM layer separated, washed with H2O (20ml) dried over MgSO4 then filtered. 
Formation of azide 103b was confirmed by IR and 1H NMR. 1H NMR (CDCl3), δ: 6.84 
(½AB, 2H, J = 9.1 Hz, 2'',6''-H), 6.76 (½AB, 2H, J = 9.1 Hz, 3'',5''-H), 3.75 (s, 3H, 
OCH3), 3.50 (t, 4H, J = 7.1 Hz, 3,3'-H), 2.52 (t, 4H,  J = 7.1 Hz, 2,2'-H); 13C NMR 
(CDCl3), δ: 179.3 (C-1,1'), 153.7 (C-4'' ), 141.1 (C-1''), 118.0 (C-3'',5''), 115.1 (C-2'',6''), 
55.8 (OCH3), 48.5 (C-3,3'), 35.3 (C-2,2'); IR (liq film) 2917w (CH2 st),  2139s (N3), 
1712s (CO), 1513s (C=C), 1159m (C-O), 817m (p-di-substituted aromatic ring) cm-1. 
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N,N-Di(2-isocyanatoethyl)-4-methoaniline 104b  
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Azide 103b solution in anhydrous DCM was stirred under nitrogen at r.t for 48 h. IR 
confirmed isocyanate 7 formation, it showed the strong band at 2271 cm-1. The DCM 
was evaporated to a pale yellow oil 104b (0.55 g, 69%). 1H NMR (CDCl3), δ: 6.87 
(½AB, 2H, J = 9.1 Hz, 3'',5''-H), 6.85 (½AB, 2H, J = 9.1 Hz, 2'',6''-H), 3.77 (s, 3H, 
OCH3), 3.43 (t, 4H, J = 6.2 Hz, 1,1'-H), 3.36 (t, 4H,  J = 6.2 Hz, 2,2'-H); 13C NMR 
(CDCl3), δ: 154.6 (NCO), 140.5 (C-4''), 124.6 (C-1''), 119.6 (C-3'',5''), 115.1 (C-2'',6''), 
55.7 (OCH3), 44.6 (C-3,3'), 41.3 (C-2,2'); IR (liq film) 2919w (CH2 st),  2268s (NCO), 
1513s (C=C), 1181w (C-O), 818m (p-di-substituted aromatic ring) cm-1; MS(ES) m/z: 
262 (100%) (M+H)+, 124 (97%) (C7H9NO+H)+. 
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N,N-Bis(2-(8-Carbamoyl-4-oxo-3H,4H-imidazotetrazin-3-yl)ethyl)-4-
methoxyaniline 58b 
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Isocyanate 104b (0.13 g, 0.49 mmol) was dissolved in DMSO (0.75 ml) then transferred 
under nitrogen to a suspension of diazo-IC 20 (0.07 g, 0.49 mmol) in DMSO (0.75 ml), 
the mixture was stirred at 35 °C protected from light. The reaction was monitored by 1H 
NMR which was shown complete after 72 h. The 1H NMR spectrum showed the 
imidazotetrazinone with some impurities. The mixture was suspended in H2O (10 ml), 
filtered, then the residue was washed with copious amounts of water until the washings 
came through colourless. The crude solid (0.24 g) was collected and then subjected to 
purification by flash column chromatography eluted with 50% glacial acetic acid in 
CHCl3. A red solid was collected from the fractions. The solid was re-dissolved in DMF 
(2 ml), filtered and then precipitated by addition of water. The red solid was collected 
by filtration, washed with copious amounts of water and then  dried to 58b (0.053 g, 
22%), m.p. 178 – 179 ºC. 1H NMR (DMSO-d6) δ: 8.76 (s, 2H, 6-H), 7.74 & 7.65 (2  br 
s, 4H, NH2CO), 6.76 (½AB, 2H, J = 9.1 Hz, 2',6'-H), 6.65 (½AB, 2H, J = 9.1 Hz, 3',5'-
H), 4.42 (t, 4H, J = 6.4 Hz, 1,1-H), 3.75 (t, 4H, J = 6.4, 2,2-H), 3.58 (s, 3H, CH3); 13C 
NMR (DMSO-d6) δ: 162.0 (CONH2), 152.1 (C-4'), 141.6 (C-1'), 139.6 (C-4), 134.8 (C-
8a), 131.3 (C-8), 129.2 (C-6), 115.3 (C-2',6'), 115.0 (C-3',5'),  55.7 (OCH3), 49.7 (C-
1,1), 46.9 (C-2,2); IR (KBr), 3438m & 3341 (NH), 2914w, (CH st), 1745s (C(4)O), 
1673s (CONH), 1612&1511 (C=C), 1093 (C-O), 826m (p-di-substituted aromatic ring) 
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cm-1; MS(ES): m/z  536.0 (73%)(M+H)+, 558.0 (80%) (M+Na)+, 261.9 (100%) 
(C13H15N3O3+H)+; CHN Found: C, 47.16; H, 3.60; N, 33.44 C21H21N13O5 , requires C, 
47.1; H, 3.95; N, 34%. 
Dimethyl N-(4-fluorophenyl)iminodipropanoate 101c79 
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p-Fluoroaniline (2.19 g, 19.7 mmol), CuCl (0.30 g, 3.15 mmol), acetic acid (20 ml) and 
methyl acrylate  (17 g, 197 mmol) were mixed together.  The reaction mixture was 
stirred at 140 ºC, overnight. TLC showed completion of the reaction, 1H NMR 
confirmed product formation. The reaction mixture was then partitioned between equal 
volumes of CHCl3/dil aqueous Na2CO3 (pH 12) (25 ml); the CHCl3 layer was then 
separated, washed with three portions of H2O (20ml), dried with anhydrous MgSO4, 
decolourised with charcoal and then filtered through celite. The CHCl3 was evaporated 
to give a yellow oil 101c (4.4g, 78.6%). 1H NMR 400 MHz (CDCl3) δ: 6.95 (t, 2H, JHH 
= JFH = 9.1 Hz, 3'',5''-H), 6.69 (dd, 2H, JHH = 9.1 Hz, 4JHF = 4.1 Hz, 2'',6''-H), 3.68 (s, 
6H, 2  CH3),  3.60 (t, 4H, J = 7.1 Hz, 3,3'-H), 2.56 (t, 4H, J = 7.1 Hz, 2,2'-H); 13C 
NMR 150.1 MHz (CDCl3) 172.5 (C-1,1'), 156.0 (d,  1JCF = 235.5 Hz, C-4''), 143.6 (C-
1''), 115.9 (d, 2JCF = 21.7 Hz, C-3'',5''), 115.0 (d, 3JCF = 7.2 Hz, C-2'',6''), 51.9 (OCH3), 
47.7 (C-3,3'), 32.3 (C-2,2'); IR (liq film) 3025m (Ar-H st), 2950m (CH st), 1725s (CO), 
1525s (C=C). 1175m (C-O) cm-1; MS(ES) m/z: 284.0 (M+H)+. 
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N-(4-Fluorophenyl)iminodipropanoyl diydrazide 102c79 
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Ester 101c (4.4 g, 15.53 mmol) was dissolved in ethanol (20 ml). Hydrazine 
monohydrate (7.8 g, 155.3 mmol) was then added and the mixture stirred at rt 
overnight. TLC confirmed the completion of the reaction. The volatile compounds were 
evaporated to give a viscous brown oil that crystallised on standing. The solid was re-
crystallised from diethyl ether, collected and dried to give 102c (3.8 g, 86%), m.p. 131 – 
132 ºC; 1H NMR (CDCl3) δ: 7.26 (br s, 2H, 2  CONH), 6.93 (t, 2H, JHH = JHF = 9.1 
Hz, 3'', 5''-H), 6.83 (dd, 2H, J HH = 9.1Hz,  4JHF  = 4.6 Hz, 2'',6''-H), 4.08 (br s, 4H, 2  
COHNNH2), 3.39 (t, 4H,  J = 5.8 Hz, 3,3'-H), 2.32 (t, 2H,  J = 5.8 Hz, 2,2'-H); 13C 
NMR (CDCl3) δ: 173.2 (C-1,1'), 155.5 (d, 1JCF = 241.3 Hz, C-4''), 144.5 (C-1'') , 115.0 
(d, 2JCF = 23.1Hz, C-3'',5''), 114.0  (d, 3JCF = 7.2 Hz, C-2'',6''), 50.1 (C-3,3'), 33.3 (C-
2,2'); IR (KBr) 3245m (NH), 3032w (Ar-H st), 2947 w (CH st), 1620s (CONH), 1507m 
(C=C), 822m (p-di-substituted aromatic ring); MS (ES) m/z 284.2 (100%) (M+H)+, 306 
(60%) (M+Na)+. 
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N-(4-Fluorophenyl)iminodipropanoyl diazide 103c 
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Hydrazide 102c (0.37 g, 1.31 mmol) was dissolved in a mixture of aq. acetic acid 
(0.66M, 15 ml) and DCM (15 ml), the mixture  was then stirred on CaCl2 ice bath at 0 
ºC, a solution of NaNO2 (0.9 g, 13.1 mmol) in H2O (25 ml) was added dropwise 
keeping the exothermic reaction at 0 – 5 ºC. A Further amount of DCM (20 ml) was 
added, the DCM layer separated, washed with H2O (50ml) dried over MgSO4, then 
filtered. Formation of azide 103c was confirmed by IR. 1H NMR showed small amount 
of impurities. 1H NMR (CDCl3), δ: 6.94 (t, 2H, JHH = JHF = 9.1 Hz, 3'', 5''-H), 6.67 (dd, 
2H, J HH= 9.1 Hz, 4JHF  = 4.3 Hz, 2'',6''-H),  3.55 (t, 4H, J = 7.1 Hz, 3,3'-H), 2.55 (t, 4H, 
J = 7.1 Hz, 2,2'-H); 13C NMR (CDCl3), δ: 179.1 (C-1,1'), 155.6 (d, 1JCF  = 235.5 Hz, C-
4''), 143.3 (C-1''), 117.0 (d, 2JCF = 23.1Hz, C-3'',5''), 116.1 (d, 3JCF  = 7.2 Hz, C-2'',6''), 
47.9 (C-3,3'), 35.1 (C-2,2'); IR (liq film) 2914w (CH st), 2137s (CON3), 1711s (CO), 
1511m (C=C), 815s (p-di-substituted aromatic ring) cm-1. 
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N,N-Di(2-isocyanatoethyl)4-fluoroaniline104c  
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The anhydrous DCM solution of azide 103c was stirred under nitrogen at rt overnight. 
Isocyanate 104c formation was confirmed by IR and 1H NMR. The DCM was 
evaporated under reduced pressure at low temperature (an ice bath was used to lower 
the temperature). Isocyanate 104c was then collected as a yellow oil (0.192 g, 56.2 %). 
1H NMR (CDCl3), δ: 6.97 (t, 2H, JHH = JHF = 9.1 Hz, 3'',5''-H), 6.79 (dd, 2H, J HH= 9.1. 
4JHF  = 4.3 Hz, 2'',6''-H), 3.49 (t, 4H, J = 6.1 Hz, 2,2'-H), 3.40 (t, 4H, J = 6.1 Hz, 1,1'-H); 
13C NMR (CDCl3), δ: 157.3 (d, 1JCF  = 239.9 Hz, C-4''), 142.9 (C-1''), 124.3 (NCO), 
117.6 (d,  2JCF  = 7.2 Hz, C-2'', 6''), 116.3 (d, 3JCF  = 23.1 Hz, C-3'', 5''), 53.8 (C-2,2'), 
41.0 (C-1,1'); IR (liq film) 3057w (Ar-H st), 2917w (CH st), 2270s (NCO), 1512m 
(C=C), 1228m, 816s (p-di-substituted aromatic ring) cm-1; MS (ES) m/z 249.9 (100%) 
(M+H)+, 206.8 (62%) (C11H12FN2O)+, 193.0 (59%) (C10H10FN2O)+. 
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N,N-Bis(2-(8-Carbamoyl-4-oxo-3H,4H-imidazotetrazin-3-yl)ethyl)-4-
fluoroaniline 58c 
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Isocyanate 104c (0.192 g, 0.77 mmol) was diluted with DMSO (1.5 ml) under nitrogen 
then added to a suspension of diazo-IC 20 (0.11 g, 0.77 mmol) in DMSO (1.5 ml), the 
mixture was stirred at rt protected from light for 48 h and the reaction monitored by 1H 
NMR. The reaction mixture was suspended in water (30 ml), filtered and the residue 
washed with copious amounts of water until the washings came through colourless, and 
then washed with ether. The dry yellow solid collected and purified by flash column 
chromatography eluting with 50% AcOH / CHCl3. 1H NMR showed some impurities 
from the silica; the solid was then dissolved in DMF, DMF solution filtered, and the 
imidazotetrazinone precipitated by addition of water. A yellow solid was collected by 
filtration and dried to give tetrazine 58c (0.067 g, 17%) m.p. 290 – 291 ºC;  1H NMR 
(DMSO-d6) δ: 8.76 (s, 2H, 6-H), 7.70 & 7.61 (2  br s, 4H, CONH2), 6.92 (t, 2H, JHH = 
JHF = 9.1 Hz, 3',5'-H), 6.89 (dd, 2H, J HH = 9.1 Hz, JH-F  = 4.3 Hz, 2',6'-H),  3.44 (t, 4H, 
J = 6.7 Hz, 1,1-H), 3.78 (t, 4H, J = 6.7 Hz, 2,2-H); 13C NMR (CDCl3), δ: 162.0 
(CONH2), 155.3 (d, 1JCF  = 235.5 Hz, C-4'), 144.1 (C-1'), 139.7 (C-4), 134.8 (C-8a), 
131.4 (C-8), 129.3 (C-6), 116.0 (d, 2JCF  = 20.2 Hz, C-3', 5'), 114.2 (d, 3JCF  = 7.2 Hz, C-
2', 6'), 49.5 (C-2, 2), 46.6 (C-1, 1); IR (KBr) 3464s (NH), 3133m (Ar-H st), 1731s 
(C(4)O), 1684s (CONH2), 1512 s & 1458m, (C=C), 823m (p-di-substituted aromatic 
ring) cm-1; MS (ES): m/z 524.0  (10%) (M+H)+, 250.1 (10%) (C12H12FN3O2 + H)+; 
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CHN Found: C, 45.47; H, 3.04; N, 33.82  C20H18FN13O4, requires C, 45.09; H, 3.41;  N, 
34.01%. 
Methyl 3-(N-methyl-N-(4-methylphenyl)amino)propanoate 106a79 
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N-Methyl-p-tolylamine 105a (2.0 g, 16.5 mmol) was dissolved in methanol (10 ml), 
then CuCl (0.16 g, 1.7 mmol), AcOH (2ml) and methylacrylate 81 (7.1 g, 82.5 mmol) 
were added.  The reaction mixture was stirred at reflux, overnight. TLC showed the 
complete disappearance of the aniline, 1H NMR confirmed the product formation. The 
reaction mixture was partitioned between equal volumes of CHCl3 / dil aqueous 
Na2CO3 solution (pH 12) (25 ml); the CHCl3 layer was then separated, washed with 
three portions of H2O (20ml), dried over anhydrous MgSO4, decolourised with charcoal 
and then filtered through celite 521. The CHCl3 was evaporated to a yellow oil 106a 
(2.3 g, 67.3%). 1H NMR (CDCl3) δ: 7.05 (½AB, 2H, J = 8.7 Hz,  3',5'-H), 6.67 (½AB, 
2H, J = 8.7 Hz, 2',6'-H), 3.68 (s, 3H, OCH3), 3.64 (t, 2H, J = 7.2 Hz, 3-H), 2.90 (s, 3H, 
NCH3) 2.56 (t, 2H, J = 7.2 Hz, 2-H), 2.26 (s, 3H, Ar-CH3); 13C NMR (CDCl3)  δ: 172.9 
(C-1), 146.7 (C-1'), 129.9 (C-2', 6'), 126.3 (C-4'), 113.1 (C-3', 5'), 51.8 (OCH3), 49.1 (C-
3), 38.5 (NCH3), 31.5 (C-2), 20.3 (CH3-Ar); IR (liq film) 2918w (CH st), 1736s (CO), 
1616m, 1520s (C=C), 1169 (C-O), 803m (p-di-substituted aromatic ring) cm-1; MS(ES) 
m/z: 208.2 (100%) (M+H)+.          
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3-(N-Methyl-N-(4-methylphenyl)amino)propanoyl hydrazide 107a79 
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Ester 106a (1 g, 4.8 mmol) was dissolved in EtOH (10 ml). Hydrazine monohydrate 
(1.4 g, 28.8 mmol) was then added and the mixture stirred at rt overnight. TLC 
confirmed completion of the reaction. The volatile compounds were evaporated to give 
a viscous brown oil.  The oil was dissolved in hot Et2O and a white solid crystallised on 
cooling, the solid was then collected by filtration, washed with cold diethyl ether, 
collected  and then dried as 107a (0.71g, 71%), mp 73 – 75 ºC;  1H NMR (CDCl3) δ: 
7.42 (br s, 1H, CONH), 7.05 (½AB, 2H, J = 8.6 Hz,  3',5'-H), 6.68 (½AB, 2H, J = 8.6 
Hz, 2',6'-H), 3.89 (br s, 2H, COHNNH2), 3.59 (t, 2H,  J = 6.7 Hz, 3-H), 2.86 (s, 3H, 
NCH3), 2.37 (t, 2H,  J = 6.7 Hz, 2-H), 2.23 (s, 3H, Ar-CH3); 13C NMMR (CDCl3) δ: 
172.7 (C-1), 146.7 (C -1'),  129.9 (C-2', 6'), 127.0 (C-4'), 113.8 (C-3', 5'), 49.7 (NCH3), 
39.1 (C-3), 31.9 (C-2), 20.3(CH3-Ar); IR (KBr), 3314s (NH), 2915w (CH st), 1630s 
(CONH), 1601w, 1523 (C=C), 1366m, 800m (p-di-substituted aromatic ring) cm-1;  MS 
(ES) m/z 208.2 (100%) (M+H)+. 
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3-(N-Methyl-N-(4-methylphenyl)amino)propanoyl azide 108a  
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Hydrazide 107a (0.11 g, 0.53 mmol) was dissolved in a mixture of AcOH (0.16 M, 10 
ml) and DCM (10 ml), the mixture was stirred on a CaCl2 ice bath at 0 – 2 ºC, a solution 
of NaNO2 (0.22 g, 3.2 mmol) in H2O (15 ml) was added gradually keeping the 
exothermic reaction between 0 – 2 ºC. A further portion of DCM (15ml) was added, the 
DCM layer was separated, washed with H2O (20ml) dried over MgSO4, then filtered. 
The formation of the azide 108a was confirmed by IR and 1H NMR. 1H NMR (CDCl3), 
δ: 7.05 (½AB, 2H, J = 8.6 Hz, 3',5'-H), 6.66 (½AB, 2H, J = 8.6 Hz, 2',6'-H), 3.63 (t, 2H, 
J = 7.1 Hz, 3-H), 2.88 (s, 3H, NCH3), 2.57 (t, 2H, J = 7.1 Hz, 2-H), 2.24 (s, 3H, CH3-
Ar); 13C NMR (CDCl3), δ: 179.4 (C-1), 146.5 (C-1'), 129.9 (C-2', 6'), 126.7 ( C-4'), 
113.3 (C-3', 5'), 48.9 (C-3), 38.6 (NCH3), 34.2 (C-2),  20.3 (CH3-Ar); IR  (liq film) 
2918w (CH st), 2137s (CON3), 1714s (CO), 1522s (C=C), 1158m, 804m (p-di-
substituted aromatic ring) cm-1. 
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2-(N-Methyl-N-(4-methylphenyl)amino)ethyl isocyanate 109a 
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The DCM solution of azide 108a (0.1g, 0.5 mmol) was stirred under nitrogen at rt 
overnight. Isocyanate 109a formation was confirmed by IR and 1H NMR. The DCM 
was evaporated under reduced pressure at low temperature (an ice bath was used to 
lower the temperature) and isocyanate 109a collected as a yellow oil (0.066 g, 69 %). 
1H NMR (CDCl3), δ:  7.05 (½AB, 2H, J = 8.6 Hz,  3',5'-H), 6.65 (½AB, 2H, J = 8.6 Hz, 
2',6'-H), 3.45 (t, 2H, J = 5.6 Hz, 2-H), 3.44 (t, 2H, J = 5.6 Hz, 1-H), 2.95 (s, 3H, NCH3), 
2.24 (s, 3H, CH3-Ar); 13C NMR (CDCl3), δ: 154.8 (NCO), 146.9 (C-1'), 129.9 (C-2',6'), 
127.0 ( C-4'), 113.4 (C-3',5'), 54.1 (C-2), 41.0 (C-1), 39.4 (NCH3),  20.3 (CH3-Ar); IR 
(liq film) 2920m (CH st), 2268s (NCO), 1522s (C=C), 805m (p-di-substituted aromatic 
ring) cm-1; MS (ES) m/z 191 (100%) (M+H)+, 213 (22%) (M+Na)+.  
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3-{2-[Methyl(4'-methylphenyl)amino]ethyl}-4-oxo-3H,4H-imidazo[1,5-
d][1,2,3,5]tetrazine-8-carboxamide 59a 
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Isocyanate 109a (0.3 g, 0.15 mmol) was diluted with DMSO (0.75 ml), then added 
under nitrogen to a suspension of diazo-IC 20 (0.8 g, 5.7 mmol) in DMSO (0.75 ml), the 
mixture was stirred at rt protected from light for 48h. The 1H NMR spectrum showed 
product formation. The reaction mixture was then suspended in water (10 ml) and 
filtered. The solid on the filter was washed with copious amounts of H2O until the 
washings came through colourless, then with Et2O, 1H NMR showed some impurities 
which were washed out from the solid by chromatography through a 5 cm height silica 
column with 10% AcOH in CHCl3. An orange solid was collected from the fractions 
59a (0.08 g, 14%), m.p. 172 – 173 ºC 1H NMR (DMSO-d6) δ: 8.72 (s, 1H, 6-H), 7.73 & 
7.64 (2  br s, 2H, NH2CO), 6.83 (½AB, 2H, J = 8.3 Hz, 3',5'-H), 6.57 (½AB, 2H, J = 
8.3 Hz, 2',6'-H), 4.45 (t, 2H, J = 6.3 Hz, 1-H), 3.77 (t, 2H, J = 6.3, 2-H), 2.87 (s, 3H, 
NCH3), 2.04 (s, 3H, CH3-Ar); 13C NMR (DMSO-d6) δ: 161.9 (CONH2), 146.9 (C-1'), 
139.5 (C-4), 134.7 (C-8a), 131.2 (C-8), 129.7 (C-2',6') , 129.1 (C-6), 125.3 ( C-4'), 
112.9 (C-3',5'), 51.5 (C-2), 43.4 (C-1), 38.1 (NCH3),  20.3 (CH3-Ar);  IR (KBr) 3429s 
(NH), 2917w (CH st), 1736s (C(4)O), 1680 (CONH2), 1523s (C=C), 1458s, 1361m, 
975m, 804 (p-di-substituted aromatic ring) cm-1;  MS(ES): m/z 350.1 (100%) (M+Na)+, 
327.9 (50%) (M+H)+ , 191 (100%) (C11H14N2O+H)+; CHN Found: C, 53.69; H, 4.92; N, 
28.03  C15H17N7O2·0.3 C2H4O2.0.1CHCl3, requires C, 53.62; H, 5.22; N, 28.15%. 
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Methyl 3-(N-methyl-N-phenylamino)propanoate 106b79 
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N-Methylaniline 105b (3.0 g, 28 mmol) was dissolved into methanol (10 ml) and then 
CuCl (0.28 g, 2.8 mmol), acetic acid (2ml) and methyl acrylate 81 (12.1 g, 138 mmol) 
were added.  The reaction mixture was then stirred at reflux, overnight. The reaction 
mixture was partitioned between equal volumes of CHCl3 / dil. aqueous Na2CO3 
solution (pH 12) (30 ml); the CHCl3 layer was then separated, washed with three 
portions of H2O (25ml), dried on anhydrous MgSO4, decolourised with charcoal and 
then filtered through celite. The CHCl3 was evaporated to give a yellow oil 106b (5.3 g, 
97%). 1H NMR (CDCl3) δ: 7.24 (t, 2H, J = 8.5 Hz, 3',5'-H), 6.74 (d, 2H, J  = 8.5 Hz, 
2',6' -H),  6.74 (t, 1H,  J  = 8.5Hz, 4'-H), 3.68 (s, 3H, OCH3), 3.67 (t, 2H, J = 7.2 Hz, 3-
H), 2.93 (s, 3H, NCH3) 2.58 (t, 2H, J = 7.2 Hz, 2-H); 13C NMR (CDCl3)  δ: 172.7 (C-1), 
148.7 (C-1'), 129.4 (C-3',5'), 116.9 (C-4'), 112.6 (C-2',6'), 51.7 (OCH3), 48.7 (C-3), 38.3 
(NCH3), 31.6 (C-2); IR (liq film) 2952 w (CH st), 1736s (CO), 1601m, 1507m (C=C), 
1171 (C-O), 750&691 (mono-substituted aromatic ring) cm-1; MS(ES): m/z 120.2 
(60%) (C8H10N)+, 194.2 (100%) (M+H)+. 
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3-(N-Methyl-N-phenyl-amino)propanoyl hydrazide 107b79 
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Ester 106b (2.44 g, 12.6 mmol) was dissolved in ethanol (10 ml). Hydrazine 
monohydrate (3.8 g, 75.8 mmol) was then added and the mixture stirred at rt overnight. 
TLC confirmed the completion of the reaction. The volatile compounds were 
evaporated to give a viscous brown oil. The oil was suspended in diethyl ether with 
stirring, it was converted to a sticky solid. The suspension was heated and then the ether 
layer decanted, a white solid crystallised on cooling. The solid was then filtered, 
collected  and dried to give white solid 107b (2.3g, 94%), m.p. 66 – 68 ºC;  1H NMR 
(CDCl3) δ: 7.49 (br s, 1H, CONH), 7.21 (t, 2H, J = 8.1 Hz, 3',5'-H), 6.71 (t, 1H,  J  = 8.1 
Hz, 4'-H), 6.70 (d, 2H, J  = 8.1 Hz, 2',6'-H), 3.84 (br s, 2H, COHNNH2), 3.64 (t, 2H, J = 
6.7 Hz, 3-H), 2.85 (s, 3H, NCH3) 2.33 (t, 2H, J = 6.7 Hz, 2-H); 13C NMR (CDCl3)  δ: 
172.6 (C-1), 148.7 (C-1'), 129.4 (C-3',5'), 117.2 (C-4'), 113 (C-2',6'), 49.3 (C-3), 38.7 
(NCH3), 31.9 (C-2); IR (KBr), 3322m (NH), 3034 (Ar-H st), 2947w (CH st), 1635s 
(CONH), 1606w, 1496 (C=C), 750&691s (mono-substituted aromatic ring) cm-1; MS 
(ES) m/z 194.2 (100%) (M+H)+, 216.1 (18%) (M+Na)+. 
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3-(N-Methyl-N-phenylamino)propanoyl azide 108b  
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Hydrazide 107b (0.54 g, 2.8 mmol) was dissolved in a mixture of aq. Acetic acid 
(0.32M, 10 ml) and  DCM (10 ml), the mixture was stirred on a CaCl2 ice bath at 0 ºC. 
A solution of NaNO2 (1.2 g, 16.8 mmol) in H2O (25 ml) was added gradually, keeping 
the exothermic reaction at 0 – 5 ºC. A further portion of DCM (10ml) was added, the 
DCM layer separated, washed with H2O (20 ml) dried over MgSO4, then filtered. 
Formation of the azide 108b was confirmed by IR and 1H NMR. 1H NMR (CDCl3), δ: 
7.25 (t, 2H, J = 8.6 Hz, 3',5'-H), 6.73 (d, 2H, J = 8.6 Hz, 2',6'-H), 6.73 (t, 1H, J = 8.6 
Hz, 4'-H),  3.68 (t, 2H, J = 7.1 Hz, 3-H), 2.91 (s, 3H, NCH3), 2.60 (t, 2H, J = 7.1 Hz, 2-
H); 13C NMR (CDCl3), δ: 179.3 (C-1), 148.5 (C-4'), 129.4 (C-3',5'), 117.2 (C-4'), 112.7 
(C-2',6'), 48.5 (C-3), 38.4 (NCH3), 34.3 (C-2);  IR (liq film)  2923w (CH st), 2142s 
(CON3), 1715s (CO), 1603s, 1523s (C=C) cm-1. 
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2-(N-Methyl-N-phenylamino)ethyl isocyanate 109b 
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The anhydrous DCM solution of azide 108b was stirred under nitrogen at rt overnight. 
The isocyanate formation was confirmed by IR and 1H NMR. The DCM was 
evaporated under reduced pressure at low temperature (an ice bath was used to lower 
the temperature) and the isocyanate 109b collected as a yellow oil (0.4 g, 70 %). 1H 
NMR (CDCl3), δ:  7.25 (t, 2H, J = 8.6 Hz, 3',5'-H), 6.76 (t, 1H, J = 8.6 Hz, 4'-H), 6.74 
(d, 2H, J = 8.6 Hz, 2',6'-H),  3.53 (t, 2H, J = 6.1 Hz, 2-H), 3.48 (t, 2H, J = 6.1 Hz, 1-H), 
3.16 (s, 3H, NCH3); 13C NMR (CDCl3), δ: 155.6 (NCO), 148.8 (C-1'), 129.4 (C-3',5'), 
117.5 (C-4'), 112.8 (C-2',6'), 53.7 (C-2), 40.9 (C-1), 39.2 (NCH3), IR (liq film) 2919w 
(CH st), 2270s (NCO), 1601s, 1506s (C=C), 750m,  694m (mono-substituted aromatic 
ring) cm-1; MS (ES) m/z  177 (100%) (M+H)+.  
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3-{2-[Methyl(phenyl)amino]ethyl}-4-oxo-3H,4H-imidazo[1,5-
d][1,2,3,5]tetrazine-8-carboxamide 59b    
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Isocyanate 109b (0.4 g, 2.3 mmol) was diluted with DMSO (1.5 ml), then added under 
nitrogen to a suspension of diazo-IC 20 (0.3 g, 2.3 mmol) in DMSO (1.5 ml), the 
mixture was stirred at rt protected from light for 48 h. The 1H NMR spectrum showed 
product formation. The reaction mixture was suspended in H2O (10 ml) and filtered. 
The solid on the filter was washed with copious amounts of H2O until the washings 
came through colourless, then with Et2O, 1H NMR showed some impurities which were 
washed out from the solid with CHCl3. Further purification using short column 
chromatography eluted with 20% glacial AcOH in CHCl3 gave a yellow solid collected 
from the fractions after evaporation of the solvent. The solid was then dissolved in DMF 
(3 ml), and the DMF solution filtered. The solid was precipitated from DMF by addition 
of water (10 ml). The solid was collected by filtration, washed with water and dried to 
give 59b (0.16 g, 22%) m.p. 186 – 187 ºC.  1H NMR (DMSO-d6) δ: 8.78 (s, 1H, 6-H), 
7.77 & 7.67 (2  br s, 2H, CONH2), 7.07 (t, 2H, J = 8.3 Hz, 3',5'-H), 6.70  (d, 2H, J = 
8.3Hz , 2',6'-H), 6.51 (t, 1H, J = 8.3Hz, 4'-H), 4.46 (t, 2H, J = 6.6 Hz, H-1), 3.80 (t, 2H, 
J = 6.6, H-2), 2.93 (s, 3H, NCH3); 13C NMR (DMSO-d6) δ: 161.9 (CONH2), 149.0 (C-
1'), 139.5 (C-4), 134.6 (C-8a), 131.3 (C-8), 129.4 (C-3',5') , 129.2 (C-6), 116.6 (C-4'), 
112.4 (C-2',6'), 50.3 (C-2), 46.4 (C-1), 38.3 (NCH3); IR (KBr) 3436m (NH), 3121w ( 
Ar-H st), 2913 (CH st), 1748s (C(4)O), 1683 (CONH), 1599,1507, 1462 (C=C), 750m 
& 694m (mono-substituted aromatic ring) cm-1;  MS(ES): m/z  335.9 (100%)(M+Na)+, 
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314 (20%) (M+H)+, 176.9 (100%)(C10H12N2O+H)+, CHN Found: C, 53.61; H, 4.84; N, 
31.63  C14H15N7O2, requires C, 53.67; H, 4.83; N, 31.29%. 
Methyl 3-(N-(4-chlorophenyl)-N-methylamino)propanoate 106c92   
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4-Chloro-N-methylaniline 105c (0.55 g, 3.9 mmol) was dissolved into MeOH (5 ml), 
then CuCl (0.12 g, 1.24 mmol), AcOH (2 ml) and methylacrylate  (1.7 g, 19.4 mmol) 
were added.  The reaction mixture was then stirred at reflux for 48 h. TLC showed the 
completion of the reaction 1H NMR confirmed product formation. The reaction mixture 
was then partitioned between equal volumes of CHCl3 / dil aqueous Na2CO3 solution 
(pH 12) (25 ml); the CHCl3 layer was separated, washed with three portions of H2O 
(20ml), dried on anhydrous MgSO4, decolourised with charcoal and then filtered 
through celite. The CHCl3 was evaporated to give a yellow oil 106c (0.70 g, 79%). 1H 
NMR (CDCl3) δ: 7.15 (½AB, 2H, J = 8.6 Hz, 3',5'-H), 6.62 (½AB, 2H, J = 8.6Hz, 2',6'-
H), 3.65 (s, 3H, OCH3),  3.62 (t, 2H, J = 7.1 Hz, 3-H), 2.89 (s, 3H, NCH3) 2.54 (t, 2H, J 
= 7.1 Hz, 2-H); 13C NMR (CDCl3) 172.6 (C-1), 147.3 (C-1'), 129.1 (C-2',6'), 121.8 (C-
4'), 113.7 (C-3',5'), 51.9 (OCH3), 48.8 (C-3), 38.4 (NCH3), 31.5 (C-2), IR (liq film) 
3025 (Ar-CH st), 2950 w (CH st), 1725s (CO), 1601m, 1507m (C=C), 1171 (C-O) cm-1;  
MS(ES): m/z  228.1 (100%) (M+H)+. 
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3-(N-(4-Chlorophenyl)-N-methylamino)propanoyl hydrazide 107c79     
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Ester 106c (0.7g, 3.1 mmol) was dissolved in EtOH (10 ml). Hydrazine monohydrate 
(0.9g, 18.4 mmol) was added and the mixture stirred at rt overnight. TLC confirmed the 
completion of the reaction. The volatile compounds were evaporated to a viscous brown 
oil that crystallised on standing. The solid was re-crystallised from Et2O, collected by 
filtration and then dried, a second crop was collected from the filtrate: 107c (0.6g, 85%), 
m.p. 103 – 105 ºC.  1H NMR (CDCl3) δ: 7.16 (½AB, 2H, J = 8.8 Hz, 3',5'-H), 6.82 (br s, 
1H, CONH), 6.63 (½AB, 2H, J = 8.9 Hz, 2',6'-H), 3.85 (br s, 2H, COHNNH2), 3.64 (t, 
2H,  J = 6.7 Hz, 3-H), 2.88 (s, 3H, NCH3), 2.35 (t, 2H,  J = 6.7 Hz, 2-H); 13C NMR 
(CDCl3) δ: 172.2 (C-1), 147.3 (C-1'), 129.2 (C-2',6'), 122.1 (C-4'), 114.0 (C-3',5'), 49.3 
(C-3), 38.9 (NCH3), 31.8 (C-2); IR (KBr) 3312s (NH), 3036w (Ar-CH st), 2946 w (CH 
st), 1637s (CONH), 1593m, 1524m, 1500m (C=C), 810m (p-di-substituted aromatic 
ring) cm-1;  MS(ES): m/z  228.0 (100%) (M+H)+, 250 (65%) (M+Na)+. 
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3-(N-(4-Chlorophenyl)-N-methylamino)propanoyl azide 108c 
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Hydrazide 107c (0.38 g, 1.6 mmol) was dissolved in a mixture of aq. Acetic acid (0.66 
M 15 ml) and DCM (15 ml), the mixture was stirred on a CaCl2-ice bath at 0 ºC. A 
solution of NaNO2 (0.7 g, 10.0 mmol) in H2O (25 ml) was added gradually, keeping the 
exothermic reaction between 0 – 3 ºC. A further portion of DCM (15ml) was added, the 
DCM layer was separated, washed with H2O (20 ml) dried over MgSO4, then filtered. 
Formation of the azide 108c was confirmed by IR and 1H NMR. 1H NMR (CDCl3), δ: 
7.20 (½AB, 2H, J = 9.0 Hz, 3',5'-H), 6.66 (½AB, 2H, J = 9.0 Hz, 2',6'-H),  3.67 (t, 2H, J 
= 7.1 Hz, 3-H), 2.93 (s, 3H, NCH3), 2.60 (t, 2H, J = 7.1 Hz, 2-H); 13C NMR (CDCl3), δ: 
179.2 (C-1), 147.1 (C-1'), 129.2 (C-2',6'), 122.1 (C-4'), 113.9 (C-3',5'), 48.6 (C-3), 38.6 
(NCH3), 34.2 (C-2); IR 2913w (CH st), 2139s (CON3), 1714s (CO), 1597m, 1501s 
(C=C), 812s (p-di-substituted aromatic ring) cm-1. 
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2-(N-(4-Chlorophenyl)-N-methylamino)ethyl isocyanate 109c 
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The anhydrous DCM solution of azide 108c was stirred under nitrogen at rt overnight. 
The isocyanate formation was confirmed by IR and 1H NMR. The DCM was 
evaporated under reduced pressure at low temperature (an ice bath was used to lower 
the temperature) the isocyanate 109c was collected as a yellow oil (0.37 g, 87.2 %). 1H 
NMR (CDCl3), δ:  7.17 (½AB, 2H, J = 9.0 Hz, 3',5'-H), 6.63 (½AB, 2H, J = 9.0 Hz, 
2',6'-H),  3.49 (t, 2H, J = 5.5 Hz, 2-H), 3.45 (t, 2H, J = 5.5 Hz, 1-H), 2.97 (s, 3H, 
NCH3); 13C NMR (CDCl3), δ: 151.6 (NCO), 147.4 (C-1'), 129.2 (C-2',6'), 122.5 (C-4'), 
113.9 (C-3',5'), 53.6 (C-2), 40.8 (C-1), 39.3 (NCH3), IR (liq film) 2916w (CH st), 2268s 
(NCO), 1597m, 1500s (C=C), 811m (p-di substituted aromatic ring) cm-1; MS (ES) m/z 
211 (100%) (M+H)+, 79 (50%) (C6H6+H)+. 
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3-(2-(N-(4-Chlorophenyl)-N-methylamino)ethyl)-4-oxo-3H,4H-
imidazo[1,5-d][1,2,3,5]tetrazine-8-carboxamid 59c  
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Isocyanate 109c (0.37 g, 1.76 mmol) was diluted with DMSO (1.5 ml), then transferred 
under nitrogen to a suspension of diazo-IC 20 (0.24 g, 1.76 mmol) in DMSO (1.5 ml), 
the mixture was stirred at rt protected from light for 48 h. The 1H NMR spectrum 
showed product 59c formation. The reaction mixture was suspended in H2O (10 ml) and 
filtered. The solid on the filter was washed with copious amounts of H2O until the 
washings came through colourless and then with i-PrOH. The 1H NMR showed a small 
amount of impurities of another tetrazine, the tetrazine 59c was collected pure from the 
fractions of column chromatography eluted with 10% acetic acid in chloroform (0.08 g, 
13.1%) m.p. 154 – 155 °C 1H NMR (DMSO-d6) δ: 8.78 (s, 1H, 6-H), 7.77 & 7.66 (2  
br s, 2H, CONH2), 7.08 (½AB, 2H, J = 9 Hz, 3',5'-H), 6.70  (½AB, 2H, J = 9 Hz, 2',6'-
H), 4.45 (t, 2H, J = 6.4 Hz, H-1), 3.79 (t, 2H,  J = 6.4 Hz, H-2), 2.89 (s, 3H, NCH3); 13C 
NMR (DMSO-d6) δ: 161.9 (CONH2), 147.8 (C-1'), 139.6 (C-4), 134.7 (C-8a), 131.4 (C-
8), 129.2 (C-6), 129.1 (C-2',6'), 120.3 (C-4'), 113.9 (C-3',5'), 50.4 (C-2), 46.3 (C-1), 
38.5 (NCH3); IR (KBr) 3441m (NH), 2911w (CH st), 1740s (C(4)O), 1672s (CONH2), 
1596 m, 1501m, 1454m (C=C), 1363m, 811(p-di substituted aromatic ring) cm-1;  
MS(ES): m/z  347.9 (40%)(M+H)+, 210 (100%) (C10H11ClN2O + H)+; CHN Found: C, 
47.16; H, 3.98; N, 26.94  C14H14ClN7O2·0.1CHCl3, requires C, 47.08; H, 3.95; N, 
27.26%. 
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Methyl 3-(N-(4-fluorophenyl)-N-methylamino)propanoate 106d79  
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4-Fluoro-N-methylaniline 105d (1.53 g, 12.2 mmol) was dissolved into methanol (7 
ml), CuCl (0.12 g, 1.2 mmol), acetic acid (2 ml) and methyl acrylate  81 (5.3 g, 61.1 
mmol) were added.  The reaction mixture was stirred at reflux overnight. The reaction 
mixture was then partitioned between equal volumes of CHCl3 / dil aqueous Na2CO3 
solution (pH 12) (25 ml); the CHCl3 layer was then separated, washed with three 
portions of H2O (20ml), dried on anhydrous MgSO4, decolourised with charcoal and 
filtered through celite. The chloroform was evaporated to give a yellow oil 106d (2.1g, 
81%). 1H NMR (CDCl3) δ: 6.92 (t, 2H, JHH = JHF = 9.1 Hz, 3',5'-H), 6.66 (dd, 2H, JHH = 
9.1 Hz, JHF = 4.3Hz, 2',6'-H), 3.65 (s, 3H, OCH3),  3.60 (t, 2H, J = 7.1 Hz, 3-H), 2.86 (s, 
3H, NCH3) 2.53 (t, 2H, J = 7.1 Hz, 2-H); 13C NMR (CDCl3) 172.8 (C-1), 156.0 (d, 1JCF  
= 237 Hz, C-4'), 145.6 (C-1'), 115.8 (d, 2JCF  = 23.1 Hz, C-3',5'), 114.3 (d, 3JCF  = 7.2 Hz, 
C-2',6'), 51.8  (OCH3), 49.5 (C-3), 38.7 (NCH3), 31.5 (C-2); IR (liq film) 3025m (Ar-
CH st), 2950m (CH st), 1725s (CO), 1525 (C=C). 1175m (C-O) cm-1; MS(ES) m/z: 
212.1 (M+H)+. 
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3-(N-(4-fluorophenyl)-N-methylamino)propanoyl hydrazide 107d79 
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Ester 106d (2.1g, 9.94 mmol) was dissolved in ethanol (10 ml). Hydrazine monohydrate 
(3g, 59.7 mmol) was then added and the mixture stirred at rt overnight. TLC confirmed 
the completion of the reaction. The volatile compounds were evaporated to give a 
viscous brown oil. Recrystallisation from Et2O gave a white solid, 107d (1.8g, 85%), 
m.p. 73  – 75 ºC;  1H NMR (CDCl3) δ: 7.03 (br s, 1H, CONH), 6.93 (t, 2H, JHH = 3JHF = 
9.1 Hz, 3',5'-H), 6.69 (dd, 2H, JHH = 9.1 Hz, 4JHF  = 4.3 Hz, 2',6'-H), 3.85 (br s, 2H, 
COHNNH2), 3.57 (t, 2H,  J = 6.7 Hz, 3-H), 2.87 (s, 3H, NCH3), 2.36 (t, 2H,  J = 6.7 Hz, 
2-H); 13C NMR (CDCl3) δ: 172.4 (C-1), 155.8 (d, 1JCF  = 237 Hz, C-4'), 145.7 (C-1'), 
115.8 (d, 2JCF  = 23.1 Hz, C-3',5'), 115.0 (d, 3JCF  = 7.2 Hz, C-2',6'), 50.2 (C-3), 39.4 
(NCH3), 31.9 (C-2); IR (KBr) 3245m (NH), 3032w (Ar-CH st), 2947 w (CH st), 1620s 
(CONH), 1507m (C=C), 822m (p-di-substituted aromatic ring) cm-1; MS (ES) m/z 
212.1(100%) (M+H)+. 
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3-(N-(4-Fluorophenyl)-N-methylamino)propanoyl azide 108d  
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Hydrazide 107d (0.25 g, 1.2 mmol) was dissolved in a mixture of aq. acetic acid (0.66M 
15 ml) and DCM (15 ml), the mixture  was then stirred on a CaCl2-ice bath at 0 ºC, a 
solution of NaNO2 (0.49 g, 7.1 mmol) in H2O (25 ml) was added drop wise keeping the 
exothermic reaction at 0 – 5 ºC. A Further amount of DCM (20 ml) was added, the 
DCM layer separated, washed with H2O (20ml) dried over MgSO4, then filtered. 
Formation of azide 108d was confirmed by IR. 1H NMR showed a small amount of 
impurities. 1H NMR (CDCl3),  δ: 6.93 (t,  2H,  JHH = 3JHF = 9.1 Hz, 3',5'-H), 6.66 (dd, 
2H, JHH = 9.1 Hz, 4JHF  = 4.3 Hz, 2',6'-H),  3.60 (t, 2H, J = 7.1 Hz, 3-H), 2.86 (s, 3H, 
NCH3), 2.55 (t, 2H, J = 7.1 Hz, 2-H); 13C NMR (CDCl3), δ: 179.2 (C-1), 155.3 (d, 1JCF  
= 237 Hz, C-4'), 145.2 (C-1'), 115.8 (d, 2JCF  = 21.7 Hz, C-3',5'), 114.3 (d, 3JCF  = 7.2 Hz, 
C-2',6'), 49.4 (C-3), 38.9 (NCH3), 34.2 (C-2); IR (liq film) 2914w (CH st), 2137s 
(CON3), 1711s (CO), 1511m (C=C), 815s (p-di-substituted aromatic ring) cm-1. 
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2-(N-(4-Fluorophenyl)-N-methylamino)ethyl isocyanate 109d  
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The anhydrous DCM solution of azide 108d was stirred under nitrogen at rt overnight. 
Isocyanate 109d formation was confirmed by IR and 1H NMR. The DCM was 
evaporated under reduced pressure at low temperature (an ice bath was used to lower 
the temperature). The isocyanate was collected as a yellow oil (0.2 g, 77%). 1H NMR 
(CDCl3), δ: 6.95 (t, 2H,  JHH = 3JHF = 9.1 Hz, 3',5'-H), 6.69 (dd, 2H, JHH = 9.1 Hz, 4JHF  
= 4.3 Hz, 2',6'-H), 3.43 (m, 4H, 1,2-H), 2.94 (s, 3H, NCH3); 13C NMR (CDCl3), δ: 157.2 
(NCO), 155.3 (d, 1JCF  = 237 Hz, C-4'), 145.2 (C-1'), 115.8 (d, 2JCF  = 21.7 Hz, C-3',5'), 
114.4 (d, 3JCF  = 7.2 Hz, C-2',6'), 54.5 (C-3), 40.9 (C-2), 39.6 (NCH3); IR (liq film) 
3057w (Ar-CH st), 2917w (CH st), 2270s (NCO), 1512m (C=C), 1228m, 816s (p-di-
substituted aromatic ring) cm-1; MS (ES) m/z 195 (100%) (M+H)+. 
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3-(2-(N-(4-Fluorophenyl)-N-methylamino)ethyl)-4-oxo-3H,4H-
imidazo[1,5-d][1,2,3,5]tetrazine-8-carboxamide 59d 
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Isocyanate 109d (0.2 g, 1.03 mmol) was diluted with DMSO (1.5 ml) under nitrogen 
then added to a suspension of diazo-IC 20 (0.14 g, 1.03 mmol) in DMSO (1.5 ml), the 
mixture was stirred at rt protected from light for 48 h. The 1H NMR spectrum showed 
product 59d formation. The reaction mixture was suspended in H2O (30 ml) and 
filtered, the residue was washed with copious amounts of H2O until the washings came 
through colourless, and then washed with Et2O. The solid was purified by flash column 
chromatography, 10% AcOH in CHCl3 was used for the elution; the fractions 
containing the product were evaporated to give an orange solid. The solid was then re-
dissolved in CHCl3 and filtered, the CHCl3 evaporated and the residue re-suspended in 
Et2O and then collected by filtration to give 59d (0.057 g, 17%), m.p. 172 – 173 ºC . 1H 
NMR (DMSO-d6) δ: 8.77 (s, 1H, 6-H), 7.75 & 7.65 (2  br s, 2H, CONH2), 6.91 (t,  2H, 
JHH = JHF = 9.1 Hz, 3',5'-H), 6.69 (dd, 2H, JHH = 9.1 Hz,  JHF  = 4.3 Hz, 2',6'-H),  3.45 (t, 
2H, J = 6.4 Hz, 1-H), 3.77 (t, 2H, J = 6.4 Hz, 2-H), 2.90 (s, 3H, NCH3); 13C NMR 
(CDCl3), δ: 161.89 (CONH2), 155.0 (d, 1JCF  = 235.5 Hz, C-4'), 145.9 (C-1'), 139.5 (C-
4), 134.7 (C-8a), 131.3 (C-8), 129.2 (C-6),  115.7 (d, 2JCF  = 21.7 Hz, C-3',5'), 113.6 (d, 
3JCF  = 7.2 Hz, C-2',6'), 50.9 (C-2), 46.3 (C-1) 38.7 (NCH3); IR (KBr) 3439s (NH), 
3117m (Ar-CH st), 2914w (CH st), 1749s (C(4)O), 1682s (CONH2), 1515 s, 1458m 
(C=C), 820m (p-di-substituted aromatic ring) cm-1; MS (ES): m/z  331.9 (20%) 
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(M+H)+, 353.9 (10%) (M+Na)+, 195.0 (100%) (C10H11FN2O+H)+; CHN Found: C, 
48.64; H, 4.22; N, 28.16 C14H14FN7O2·0.75H2O·0.1CHCl3, requires C, 48.77; H, 4.53; 
N, 28.43%. 
3-(N-Methyl-N-(4-nitrophenyl)amino)propanoyl azide 108e and 3(N-
methyl-N-(2-nitrophenyl)amino)propanoyl azide 108f   
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Hydrazide 107b (0.3g, 1.6 mmol) was dissolved in a mixture of DCM (10 ml) and HCl 
(10 ml, 14.8%), the solution was stirred at 0 ºC on a CaCl2-ice bath, NaNO2 (0.66 g, 9.6 
mmol) solution in H2O (10 ml) was added gradually, keeping the exothermic reaction 
between 0 – 5 ºC. A further portion of DCM (15 ml) was added, the DCM layer was 
separated, washed with two portions of H2O (20 ml) dried over MgSO4, then filtered. 
Formation of the azide 108e was confirmed by IR and 1H NMR which also showed the 
formation of small amount of the ortho nitrated azide 108f in ratio 1:5 to azide 108e. 
Azide 18 e 1H NMR (CDCl3) δ: 8.12 (½AB, 2H, J = 9.5 Hz, 3',5'-H), 6.61 (½AB, 2H, J 
= 9.5 Hz, 2',6'-H), 3.77 (t, 2H, J = 7.0 Hz, 3-H), 3.10 (s, 3H, NCH3) 2.62 (t, 2H, J = 7.0 
Hz, 2-H);  13C NMR (CDCl3) δ: 178.5 (CON3), 152.8 (C-4'), 133.2 (C-1'), 126.4 (C-
3',5'), 110.6 (C-2',6'), 48.0 (C-3), 39.1 (NCH3), 34.4 (C-2); IR (liq film) 2918w (CH st), 
2140s (N3), 1711s (CO), 1597s (NO2 st as), 1518 s (C=C), 1311s (NO2 st sy) cm-1.  
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Azide 108f 1H NMR (CDCl3) δ: 7.72 (d, 1H, J = 8.9 Hz, 5'-H), 7.42 (t, 1H,  J = 8.9 Hz, 
4'-H), 7.21 (d, 1H, , J = 8.9 Hz, 2'-H ), 6.96 (t, 1H, J = 8.9 Hz, 3'-H), 3.46 (t, 2H, J = 7.1 
Hz, 3-H), 2.80 (s, 3H, NCH3) 2.62 (t, 2H, J = 7.1 Hz, 2-H). 
2-[(4-Nitrophenyl)methylamino]ethylisocyanate 109e  
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The anhydrous DCM solution of the crude azide 108e was stirred under nitrogen at rt 
for overnight. Isocyanate formation was confirmed by IR. The 1H NMR showed two 
isocyanates 109e and 109f in ration of 5:1. The DCM was evaporated under reduced 
pressure at low temperature (an ice bath was used to lower the temperature) and the 
crude isocyanate  collected as a yellow oil (0.27 g, 90 %). 1H NMR (CDCl3) δ: 8.15 
(½AB, 2H, J = 9.4 Hz, 3',5'-H), 6.67 (½AB, 2H, J = 9.4 Hz, 2',6'-H), 3.66 (t, 2H, J = 6.2 
Hz, 2-H), 3.57 (t, 2H, J = 6.2 Hz, 1-H), 3.15 (s, 3H, NCH3); 13C NMR (CDCl3) δ: 153.1 
(NCO), 145.2 (C-4'), 138.1 (C-1'), 126.4 (C-3',5'), 110.7 (C-2',6'), 52.6 (C-2), 40.7 (C-1) 
, 39.5 (NCH3); IR (liq film) 2919w (CH st), 2270s (NCO), 1597s (NO2 st as), 1517 s 
(C=C), 1311s (NO2 st sy) cm-1.  
Isocyanate 109f 1H NMR (CDCl3) δ: 7.74 (d, 1H, J = 8.4 Hz, 5'-H), 7.45 (t, 1H, , J = 8.4 
Hz, 4'-H), 7.18 (d, 1H, , J = 8.4 Hz, 2'-H ), 6.99 (t, 1H, J = 8.9 Hz, 3'-H), 3.48 (t, 2H, J 
= 6.0 Hz, 3-H), 2.90 (s, 3H, NCH3), 3.31 (t, 2H, J = 7.1 Hz, 2-H). 
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3-(2-N-Methyl-N-(4-nitrophenyl)-N-methylamino)ethyl)-4-oxo-3H,4H-
imidazo[1,5-d][1,2,3,5]tetrazine-8-carboxamide 59e and 3-(2-(N-
methyl-N-(2-nitrophenyl)-N-methylamino)ethyl)-4-oxo-3H,4H-
imidazo[5,1d][1,2,3,5]tetrazine-8-carboxamide 59f 
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The crude mixture of the isocyanates 109e & f (0.27 g, 1.22 mmol) was diluted with 
DMSO (1.5 ml) under N2 then added to a suspension of diazo-IC 20 (0.17 g, 1.22 
mmol) in DMSO (1.5 ml), the mixture was stirred at rt protected from light for 48 h. 
The reaction mixture was then suspended in water (30 ml) and filtered. The solid on the 
filter was washed with copious amounts of H2O until the washings came through 
colourless, then with Et2O. The dry solid was purified by flash column chromatography 
eluted with a gradient 5 – 20% AcOH in CHCl3. 1H NMR showed impurities from 
silica, the imidazotetrazinone solid was then  dissolved in DMF and filtered, the 
imidazotetrazinone precipitated as a yellow solid by H2O addition, the solid collected by 
filtration, washed with copious amounts of water and then dried to 59e (0.025g, 6 %), 
m.p. 179 – 180 ºC. 1H NMR (DMSO-d6) δ: 8.81 (s, 1H, 6-H), 8.00 (½AB, 2H, J = 9.2 
Hz, 3',5'-H), 7.77 & 7.67 (2  br s, 2H, CONH2), 6.82 (½AB, 2H, J = 9.2 Hz, 2',6'-H), 
4.52 (t, 2H, J = 6.3 Hz, 1-H), 3.96 (t, 2H, J = 6.3 Hz, 2-H), 3.07 (s, 3H, NCH3); 13C 
NMR (DMSO-d6) δ: 161.9 (CONH2), 154.0 (C-4'), 139.7 (C-4), 136.6 (C-1'), 134.7 (C-
8a), 131.6 (C-8), 129.5 (C-6),  126.3 (C-3',5'), 111.4 (C-2',6'), 50.3 (C-2), 46.4 (C-1) 
39.2 (NCH3); IR (KBr) 3443m (NH), 2919w (CH st), 1749s (C(4)O), 1684s (CONH), 
1597s (NO2 st as), 1457m (C=C), 1316s (NO2 st sy) cm-1; MS(ES): m/z 359.1(80%) 
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(M+H)+, 381.1(100%) (M+Na)+; CHN Found: C, 44.9; H, 3.70; N, 27.08 C14H14N8O4 
·0.6 AcOH·0.2 CHCl3, requires C, 44.76; H, 4.03; N, 27.38%. 
59f 1H NMR (DMSO-d6) δ: 8.83 (s, 1H, 6-H), 7.83 & 7.71 (2  br s, 2H, CONH2), 7.65 
(d, 1H, J = 9.1 Hz, 5'-H), 7.46 (t, 1H, J = 9.1 Hz, 4'-H),  7.31 (t, 1H, , J = 9.1 Hz, 2'-H), 
6.92 (d, 1H, J = 9.1 Hz, 3'-H), 4.52 (t, 2H, J = 6.1 Hz, 1-H), 3.59 (t, 2H, J = 6.1 Hz, 2-
H), 2.83 (s, 3H, NCH3). 
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E.4 Methods for Mechanistic Investigation of Aziridinium-ion-
release-imidazotetrazinones in Chapter 3 
E.4.1 NMR Study of the hydrolysis reaction mechanism of 13C-
labelled and unlabelled 3-{2-[Methyl(4'-methylphenyl)amino]ethyl}-4-
oxo-3H,4H-imidazo[1,5-d][1,2,3,5]tetrazine-8-carboxamide 59a 
 
 
Imidazotetrazinone 59a, (13C-labelled and the unlabelled) stock solution was prepared 
by dissolving (1.5 mg, 4.6  10-3 mmol) in DMSO-d6 (100 μl); 0.2 M deuteriated 
phosphate buffer pD 7.8 was prepared from disodium hydrogen phosphate (0.36g) in 
D2O (10 ml), the pH was then adjusted to pD 7.8 (equivalent to 7.4) with 0.2 M sodium 
dihydrogen phosphate (0.28 g) in D2O (10 ml); a digital pH-meter was used for the pH 
measurement. Buffer solution pD 7.8 (0.5 ml) was placed in a 5 mm diameter NMR 
tube. The tube was inserted into the magnet (Jeol ECA 600 instrument), incubated at 37 
°C for 10 mins and then the magnet was shimmed. A 1D 1H spectrum was acquired to 
determine the frequency of the residual water peak. Tetrazine stock solution (100 μl) 
was added and 1D 1H spectra with water presaturation were recorded every 0.5 h for 15 
h [16 scans, 0 – 12 ppm]. The reaction mixture of the final products was spiked with 
authentic samples of 2-(methyl-p-tolylamino)ethanol (9.08  10-3 mmol in buffer 10 μl) 
and AIC (6.9  10-6 mmol in 10 μl buffer), and further 1D 1H spectra were acquired 
after each addition.  
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E.4.2 UV-Visible study of the pseudo 1st order hydrolysis kinetic of 
aziridinium-ion-release imidazotetrazinones. 
 
Stock solutions 20 mM of the imidazotetrazinones synthesized for aziridinium ion 
release were prepared in DMSO. Buffer solutions were prepared from citric acid (0.1 M, 
500 ml) and Na2HPO4 (0.2 M, 500 ml) a digital pH-meter was used for the pH 
adjusting; Aliquots of the stock solutions of the tetrazines (2 – 3.5 μl) were added to a 
quartz cuvette (1 cm pathlength) containing 1200 μl buffer solution maintained at 37 
°C. [The buffer solutions used were citrate/phosphate pH 4, citrate/phosphate pH 7.4 
and citrate/phosphate pH 8.] UV spectra (400 – 200 nm) were recorded every 4 min (pH 
7.40, for 1 h), 1 min (pH 8 for 15 min) and 1h (pH 4 for 12 h). The decrease in the 
absorbance with time for the tetrazines and the appearance of AIC as a decomposition 
product at each pH were measured. Data were transferred to Excel for processing and 
the pseudo 1st order rate constant (k′) and half life (t1/2) calculated. All values were mean 
(± SD) of three separate determinations. 
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E.5 Synthesis of alcohol or phenol-release-imidazotetrazinone 
in Chapter 4 
Ethyl 2-(furan-2'-ylmethoxy) acetate 118a93 
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Furfuryl alcohol (1 ml, 11.6 mmol) was dissolved in anhydrous THF (20 ml), NaH 
(0.57g, 60% in oil, 14 mmol) was added portion-wise to the solution. After gas 
evolution ceased, ethyl bromoacetate (1.3ml, 11.7 mmol) was added and the mixture 
heated to reflux for 2.5 h, then cooled to ambient temperature overnight. The mixture 
was partitioned between equal volumes of EtOAc and H2O (25 ml), the aqueous layer 
was separated and then extracted with another two portions of EtOAc (20 ml). The 
organic layers were combined and then washed with brine, dried over MgSO4 , filtered 
and then concentrated to a brown oil 118a (2.1g), 1H NMR confirmed the product. 1H 
NMR (CDCl3) δ: 7.41 (dd, 1H, Jab = 1.8 Hz, Jac = 0.9 Hz,  5'-H), 6.35 (dd, 1H, J bc= 3.1 
Hz, Jab = 1.8 Hz, 4' H), 6.34 (dd, 1H, J bc= 3.1 Hz, Jac = 0.9 Hz,  3'-H), 4.59 (s, 2H, 
CH2O), 4.21 (q, 2H, J = 7.1 Hz, OCH2CH3), 4.08 (s, 2H, 2-H), 1.27 (t, 3H, J = 7.1 Hz,  
CH3); 13C NMR (CDCl3) 170.3 (C-1), 150.8( C-2'), 143.3 (C-5'), 110.5 (C-4'), 110.3 (C-
3'), 66.9 (OCH2), 64.9 (C-2), 61.1 (OCH2CH3), 14.3 (OCH2CH3) ;  MS(ES): m/z  
207(100%)(M+Na)+. 
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2-(Furan-2'-ylmethoxy)acetohydrazide 119a 
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Ester 118a (1.4g, 7.6mmol) was dissolved in EtOH (10 ml) then hydrazine monohydrate 
(2.2 ml, 45.6 mmol) was added and the mixture stirred at rt overnight. The volatile 
compounds were evaporated under vacuum at 70 ºC to give a thick brown oil (1.2g). 1H 
NMR confirmed the product 119a. 1H NMR (CDCl3) δ: 7.63 (bs, 1H, CONHNH2), 7.42 
(dd, 1H, Jab = 1.8 Hz, Jac = 0.9 Hz,  5'-H), 6.35 (dd, 1H, J bc= 3.1 Hz, Jab = 1.8 Hz, 4'-H), 
6.34 (dd, 1H, J bc= 3.1 Hz, Jac = 0.9 Hz,  3'-H), 4.50 (s, 2H, CH2O), 4.05 (s, 2H, 2-H), 
3.81 (bs, 2H, CONHNH2); 13C NMR (CDCl3) 169.8 (C-1), 150.3( C-2'), 143.6 (C-5'), 
110.60 (C-4'), 110.55 (C-3'), 68.8 (OCH2), 65.4 (C-2); MS(ES): m/z  
193.1(100%)(M+Na)+. 
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2-(Furan-2'-ylmethoxy)acetyl azide 120a 
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O O
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1
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0 º5  C
119a 120a        
                                                                                                                      
Hydrazide 119a (1.2 g, 7.1 mmol) was dissolved in mixture of H2O and DCM (15 ml 
each) then aq. HCl (4 ml, 37%) was added, the mixture was cooled on a CaCl2-ice bath 
to   0 ºC. NaNO2 (2.9 g, 42.3 mmol) solution in (10 ml) H2O was added gradually to the 
reaction mixture, keeping the exothermic reaction between 0 – 5 ºC. A further amount 
of DCM (20 ml) was added and then the DCM layer was then separated, washed with 
H2O, dried over MgSO4 and then filtered and kept to stir at rt under nitrogen for 
isocyanate preparation. 1H NMR and IR confirmed the clean product azide 120a.  1H 
NMR 400 MHz (CDCl3) δ: 7.46 (dd, 1H, Jab = 1.8 Hz, Jac = 0.9 Hz,  5'-H), 6.40 (dd, 1H, 
Jbc= 3.1Hz, Jab = 1.8 Hz, 4'-H), 6.39 (dd, 1H, Jbc= 3.1 Hz, Jac = 0.9 Hz,  3'-H), 4.61 (s, 
2H, CH2O), 4.15 (s, 2H, 2-H); 13C NMR (CDCl3) 177.6 (C-1), 150.3 ( C-2'), 143.5 (C-
5'), 110.7 (C-4'), 110.6 (C-3'), 68.8 (OCH2), 65.1 (C-2); IR (liq film), 2919w (CH st), 
2146s (N3), 1731s (CO), 1187m (C-O), 1152s, 1057m, 750m cm-1. 
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(Furan-2′-ylmethoxy)methylisocyanate 121a 
 
 
                                                                                                                                                               
                 
O O
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O O
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rt
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4'
5'
120a 121a                                 
 
The anhydrous DCM solution of azide 120a was stirred under nitrogen at rt overnight. 
DCM was evaporated at reduced temperature and pressure to a pale yellow oil, 
isocyanate 121a (0.63 g, 58%). 1H NMR (CDCl3) δ: 7.42 (dd, 1H, Jab = 1.8 Hz, Jac = 0.9 
Hz,  5'-H), 6.41 (dd, 1H, J bc= 3.1 Hz, Jab = 1.8 Hz, 4'-H), 6.38 (dd, 1H, J bc= 3.1 Hz, Jac 
= 0.9Hz,  3'-H), 4.79 (s, 2H, CH2O), 4.59 (s, 2H, 2-H); 13C NMR (CDCl3) 150.0 (C-2'), 
145.0 (NCO), 143.6 (C-5'), 110.7 (C-4'), 110.6 (C-3'), 74.0 (OCH2), 62.5 (CH2NCO); 
IR (liq film), 2921w (CH st), 2254s (NCO), 1679 (C=C), 118m (C-O) cm-1. 
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3-[(Furan-2'-ylmethoxy)methyl]-4-oxo-3H,4H-imidazo[1,5-
d][1,2,3,5]tetrazine-8-carboxamide 117a 
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Isocyanate 121a (0.63 g, 4.11 mmol) was diluted with DMSO (1.5 ml), under nitrogen 
then added to a suspension of diazo-IC 20 (0.56 g, 4.11 mmol) in DMSO (1.5 ml), the 
mixture was stirred at 35 °C protected from light for 48 h. The reaction mixture was 
then suspended in H2O (30 ml) and extracted with three portions of CHCl3 (20 ml), the 
CHCl3 layers were combined, washed twice with H2O (20 ml), dried over anhydrous 
MgSO4 filtered and the CHCl3 evaporated to give a brownish solid. The solid was then 
purified by column chromatography eluted with 10% AcOH in CHCl3 to give a white 
solid. The solid  was dissolved in DMF, filtered and precipitated by addition of water to 
the DMF solution of the imidazotetrazinone, the white solid was collected by filtration, 
washed with copious amounts of H2O, Et2O and then dried to 117a (0.15 g, 13%), mp 
138 – 140° C.  1H NMR (DMSO-d6) δ: 8.87 (s, 1H, 6-H), 7.83 & 7.70 (2  br s, 2H, 
CONH2), 7.62 (dd, 1H, Jab = 1.8Hz, Jac = 0.9Hz,  5'-H), 6.44 (dd, 1H,  J bc= 3.1Hz, Jab = 
1.8Hz, 4'-H), 6.42 (dd, 1H, J bc= 3.1Hz, Jac = 0.9Hz,  3'-H), 5.69  (s, 2H, 1'-H), 4.64 (s, 
2H, 2'-H); 13C NMR (DMSO-d6) δ: 162.0 (CONH2), 151.0 (C-3'), 144.1 (C-6'), 140.0 
(C-4), 134.7 (C-8a), 131.9 (C-8), 130.1 (C-6), 111.1 (C-5'), 110.8 (C-4'), 77.3 (C-1'), 
63.0 (C-2') ; IR (KBr) 3375m (NH), 3094m (Ar-CH st),  2923w (CH st), 1740s (C(4)O), 
1693s (CONH2), 1609 m, 1459m (C=C), 1092m (C-O) cm-1;  MS(ES): m/z  291.1 
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(100%)(M+H)+, 137.9 (25%) (diazoIC + H)+; Found: C, 45.67; H, 3.52; N, 28.84 
C11H10N6O4, requires C, 45.52; H, 3.47; N, 28.96%. 
Phenoxyacetic acid ethyl ester 118b94 
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O
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O O
K2CO3
THF / 70  C°
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2
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4
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2'
                             
Phenol (1.88 g, 20 mmol), ethyl bromoacetate (2.34 ml, 21 mmol) and K2CO3 (3.03 g, 
22 mmol) were stirred in DMF (20 ml) at 70 °C for 18 h. The mixture was cooled to rt, 
then partitioned between Et2O and H2O (25ml each), the aqueous layer was separated 
and then extracted with another two portions of Et2O (20 ml), the organic layers were 
combined and then washed with H2O, then with brine, dried over MgSO4, filtered and 
then concentrated to give a brown oil 118b (1.8 g, 50%). 1H NMR (CDCl3) δ: 7.30 (t, 
2H,  J = 8.1 Hz, 3,5-H), 7.00 (t, 1H,  J  = 8.1 Hz, 4-H), 6.91 (d, 2H, J  = 8.1 Hz, 2,6-H), 
4.62 (s, 2H, 2'-H), 4.28 (q, 2H, J = 7.1 Hz, OCH2CH3), 1.31 (t, 3H, J = 7.1 Hz, 
OCH2CH3); 13C NMR (CDCl3)  δ: 169.2 (C-1'), 157.9 (C-1), 129.7 (C-3,5), 121.9 (C-4), 
114.8 (C-2,6), 65.5 (C-2'), 61.6 (OCH2CH3), 14.3 (OCH2CH3); IR (liq film) 2983w (CH 
st), 1757s (CO), 1597s (C=C), 1201s (C-O), 754&691 (mono-substituted aromatic ring) 
cm-1; MS(ES) m/z: 181.1 (100%) (M+H)+. 
 
 
 195 
 
Phenoxyacetyl hydrazide119b94 
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Ester 118b (1.6 g, 8.88 mmol) was dissolved in EtOH (10 ml). Hydrazine monohydrate 
(2.7 g, 53.3 mmol) was then added and the mixture stirred at rt overnight. The volatile 
compounds were evaporated to leave a white solid. The solid was suspended in hot 
Et2O, then collected by filtration and dried to give 119b (0.8 g, 54%), m.p. 113 – 115 ºC 
(lit 112 ºC)10;  1H NMR (CDCl3) δ: 7.74 (br s, 1H, CONH), 7.30 (t, 2H, J = 8.1 Hz, 3,5-
H), 7.02 (t, 1H,  J  = 8.1 Hz, 4-H), 6.89 (d, 2H, J  = 8.1 Hz, 2,6-H), 4.56 (s, 2H, 2'-H), 
3.91 (br s, 2H, NH2); 13C NMR (CDCl3)  δ: 168.7 (C-1'), 157.1 (C-1), 130.0 (C-3,5), 
122.4 (C-4), 114.6 (C-2,6), 67.0 (C-2'); IR (KBr), 3313s (NH), 3042m (Ar-CH st), 1667 
(CONH), 1543m&1497s (C=C), 1243 (C-O), 742&687s (mon-substituted aromatic 
ring) cm-1; MS (ES) m/z 167.1  (100%) (M+H)+.  
 
 
 
 
 
 196 
 
Phenoxyacetic acid azide 120b                                               
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Hydrazide 119b (0.75 g, 4.96 mmol) was dissolved in a mixture of H2O (10 ml) and 
DCM (10 ml) then HCl (4 ml, 37%) was added, the mixture was stirred on a CaCl2-ice 
bath at 0 °C. NaNO2 (2.05 g, 29.8 mmol) solution in (10ml) H2O was added gradually 
to the reaction mixture, keeping the exothermic reaction between 0 – 5 °C. A further 
portion of DCM (20 ml) was added and then the DCM layer was separated, washed 
with water dried over MgSO4, filtered and kept stirred at rt under nitrogen for 
isocyanate preparation. 1H NMR and IR confirmed the formation of azide 120b. 1H 
NMR (CDCl3), δ: 7.29 (t, 2H, J = 8.1 Hz, 3,5-H), 7.00 (t, 1H, J = 8.1 Hz, 4-H),  6.88 (d, 
2H, J = 8.1 Hz, 2,6-H), 4.65 (s, 2H, 2'-H); 13C NMR (CDCl3), δ: 176.5 (C-1'), 157.5 (C-
1), 129.8 (C-3,5), 122.3 (C-4), 114.8 (C-2,6), 67.3 (C-2');  IR (liq film)  2920w (CH st), 
2145s (CON3), 1734s (CO), 1595s (C=C), 753&680m (mono-substituted aromatic ring) 
cm-1. 
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Phenoxymethylisocyanate 121b 
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The anhydrous DCM solution of azide 120b was stirred under nitrogen at rt overnight. 
IR and 1H NMR confirmed the formation of the isocyanate 121b. The DCM was 
evaporated at reduced temperature and pressure to give a pale yellow oil 121b (0.54 g, 
73%). 1H NMR (CDCl3), δ: 7.34 (t, 2H, J = 8.1 Hz, 3,5-H), 7.06 (t, 1H, J = 8.1 Hz, 4-
H),  6.97 (d, 2H, J = 8.1 Hz, 2,6-H), 5.30 (s, 2H, 1'-H); 13C NMR (CDCl3), δ: 159.6 
(NCO), 157.5 (C-1), 130.0 (C-3,5), 123.0 (C-4), 115.9 (C-2,6), 72.5 (C-1'); IR (liq film) 
3066w (Ar-CH st), 2919w (CH st), 2257s (NCO), 1595s, 1495s (C=C), 755m,  680m 
(mono-substituted aromatic ring) cm-1. 
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4-Oxo-3-(phenoxymethyl)-3H,4H-imidazo[1,5-d][1,2,3,5]tetrazine-8-
carboxamide 117b 
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Isocyanate 121b (0.54 g, 3.6 mmol) was diluted with DMSO (0.75 ml) under nitrogen, 
then added to a suspension of diazo-IC 20 (0.5 g, 3.6 mmol) in DMSO (0.75 ml). The 
mixture was stirred at 35 °C protected from light for 48 h. The reaction mixture was 
then suspended in H2O (30 ml) and then extracted with three portions of CHCl3 (20 ml); 
the CHCl3 layers were combined, washed twice with H2O (20 ml), dried over anhydrous 
MgSO4 filtered and the CHCl3 evaporated to give an orange solid. The 1H NMR showed 
impurities. The solid was then purified by flash column chromatography eluted with 
10% AcOH in CHCl3. The resultant solid was dissolved in DMF, the solution filtered 
and  water added to precipitate the imidazotetrazinone as a white solid  that was 
collected by filtration, washed with copious amounts of H2O, Et2O and then dried to 
give 117b (0.064 g, 32%), mp 146 – 148 °C 1H NMR (DMSO-d6) δ: 8.87 (s, 1H, 6-H), 
7.82 & 7.69 (2  br s, 2H, CONH2), 7.32 (t, 2H, J = 8.1, 3',5'-H), 7.15 (d, 2H, J = 8.1Hz, 
2',6'-H), 7.03 (t, 1H, J = 8.1, 4'-H), 6.22  (s, 2H, CH2); 13C NMR (DMSO-d6) δ: 161.9 
(CONH2), 156.9 (C-1'), 139.7 (C-4), 134.4 (C-8a), 132.4 (C-8), 130.4 (C-6), 130.3 (C-
3',5'), 123.1 (C-4'), 117.1 (C-2',6'), 76.3 (CH2); IR (KBr) 3426m (NH), 3092m (Ar-H 
st), 2920w (CH st), 1741s (CO-4), 1669s (CONH2), 1609 m, 1493m (C=C), 1217m (C-
O), 742m, 689 (mono substituted aromatic ring) cm-1; MS(ES): m/z 138.2 (80%) 
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(diazoIC + H)+, 287.1 (100%)(M+H)+; CHN Found: C, 50.27; H, 3.21; N, 29.63. 
C12H10N6O3 , requires C, 50.35; H, 3.52; N, 29.36%.      
                                                                                                                                                                 
E.5.2 1H NMR Study of hydrolysis reaction mechanism of alcohol- 
and phenol-release imidazotetrazinones (117a and b)   
 
The imidazotetrazinone 117a stock solution was prepared by dissolving (0.002 g, 6.89  
10-3 mmol) in DMSO-d6 (50 μl), the rest of the experiment performed same as in E 4.1, 
50 μl tetrazine stock solution was used for the study.  1H NMR confirmed the hydrolysis 
of the tetrazine and showed decomposition products. The reaction mixture of the 
finished products was spiked with authentic samples of furfurlal cohol and AIC (6.9  
10-6 mmol each in 10 μl deuteriated phosphate buffer), subsequent 1H NMR spectra 
confirmed their identities.  
 
The experiment repeated for imidazotetrazinone 117b (0.002 g, 6.99  10-3 mmol) in  
DMSO-d6  (100 μl), and the instrument programmed to record a 1H NMR spectrum at 
intervals of 0.5 h for 12 h. 1H NMR confirmed the decomposition of the tetrazine and 
showed hydrolysis products. The reaction products mixture was spiked with authentic 
samples of phenol (3.2  10-8 mmol in deuteriated phosphate buffer 10 μl) and AIC 
(13.8  10-6 mmol in 20 μl buffer).  1H NMR spectra confirmed their formation. 
 
E.5.3 UV-Visible study of the kinetic of decomposition of alcohol / 
phenol-release-imidazotetrazinones 
 
This experiments was performed exactly same as in E 4.2, the calculated rate constants 
(k′) and t1/2 showed that hydrolysis was faster than the aziridinium ion release tetrazines. 
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